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Abstract 
Single gene mutations leading to obesity though rare have provided critical insights into the 
molecular and physiological mechanisms underlying control of energy homeostasis and body 
weight. No systematic studies have been carried out to assess the genetic spectrum of extremely 
obese cases (SDS>3) in a predominantly consanguineous population. In the present study we 
searched for obesity-associated mutations by a multi-layered combination of sequencing 
techniques in a cohort of 175 unrelated subjects with early onset severe obesity and their family 
members, from a Pakistani consanguineous population. All subjects were, initially, screened for 
mutations in of leptin (LEP) and melanocortin 4 receptor (MC4R) genes by Sanger sequencing. 
Subjects negative for mutations in these genes were screened for 27 obesity-associated genes 
using microdroplet PCR-enrichment followed by next generation sequencing (NGS). Genomic 
structural variations were assessed by genome-wide genotyping. Forty severely obese children 
and family members in whom mutations in known obesity-associated genes could not be 
identified using the aforementioned procedures were analysed by whole exome sequencing 
(WES). Hormone levels were analysed by immunoassays. Using Sanger and microdroplet-based 
sequencing, and genotyping, we identified 54 probands carrying 20 different homozygous loss-
of-function mutations in 7 genes: LEP (n=35), leptin receptor (LEPR) (n=11), MC4R (n=4), Bardet–
Biedl syndrome (BBS) (n=4) and Prader–Willi syndrome (PWS) (n=2). We also found a ~59 kb 
deletion in chromosome 1, encompassing LEPR. Lastly, WES revealed potentially pathogenic 
mutations in three susceptible genes, insulin induced gene 2 (INSIG2), Rho-associated protein 
kinase 1 (ROCK1), adenylyl cyclase 3 (ADCY3). Link of these genes to obesity is further supported 
by previous GWASs and/or animal studies. Notably, leptin values were significantly increased in 
LEPR deficient and cortisol levels raised in leptin deficient subjects as compared to those with 
MC4R mutations. Furthermore, gut hormones were shown to play a minimal role in inducing 
hyperphagia in subjects with congenital deficiency. A high prevalence (32%) of pathogenic 
mutation in this population, underscores the importance of comprehensive genetic screening of 
inbred populations to unravel new genes and signalling pathways modulating energy balance and 
providing leads to evidence-based patient management and wherever possible personalized 
treatment. 
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Overweight and obesity are defined as abnormal or excessive fat accumulation that presents a 
risk to health [1]. The most commonly agreed measure of weight status in adults is the body mass 
index (BMI), which is based on the ratio of height and weight (BMI = kg/m2). A BMI of 30 or higher 
is considered obese whereas a BMI of 35 or higher represents morbid obesity. For children, 
however, a BMI percentile for age is calculated by using a standard growth chart drawn from 
normal population where BMI greater than or equal to 97th and 99th percentile for gender and age 
are considered obese and morbidly obese, respectively [2]. 
1.1 A historical perspective  
“We do not live in our own time alone; we carry our history within us.” [3] 
Mankind has faced scarcity of food especially in times of recurrent droughts and famines for 
centuries in its early history. Procuring of food was a daunting task that involved strenuous efforts. 
Therefore, natural selection favoured development of integrated mechanisms of storing its own 
reserves of energy in the form of fat to be utilised during times of scarcity. In this inclement 
environment the individuals who could accumulate sufficient stores of fat from the amount of 
food available had an obvious advantage in survival and procreation. In ancient times, a woman 
who was bulky or overweight was thought to exhibit characteristics of fertility and of well-being. 
Such beliefs are probably manifested in the creation of ancient figurines found around the world 
such as the Venus of Willendorf, the lime stone statuette  discovered in Austria (Figure 1.1) dating 
back to 25,000 BCE (late Palaeolithic period).  
With the first agricultural revolution that started 10,000 year ago, the primitive method of 
procurement of food by hunting and gathering gave way to farming, herding and domestication 
of animals. Though production remained largely dependent on environmental or climatic 
conditions, the supply of food became more plentiful. Abundant food was available mostly to an 
elite group, that is members of the ruling and merchant classes, allowing them to grow large and 
put on weight. To be ‘stout’ or fat was considered a sign of affluence and power. Still, the common 
man, who toiled hard and long in the field for a pittance to grow crops for human and animal 
consumption remained lean and hungry. One of the earliest references to the ill effects of obesity 
on quality of life can be attributed to the famous Greek physician Hippocrates (c. 460-377 BC) 
who pronounced that ‘sudden deaths were more common in those who were naturally fat than 
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in the lean’. Some 500 years later, the leading Roman physician of his times , Galen (c. 129-199), 
categorised obesity into two types: ‘moderate’ and ‘immoderate’, perhaps the latter type 
referring to morbid form of obesity as we know it today. Avicenna (or Ibne-Sinä; 980-1037) the 
well-known thinker and philosopher who wrote more than 100 works on medicine, for the first 
time listed obesity as a disease. He also pointed out the association of obesity with diabetes. 
From the Second Agricultural Revolution (1740-1850) triggering and coinciding with the First 
Industrial Revolution (1760-1840) in Europe and followed by the Green Revolution of the 
twentieth century in many parts of the globe (1945- late 1970’s), food became progressively more 
plentiful, cheap and readily available. Research, development and technology transfer changed 
conventional farming and dairy methods to industrialised food production and brought about a 
significant change in the quality of life and human activity. In the apt words of Eknoyan [4], the 
history of obesity relates to “….. how what was (once) good became ugly and bad”. Indeed the 
history of obesity cannot be separated from the history of food availability and an overt shift in 
quality and style of life. 
In the first decades of the twentieth century, insurance companies were the first to express 
concern about the ill effects of obesity on health and were soon joined by the medical profession 
[5]. Obesity was medically documented as a morbidity and a forerunner of life-threatening 
complications such as cardiovascular disease, diabetes, some common types of cancer and 
respiratory afflictions [5, 6]. However, it has not been easy convincing the public that obesity is a 
disease. 
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Figure 1.1 The Venus of Willendorf. Created ~ c. 25,000 BCE in Vienna, Austria. 
 
1.1.1 Human obesity in evolutionary context 
Energy homeostasis depends on a balance of expenditure of energy with energy intake and 
whereas the former is continuous, the latter is an episodic process. The short term energy 
requirements during food intake intervals are met with glucose and glycogen metabolism 
(mobilization and storage). However, to ensure supply of energy during relatively long periods of 
food shortfall or deprivation (e.g. starvation, hibernation) or in anticipation of excessive energy 
expenditure (e.g. reproduction, migration) animals including humans have evolved mechanisms 
of storing energy as fat in periods of plentiful food supply for long-term sustenance in face of 
energy crises. 
To explain the relatively recent emergence and phenomenal rise in incidence of obesity 
(metabolic syndrome) presumably in response to the developing scenario of food abundance and 
decline in physical activity, the ‘thrifty gene’ hypothesis was advanced by James Neel [7] almost 
more than half a century ago when present day knowledge about human genetics was still in its 
infancy. According to this concept genes favouring fat deposition were positively selected early in 
human evolution, to counteract frequent periods of starvation and famine experienced by 
ancestors of modern man [8]. Such a notion would imply that  inheritance of ‘thrifty genes’ and 
thus of physiological mechanisms perfected over centuries favouring storage of body fat that once 
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served a useful purpose, is mainly responsible in the present day energy-permissive environment 
for the onset of obesity epidemic  
The thrifty gene hypothesis to explain the emergence and prevalence of obesity in the present 
day obesogenic environment has been criticised mainly due to its failure to account for why some 
individuals grow fat while others do not while living under the same environmental conditions. 
To overcome this difficulty, an alternate proposition to explain the present day obesity epidemic 
in an evolutionary context, has been advanced by Speakman termed as the ‘drifty gene’ 
hypothesis [9, 10]. It argues that animals have evolved a ‘dual intervention system’ preventing 
them from storage of too little or too high amounts of fat, presumably regulated by two distinct 
albeit interacting, physiological mechanisms. Storing low amounts of fat will be under a strong 
negative selection pressure as paucity of food supply over any extended period will compromise 
survival and lead to starvation and death. Storage of fat will, therefore, be favoured by selection 
but up to a certain point. The resulting large size and consequent lack of agility due to excessive 
fat storage increases the risk of predation. The proposed dual intervention system will thus 
regulate the amount of fat so as to prevent its very low as well as very high build up. According to 
the drifty gene hypothesis, during the past 2 billion years of human evolution the risk of predation 
has been drastically reduced (due to bipedal mode of locomotion and use of fire and weapons) 
and the selection pressure on control of mechanisms responsible for the upper intervention point 
preventing excessive fat accumulation, has slackened. Consequently, random mutations in genes 
causing a variable drift in the upper intervention point would explain why some individuals are 
more disposed to obesity than others when exposed to the same scenario of food abundance and 
its uninterrupted availability [9]. However, notwithstanding the flaws inherent in the ‘thrifty gene’ 
hypothesis, the concept did bring into focus the obesity associated genes a study of which since 
then  has led to our current understanding  of the genetic and physiological basis of energy 
homeostasis. 
1.2 Obesity epidemic 
The previous four decades have seen a rapid change in human diet to high caloric food and 
adoption of a sedentary life style driven by a technologically advanced obesogenic environment, 
thus contributing to a phenomenal rise in the incidence and prevalence of obesity over a relatively 
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short time interval [11, 12]. Once considered a problem of technologically advanced and affluent 
countries, obesity together with its associated complications has now emerged as a major 
contributor to the global health burden and assumed the status of an epidemic as declared by the 
World Health Organisation (WHO) and considered a worldwide public-health crisis. According to 
WHO statistics, in 2014 more than 1.9 billion (39%) adults were overweight (BMI >25) and of these 
600 million (13%) were obese (BMI >30) showing a 100% increase in worldwide prevalence of 
obesity since 1980 [1, 13]. At present, 50 per cent of the UK population is overweight and this 
percentage is set to increase. Among continents, Americas has the highest incidence of 
overweight and obesity with 62% overweight and 35% obese [14]. There has also been a 
phenomenal increase in prevalence of child obesity in recent years. In 2012, about 44 million 
children (<5 years of age) were overweight or obese showing almost an increase of 31 million 
since 1990 [15]. The staggering cost needed to deal with obesity epidemic is particularly 
detrimental to economies of developing countries that are already under a heavy burden of 
malnutrition and infectious diseases [16].  
Obesity leading to serious health consequences like diabetes, cardiovascular disorders and many 
types of cancer, has emerged in recent times as one of the main causes of death globally. Statistics 
show that at least 2.8 million people die each year as a result of being overweight or obese [14].  
This has led to an unprecedented explosion of research in all aspects of the disease - from 
molecular to sociological. However, it still remains an uphill task to find ways and means to 
contain the obesity epidemic. 
1.3 Factors influencing obesity 
A large body of evidence shows that both environmental and hereditary factors are important in 
determining the extent of adiposity and contribute to obesity epidemic [17, 18]. These two factors 
interact in an intricate manner hence in most cases it is difficult to clearly separate the genetic 
from the environmental contribution towards the obese phenotype. 
1.3.1 Environmental contribution to obesity 
Availability and abundance of cheaply marketed energy-dense food and decline of physical 
activity have been regarded as the two major components of the permeating obesogenic 
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environment over the last 2-3 decades resulting in the present day obesity epidemic (or 
pandemic) [19, 20]. In addition, there is growing evidence that other factors mostly accentuated 
by the changing environment and living conditions, may also significantly contribute to prevalence 
of obesity. 
Infection by a number of microorganisms has been demonstrated to induce obesity in animal 
models and humans. Of various types of adenoviruses that cause obesity, the human adenovirus-
36 (Ad-36) has been studied relatively well for its obesogenic effect in experimental animals as 
well as in humans [21]. However, not all types of adenoviruses cause obesity. Another well 
documented example of development of obesity due to infection in mice is provided by the canine 
distemper virus (CDV) and its effect has been attributed to a down regulation of hypothalamic 
leptin receptors [22, 23]. The relationship of infection with increased fat mass is not unexpected 
since immune cells like macrophages and adipocytes share a number of morphological 
homologies and functional characteristics [24]. 
In recent years there has been a growing interest in investigating the role of natural gut 
microbiome in health and disease. Various investigations demonstrate a significant role of gut 
microbiota in energy homeostasis and pathogenicity of obesity. The first concrete evidence of this 
effect came from an experiment where germ free mice were reported to carry 40% less body fat 
as compared to conventionally raised mice [25]. Furthermore, marked differences in the gut 
microbiota of genetically obese mice (ob/ob) and lean mice have been demonstrated [26]. 
Additionally obesity can be induced in germ free mice by introducing gut microbiota of genetically 
obese mice but not by colonising with gut microbiota from lean animals [27]. 
Epigenetic mechanisms enable differential expression of genes by switching on and off a 
particular set of DNA nucleotides mainly by methylation and demethylation or through other 
processes. Emerging evidence shows that epigenetic mechanisms are amenable to environmental 
influences especially during prenatal and early postnatal life and the changes could be permanent 
and heritable. Thus exposure to environmental factors during development can induce 
permanent alterations in epigenetic gene regulation. The increasing magnitude of some of the 
environmental factors can, therefore, potentially alter the epigenetic mechanisms of energy 
homeostasis and a change in epigenetic regulation of obesity genes could lead to obesity [17, 28].  
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Many chemicals used in industry as pesticides such as bisphenol A (BPA), polybrominated 
diphenyl ether (PBDE), organophosphates, phthalate, DDT, solvents and many others, are 
remarkably stable and through their release in the environment progressively accumulate and 
stored in fat and liver tissues of man and animals, concentrate in food chains and act as endocrine 
disruptors. There is evidence that these endocrine disrupting chemicals (EDC’s) interfere mainly 
with androgen and estrogen signalling and bring about changes in metabolic homeostasis. 
Embryos are highly sensitive to the chemicals that are passed on through placenta or eggs. Since 
hormonal signals during development alter the timing and setting of gene expression during 
development through epigenetic mechanisms, these chemical agents bring about changes in the 
hormonal balance affecting not only reproductive processes but also a derangement of 
homeostatic mechanisms later in life that may lead to obesity [29]. 
Significant increase in the use of medications during the recent past, such as of psychotropic 
drugs, antihistamines, antihypertensives, antidiabetics, steroids, contraceptives and others, has 
been associated with increased weight gain and adiposity. According to the Third NAHNES report 
the use of psychotropic drugs alone in the United States has increased from 2.5% in 1988 to 8.1% 
in 2002 in adults [30]. Although the individual effects on weight gain due to these medications are 
small yet the increased prevalence of disorders for which these are prescribed, has appreciably 
contributed to the present day obesity epidemic. 
In addition, the risk factors for development of obesity also include age, gender and ethnicity, 
amongst others [31]. A differential susceptibility to obesogenic environment has been 
demonstrated in different ethnic populations [32, 33]. Pima Indians, Pacific Islanders, and African- 
and Hispanic-Americans are more prone to obesity than their Caucasian counterparts when living 
under similar permissive environmental conditions [34, 35]. More recently, evidence though 
incomplete, has accumulated pointing out that sleep deficit, socio-economic and educational 
level, may also prove to be significant contributors to the obesity pandemic [31]. Environmental 
factors have also been shown to influence epigenetic mechanisms especially during early 
development and thus a change in epigenetic regulation of obesity genes could result in obesity 
[17, 28].  
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1.3.2 Genetic contribution to obesity 
Although environmental factors contributing to the obesogenic environment, have undoubtedly 
driven the obesity epidemic in recent times, yet the wide inter-individual variation in BMI 
observed under more or less the same environmental conditions can only be attributed to a 
genetic (or heritable) predisposition to the condition [36]. The pioneering work of Stunkard and 
colleagues on twin studies in 1980’s provided a heritability estimate of ~0.80 for body weight [37, 
38]. Convincing evidence of a strong genetic influence on human obesity also came from an 
adoption study in Denmark that showed a high correlation of BMI of adopted children with that 
of their biological parents but no correlation with their adoptive parents [39]. Together, these and 
similar findings estimate heritability of obesity to be about 50-90%, implying that 50-90% of the 
variation in body weight in individuals sharing the same environment, is genetically attributable 
[40, 41]. However, a study on twins carried out in Finland, provides evidence that physical activity 
can modify to some extent the genetic risk for developing obesity [42].  
Mainly based on genetic background and to some extent phenotypic characterization, obesity is 
conventionally categorized into 3 types - common polygenic, monogenic and syndromic. 
1.4 Insights into molecular genetics of obesity  
1.4.1 Common polygenic obesity 
The genetic contribution to common obesity is complex and attributable to multiple obesity 
susceptibility loci. The individual effect size of these contributing variants is rather small that can 
so far explain only 2.7% of the BMI variation [43]. Initial efforts to uncover genetic basis of 
common form of obesity relied on two approaches – the genome-wide linkage studies and the 
candidate gene association approach. Later, the advent of array platforms for genome-wide SNP 
genotyping, a high-throughput methodology, enabled genome-wide association studies (GWAS), 
leading towards a better understanding of the genetic basis of complex disease.  
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1.4.1.1   Genome-wide linkage studies 
Earlier, genome wide linkage approach has been used to search for previously unknown loci 
associated with the obesity phenotype. This approach relies on the relatedness of the individuals 
under investigation on the basis of co-segregation for certain regions in the genome with 
phenotypes in question [44]. Contrary to the candidate gene approach that relies on prior 
knowledge related to a disease gene, this technique identifies novel, previously unsuspected 
genetic loci associated with the disease. Although this method has been useful in mapping disease 
associated genes presenting monogenic form of obesity, it has demonstrated only a partial 
success in linking novel genomic loci with adiposity quantitative trait loci (QTLs) by analysing large 
pedigrees from populations. More than 30 genome-wide scans have resulted in identification of 
250 susceptible loci with positive linkage results [45]. Some of these loci have attained significance 
levels and were identified in more than one study, such as 2p21–p23 [46-48], 6q22.31–q23.2 [49-
51] and 20q11–q13 [52, 53]. However, no consistent replication for most of these loci could be 
reported [44] and even an effort to carry out a meta-analysis on more than 30,000 subjects, failed 
to identify a conclusive obesity related locus [54]. 
1.4.1.2   Candidate gene association studies  
Candidate gene association study is a hypothesis driven approach that relies on the existing 
knowledge related to biology and pathophysiology of a particular disease. The candidacy of a gene 
is inferred from either positional or functional relevancy of the gene with susceptibility to the 
disease. The information could be derived from either animal models or from subjects with 
extreme phenotype [55]. Also, the candidacy of the gene may be inferred from position of the 
gene that lies near or within the genomic region that has been associated with the disease 
through linkage/association or due to any gene disruption event such as a chromosomal 
translocation or deletion [44]. These candidate genes are then tested at population level for their 
association with obesity-related traits. 
A large number of candidate gene studies in relation to obesity have been carried out in previous 
years. These studies have brought about a steady increase in the number of associated loci. As 
per the latest update of Human Obesity Gene Map, 127 candidate genes have been reported [45]. 
Of the most widely replicated genes were melanocortin 4 receptor (MC4R) [56-58], prohormone 
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convertase 1/3 (PCSK1) [59, 60], brain-derived neurotrophic factor (BDNF) [61, 62], and b-
adrenergic receptor 3 (ADRB3) [63, 64] genes. However, majority of the genes associated with 
obesity traits using this approach, failed to show consistent replication in successive studies [65]. 
1.4.1.3   Genome-wide association studies (GWAS) 
Following the limited success achieved through genome-wide linkage and candidate gene studies 
[55, 66], development and use of GWAS enabled a hypothesis free association analysis of common 
variants at the genomic level. GWAS searches across the whole genome for single nucleotide 
polymorphisms (SNPs) that are more frequently associated with complex common disease and 
these studies have made it possible to identify a number of previously unknown disease 
associated loci. 
FTO –the first GWAS identified obesity susceptibility locus 
In 2007, three independent genome-wide association studies led to the identification of FTO 
(renaming it the fat mass and obesity-associated gene), as the first success story of a GWAS-
identified obesity susceptibility gene [67-69]. Since this discovery, SNPs mainly in the first intron 
of FTO have been shown to be consistently and robustly associated with body mass index (BMI) 
and other obesity related traits such as fat mass, waist-to-hip ratio and leptin levels across diverse 
populations and ethnicities and in adults as well as children [67, 70-72]. 
The unambiguous association of FTO intronic SNPs with BMI triggered a profusion of studies 
attempting to explain the causal relationship of FTO with body composition and energy 
homeostasis. Historically, Fto was one of the six deleted genes in chromosome 8 of the ‘Fuse toe’ 
(Ft) mouse (the other five genes included in the deletion were Irx3, Irx5, Irx6, Fts and Rpgrip1l) 
[73]. The Ft mutation was associated with fusion of the first to fourth toes and hyperplasia of 
thymus. Fto was later identified by cloning in 1999 [74]. 
Mice with global loss of Fto are characterized by growth retardation with a significant reduction 
in adipose tissue and lean body mass that has been attributed to an increase in energy 
expenditure [75]. Furthermore, Fto loss of function mutations in mice result in reduced body 
weight [76, 77]. Conversely, mice expressing extra copies of Fto are reported to have a dose 
dependent increase in body mass accompanied by an increase in food intake [78]. That FTO is 
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implicated in energy balance is also indirectly evidenced by its high expression in the 
hypothalamus [67] and reduced mRNA levels in the negative energy state [79]. These and similar 
studies strongly suggest that a disruption in Fto expression could lead to an imbalance in the 
control of energy homeostasis and body composition. 
First direct observation of FTO deficiency in the human population came from study of a 
consanguineous family in which affected subjects carried a homozygous p.Arg316Gln mutation in 
a highly conserved region of FTO [80]. Affected individuals suffered growth retardation and early 
postnatal mortality like the Fto null mice but in addition, presented a number of malformations 
including developmental defects in the CNS and cardiovascular system. The parents of affected 
children were not reported obese. In vitro assays provided evidence of pathogenicity of the 
mutation that rendered the homozygous carriers of p.Arg316Gln mutation completely FTO 
protein deficient. 
FTO protein has been shown to be a 2-oxyglutarate dependent oxygenase [81] and can 
demethylate single-stranded nucleic acids such as 6-methyladenosine (6meA), 3-methyluracil 
(3meU) and 3-methylthymine (3meT) [82]. Consequently it has been suggested that FTO might 
regulate the expression of genes involved in metabolism and energy balance. In line with its 
catalytic role FTO’s SNPs have been linked to the expression of gut hormones such as ghrelin [83]. 
It has been suggested that an over expression of FTO by high risk (AA) allele may enhance food 
intake through increased ghrelin production in response to reduced m6A methylation of ghrelin 
mRNA.  
Another role of FTO, on similar lines, has been proposed in modulation of the reward system by 
its influence on dopaminergic circuitry within the mid-brain [84]. It was shown that in the Fto null-
mouse there is less increase in extracellular dopamine when cocaine known to block dopamine 
transporter was administered as compared to the wild type littermate. Fto inactivation impairs 
cocaine induced increase in locomotor activity as compared to the control and have blunt increase 
in extracellular dopamine mirroring the phenotype observed when dopamine receptor type 2 
(D2R) and type 3 (D3R) are impaired. Hess and co-workers  further suggest a link of FTO’s role as  
m6A demethylase (described above ) and  neuronal synapticity and demonstrate that transcripts 
that are selectively methylated in the Fto deficient mice are  excessively linked to synaptic 
transmission and cell-cell signalling [84]. 
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Recently influence of FTO on body composition and leptin sensitivity has been studied using Fto 
deficient mice on a high fat diet (HFD) [85]. It was observed that Fto+/- and Fto-/- mice on HFD in 
contrast to previous findings [75] increased their body fat but unlike similarly treated wild type 
mice, remained sensitive to leptin. Experimental evidence demonstrated that whereas normally 
NFKB signalling is up-regulated in response to HFD, Fto deficiency induces a down regulation of 
this signalling pathway. When NFKB signalling pathway was reactivated by TNFα, the Fto deficient 
animals became less sensitive to leptin. Furthermore, it was suggested that TRIP4, a 
transcriptional coactivator functionally links FTO to NFKB signalling. These investigations 
demonstrate that FTO can influence NFKB signalling and thereby leptin sensitivity under specific 
nutritional states. 
There is emerging evidence that the association between FTO SNPs and BMI might be due to a 
role of intronic SNPs not only in the regulation of FTO itself but also of its neighbouring genes. 
Most of the focus has been drawn in this context to two of the neighbouring genes of FTO, 
RPGRIP1L and IRX3. In vitro and in silico studies suggest that Rpgrip1l might provide a mechanistic 
link connecting the FTO risk allele with obesity by way of its involvement in impairing leptin 
signalling [86]. Rpgrip1l encodes a protein localized in the primary cilium that regulates the 
correct positioning of the long form of leptin receptor (LEPR-b) [86]. The first intron of FTO 
contains a binding site for CUX1 that acts as transcriptional regulator of Rpgrip1l as well as Fto 
and the presence of a risk allele in the binding site of CUX1 weakens its affinity and interferes with 
its normal regulatory role [87]. Such an assumption is also supported by the observation that in 
vitro supression of CUX1 expression results in a reduced expression of FTO and RPGRIP1L. The 
proposed model therefore suggests that FTO risk allele lowers the efficiency of the CUX1 leading 
to a reduced expression of RPGRIP1L which in turn interferes/inhibits localization of the long form 
of LEPRb  in the vicinity of the primary cilium. The foregoing cascade of events would, therefore, 
result in reduced leptin signalling [86].  
Intronic FTO SNPs have also been functionally linked to another neighbouring gene, iroquois-class 
homeodomain protein (IRX3). IRX3 was one of the six deleted genes in the ‘Fuse toe’ (Ft) mouse 
model described earlier. In 2010 computational analysis suggested that FTO may contain highly 
conserved noncoding elements that could act as a potential regulatory element for IRX3 [88]. Thus 
mapping of expression of quantitative trait loci in human brain samples demonstrated that BMI 
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associated SNPs (e.g. rs9930506) were linked to IRX3 expression. Furthermore, mouse reporter 
assay provides convincing evidence that IRX3 receives regulatory inputs from FTO [89]. Recently 
a study has attempted to explain the mechanistic basis for the association between the FTO locus 
and obesity by pointing to a pathway for adipocyte thermogenesis regulation that involves an 
upstream regulator - ARIDB5, the FTO SNP (rs1421085), and downstream target genes (IRX3 and 
IRX5). It was proposed that the risk allele contributes towards obesity by reducing mitochondrial 
thermogenesis in pre-adipocyte cells by way of disrupting conserved ARID5B repressor motif. This 
results in an increased expression of IRX3 and IRX5 implicating a developmental shift preferring 
lipid-storing white adipocytes over energy-dissipating beige adipocytes [90]. 
The influence of FTO SNP’s on neighbouring genes and the possible underlying mechanisms have 
been reviewed in detail by Fawcett and Boroso [91] and Tung et al [92].  
Meta-analyses of GWAS datasets 
Since the discovery of FTO, large-scale genome-wide association studies have been carried out 
involving thousands of obese individuals in an attempt to uncover new loci associated with 
common and complex forms of obesity. The effort has made it possible to carry out meta-analyses 
of data derived from multiple populations and has led to the establishment of large international 
consortia such as the Genetic Investigation of Anthropometric Traits (GIANT).  
The first meta-analysis of ~17,000 Caucasians combining 7 GWASs for BMI, confirmed a strong 
association of SNPs located 188 kb downstream from the MC4R gene with obesity related traits 
[93]. At the same time, in GWAS analysis of subjects of Indian origin the same locus was identified 
to be associated with waist circumference [94]. Since then several studies have successfully 
replicated a near-MC4R locus to be significantly associated with obesity related traits across 
diverse populations [95, 96] and in subjects of different age groups [97, 98]. 
In 2009 meta-analysis on more than 32,000 Caucasian samples from GIANT consortium [99] and 
almost a similar sample size (34,416) from the Diabetes Epidemiology: Collaborative Analysis Of 
Diagnostic criteria in Europe (DECODE) [100], while confirming association of with MC4R and FTO, 
found 6 and 7 new loci, respectively, 4 of which were common (NEGR1, TMEM18, KCTD15 and 
SH2B1) from both sources. A study focused on subjects with early-onset extreme obesity reported 
another four putative loci including NPC1, MAF, PTER and PRL, associated with obesity [101]. 
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In 2010, a GWAS was carried out by further expanding the sample number to 250,000 of 
individuals from 46 different populations of European origin. In this study Speliotes et al published 
18 new loci and confirmed another 12 previously established BMI-associated loci [102]. By the 
end of 2010, 32 loci were associated with BMI through GWAS efforts. In 2012, two simultaneous 
investigations exclusively on Asian population that was the largest GWAS of BMI in individuals of 
non-European ancestry, jointly reported four new loci [103, 104]. 
In addition to GWASs for BMI, other obesity measures such as waist circumference and waist/hip 
ratio (WHR), fat percentage or fat mass have also been considered. These studies have resulted 
in establishment of several loci. For example in a study comprising ∼77 000 individuals using WHR 
adjusted for BMI as the obesity measure, led to the identification of 13 loci [105]. By 2014, 77 loci 
were found to be associated with obesity related traits [66]. These studies have clearly indicated 
that differential fat distribution patterns could be attributed to distinct genetic components [106, 
107].  
Since for most of these identified loci we know very little about their pathophysiological role in 
relation to obese phenotype, therefore, these loci currently add very little to our understanding 
of their functional relationship to body composition and energy homeostasis. In an attempt to 
narrow down the gap between association and causation, a recent GWAS investigation aimed at 
not only to further expand the list of obesity associated loci but also to gain an insight into the 
physiological processes and molecular pathways that contribute to obesity. Recently a GWAS 
meta-analysis relating to BMI, by incorporating results from 300,000 subjects, was carried out to 
add to our understanding of the pathophysiology of common obesity [108]. This particular study, 
by using multiple complementary methods and expanding the number of BMI associated loci to 
97, highlights the biology of potential causative genes at the associated loci. The aforementioned 
study provided evidence of contribution of the genes that were involved in synaptic plasticity, 
glutamate receptor activity and neuronal development, and thus could possibly modulate BMI. 
Furthermore, this study corroborates and compliments the well-founded evidence derived from 
monogenic form of obesity of the role of CNS and more specifically of genes expressed in 
hypothalamic part, in energy homeostasis and body weight regulation. 
Another concurrent investigation aimed to enhance understanding of the genetic basis of body 
fat distribution, identified 49 loci associated with WHR adjusted for BMI, 33 of which were new 
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[109].  Majority of the variants were shown to be present in genes that are expressed in adipose 
tissue or in regions involved in regulatory control of adipocytes. Further pathway analyses 
provided insight into involvement of different processes affecting fat distribution such as 
adipogenesis, angiogenesis, transcriptional regulation and insulin resistance. To sum up, the 
aforementioned two studies have substantially increased our understanding of the molecular 
basis of obesity related traits and determined a direction for future research to uncover the 
complex biology of common obesity in terms of physiological and molecular mechanisms.  
Interestingly, the GWASs demonstrated that most of the genes associated with Mendelian forms 
of human obesity (LEPR, POMC, MC4R, BDNF, SH2B1 and PCSK1) are also enriched with more 
common variants associated with relatively small effects on BMI predisposing the individual to 
mild or moderate form of obesity in the general population [100, 101, 110-112]. This overlap with 
the monogenic obesity associated genes presumably indicates shared underlying mechanisms 
that could predispose an individual to a more severe monogenic as well as a more subtle polygenic 
form of obesity [113]. Conversely, the aforementioned findings also suggest the advisability to 
screen established loci identified through GWAS, in severely obese subjects with the objective to 
identify novel loci that could be associated with large effects on BMI to help pinpointing the causal 
genes [114]. 
1.4.2 Monogenic forms of obesity 
Incidence of obesity due to a loss-of-function/pathogenic mutation in a single gene is a rare event. 
The first potential evidence of monogenic obesity was provided by the finding of two mutant 
mice, ob/ob and db/db belonging to different strains. The ob/ob mouse that was three times 
heavier than a normal mouse and also had reproductive dysfunction, was found in 1950 at Jackson 
Laboratories [115] whereas db/db mouse which was phenotypically very similar to ob/ob but also 
had diabetes, was discovered in the same laboratory in 1965 [116]. An elegant series of 
experiments carried out by Coleman through parabiosis of ob/ob, db/db and normal mice led to 
the suggestion of the presence of a circulating ‘satiety factor’ in normal mice which was absent in 
ob/ob mice and was produced in excess in db/db animals that were unresponsive or resistant to 
it [117, 118]. It was twenty years later that positional cloning of the LEP gene led to the discovery 
of its encoded adipocyte secreted hormone leptin [119] and thus confirmed the presence of the 
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blood-borne ‘satiety factor’ postulated earlier. Subsequent cloning of the leptin receptor (LEPR) 
[120] and the elucidation of the central leptin driven melanocortin 4 signalling [121], as the critical 
and principal mechanism for regulation of body weight and energy balance, spurred 
unprecedented research activity in the field of molecular and physiological basis of obesity.  
Although the common form of obesity and its associated health and economic burden have been 
the major driving force for pursuit of unravelling the genetics of obesity yet the complexity of 
gene-gene and gene-environment interactions pose an obvious obstacle to such efforts in making 
a significant discovery. On the other hand, investigations on subjects with extreme obesity due to 
a single gene aberration provides an exceptionally strong association between the genetic make-
up and the disease phenotype and has substantially contributed to our understanding of the 
pathophysiology of the disease revealing the underlying genetic basis of rare monogenic disorders 
[61, 71, 122-124]. 
First direct evidence in the human that obesity could be caused by mutations in a single gene 
came in 1997 through identification of a recessive homozygous mutation in the leptin gene in two 
severely obese cousins from an inbred family of Pakistani origin [125].  Extreme obesity presented 
by these two patients was shown to be due to a complete lack of leptin hormone (congenital 
leptin deficiency). This finding was followed by several investigations into possible contribution 
of other obesity related genes involved in the central leptin-melanocortin signalling and has led 
to extensive research on its mechanism of action fuelled by a quest to find novel therapeutic 
strategies for the treatment of human obesity [71, 126, 127]. Further impetus to these 
investigations was provided by an alarming rise in prevalence of obesity with its co-morbidities 
almost at the same period.  
Monogenic forms of obesity have been identified in only 4-6% of severely obese subjects of 
European descent [71, 122], and are due to loss-of-function mutations in genes that have a key 
involvement in the hypothalamic control of energy balance via the leptin-melanocortin pathway 
and/or in regulation of neural development [128]. Mutations in these genes that disrupt these 
processes almost invariably result in severe obesity and hyperphagia in early childhood and are 
associated with various endocrine and immune disorders [128-130]. These include mutations in 
leptin (LEP) [125], leptin receptor (LEPR) [131, 132], preopiomelanocortin (POMC) [133], 
prohormone convertase 1 (PCSK1) [134, 135] or melanocortin 4 receptor (MC4R) gene [136-138]. 
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Signals from other relatively recently proposed centrally located and presumably leptin-
independent systems, implicated in regulation of body weight and energy balance such as those 
involving brain-derived neurotropic factor (BDNF) [61] and its receptor, tropomyosin receptor 
kinase (NTRK2) [139, 140], and the transcription factor, single-minded 1 (SIM1) [141, 142], may 
also converge to influence the melanocortin pathway [143, 144]. Furthermore, there is growing 
evidence that some of the common variants associated with small increments in BMI identified 
by genome-wide association studies (GWAS) map within or in the vicinity of genes carrying rare 
variants with large effects [57, 58, 145]. 
Leptin  
Leptin, the product of LEP gene, is an adipocyte derived hormone [119] and is also produced in 
smaller concentrations in other parts including brown adipocytes, stomach, placenta and skeletal 
muscle [146, 147]. Discovery of leptin gene in mice and subsequently in the human was 
undoubtedly a landmark in the field of obesity research. Indeed, well before its discovery, leptin’s 
important role in regulation of body weight was foreseen through experiments carried out by 
Coleman described above [117, 118]. 
Studies both in animals and the human have demonstrated the close association between body 
fat, leptin mRNA and the plasma leptin levels [148, 149]. Leptin levels signal the state of energy 
stores to the brain and are elevated in situations of positive energy balance or obesity and 
decrease during negative energy balance such as in anorexia.  Hence, leptin acts as a negative 
feedback regulator that helps the central nervous system in maintaining a set point for body fat 
stores and thus functions as a lipostat (control appetite and maintain constant body weight) [150]. 
Because of its crucial and vital role in control of body weight and energy balance, its biological 
and cellular characteristics have been extensively studied [150, 151]. 
Mutations in the LEP gene typically lead to complete absence of circulating hormone leptin – 
congenital leptin deficiency. Subjects with early onset obesity associated with congenital leptin 
deficiency lack satiety and consequently suffer from hyperphagia and severe obesity [61, 125]. 
Although leptin exerts its major effect on energy homeostasis by acting mainly through the 
arcuate melanocortin pathway (discussed below), recent evidence indicates other sites of its 
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action and pathways by which leptin may regulate a diverse range of physiological processes and 
functions [152].  
Complete leptin deficiency besides leading to severe obesity at an early age, is also accompanied 
by hypogonadotropic hypogonadism and abnormal pubertal development [153]. ob/ob mice are 
infertile but the condition is reversible by recombinant leptin administration [154]. Likewise in the 
human, congenital leptin deficiency is associated with insufficient GnRH secretion establishing a 
hypogonadotrophic hypogonadism state and a failure to reach puberty. Lack of growth spurt, 
secondary sex characteristics, and menarche are also some of the characteristics that may be 
associated with congenital leptin deficiency in the human [153]. Exogenous leptin administration 
in these subjects, allows timely pubertal advancement signifying importance of leptin in pubertal 
development and reproductive health [155] indicating that the presence of circulating levels of 
leptin is required for normal activation of the hypothalamic-pituitary-gonadal axis at puberty 
[156]. 
Another significant role of leptin is its relationship to the immune system. Mice lacking leptin 
suffer from immunological abnormalities that are also normalized by administering recombinant 
leptin. Similarly, leptin deficiency in humans is accompanied by a down regulation of the immune 
response resulting in recurrent infection and mortality in childhood [156, 157]. In ex vivo studies, 
leptin has been shown to enhance macrophage activity thus promoting production of various 
cytokines like tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-12 (IL-12) 
[158].  
In recent years leptin’s involvement in mediating reward related activities has also been 
proposed. In rodents, leptin receptors are expressed in the ventral striatum (VS) - an area 
associated with pleasure and reward, through which leptin exerts its effect on the mesolimbic-
dopamine system to decrease the incentive/reward associated with food intake [159]. Consistent 
with the idea of a role of leptin in the mesolimbic system, studies using functional magnetic 
resonance imaging (fMRI) have been used in subjects with leptin deficiency to elucidate leptin’s 
role in both homeostatic and hedonic regulation of food intake. In the leptin-deficient state 
visualization of food images triggered a marked increase in neuronal activation of ventral striatum 
as compared to normal leptin sufficient subjects whereas, no differential activation of mesolimbic 
areas was noted following 7 days of leptin replacement [160]. 
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With the exception of subjects with congenital leptin deficiency, obese individuals have higher 
leptin levels than their lean counterparts [150]. In common forms of obesity, the role of leptin as 
a negative feedback signal of adiposity appears to be attenuated and high levels of leptin in 
proportion to their fat mass fail to induce a loss of body weight [161]. The ineffectiveness of 
endogenous or exogenous leptin in obesity to regulate body weight is ascribed to leptin 
resistance; mechanisms that still remain largely controversial [126, 162]. One of the more 
plausible mechanisms proposed to explain leptin resistance in individuals with obesity involves 
the effect of over expression of the suppressor of cytokine signalling-3 (SOCS3) and/or protein-
tyrosine phosphatase 1B (PTP1B) on downstream signalling of leptin [163]. Leptin resistant obese 
mice have increased hypothalamic SOCS3 and PTP1B mRNA expression [164-166] whereas both 
SOCS3 and PTP1B knockout mice have increased leptin sensitivity and reduction in body weight 
[126, 165]. A suppression of expression of these ligands could, therefore, provide a therapeutic 
strategy to overcome leptin resistance in cases of common obesity [161].  
Some evidence in support of the blood brain barrier (BBB) as a crucial site mediating leptin 
resistance [167] is also available. Elevated level of triglycerides (hypertriglyceridemia) found 
associated with obesity are suggestive to some measure in inhibiting the transport of leptin across 
the BBB thus providing a mechanism for peripheral leptin resistance. Also, activity of the BBB 
transport system is shown to be reduced in diet-induced obesity (DIO) in mice [168]. 
Until 2011, in humans, only five distinct leptin mutations in 14 subjects had been described in 
the literature worldwide, which in the homozygous or compound heterozygous state led to 
congenital leptin deficiency and early onset severe obesity [125, 153, 157, 169-172]. During the 
course of this study another 3 mutations in 3 subjects have been identified [173-175]. The 
majority of the affected individuals belonged to consanguineous families.  
The use of personalized medicine for obesity has so far been shown to be exceptionally successful 
only in relation to congenital leptin deficiency, a condition that can be completely reversed by 
treatment with recombinant leptin. Such an arrangement has been in place in the Western 
counties for more than a decade to treat leptin deficient subjects [156, 169, 176]. The recent 
approval of the recombinant leptin (Myalept) by US FDA, for treatment of congenital leptin 
deficiency and lipodystrophy, brings hope that treatment may soon become available to affected 
subjects in all other places irrespective of the geographical boundaries. 
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Leptin receptor (LEPR) 
Leptin exerts its biological action through binding to the leptin receptor (LEPR), a member of class-
1 cytokine receptor family. The expression of LEPR results in at least six isoforms of leptin 
receptors (ObRa-ObRf) due to alternative mRNA splicing. Whereas these isoforms have common 
extracellular domains, they differ in the length and sequence of their intracellular motifs. It is 
widely expressed in a variety of human tissues and is highly expressed in the hypothalamus, heart, 
liver, small intestine, prostate, and ovary [177-179]. Leptin signalling is effected only through the 
long isoform of receptor (ObRb) [177]. This receptor isoform is expressed mainly in the 
hypothalamus and mediates the downstream leptin signalling through activation of Janus kinase 
(JAK) and signal transducer and activator of transcription (STAT) proteins following the ligand 
binding and its dimerization [180]. The short isoforms ObRa and ObRc are believed to act as leptin 
transporters across the blood brain barrier (BBB) [177]. The ObRe is the soluble isoform that lacks 
an intracellular and transmembrane domain. ObRe has been shown to function as a leptin binding 
protein and its peripheral concentrations are used as a measure of free leptin index (FLI) [181].  
In mice and humans both leptin and leptin receptor deficiency result almost in an identical 
phenotype of early-onset severe obesity accompanied by hyperphagia [131]. The absence of 
leptin action caused by functional pathogenic mutations in the LEPR like those of LEP, have been 
linked to hypogonadotropic hypogonadism and a failure of normal pubertal development in 
rodents and humans [131, 132, 154]. However, indication for a delayed but spontaneous onset of 
menstrual cycle in a few of the leptin receptor-deficient adults is on record [157]. In such cases it 
has been suggested that excessive accumulation of fat mass in these subjects may result in release 
of estrogen adequate for uterine development and onset of irregular menstrual cycles without 
development of secondary sexual characteristics [182]. One of these LEPR deficient patient has 
been reported to carry a natural pregnancy and given birth to a healthy child thus raising the 
question about the role of leptin signalling in human reproductive function [183].  
Whereas LEP mutations result in a complete lack of its encoded protein, the pathogenic mutations 
in the LEPR render the carrier resistant to leptin action. The first reported pathogenic mutation in 
human LEPR was shown to be located in the splice donor site of exon 16 [131]. The resulting 
truncated LEPR protein, lacking both transmembrane and intracellular domains, was found to be 
secreted in the blood and to actively bind circulating leptin in high concentrations [132, 184]. 
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Since then LEPR mutations have been identified in less than 25 subjects from diverse populations 
[63, 132, 185-188]. 
Proopiomelanocortin (POMC)  
Proopiomelanocortin (POMC), a 241 amino acid polypeptide encoded by the POMC gene, is 
expressed mainly in the CNS (arcuate nucleus) and the anterior and intermediate (in rodents) 
lobes of the pituitary gland. Post-transcriptional tissue specific cleavage of POMC into smaller 
biologically active peptides (Figure 1.2) that also activate the melanocortin receptors (MCRs),  
influence diverse biological functions in the central nervous system, the adrenal gland, the skin 
and some other tissues. Amongst these cleavage products, α -melanocyte-stimulating hormone 
(α-MSH) serves as a ligand for MC4R in the CNS and thus mediates the downstream signalling of 
the melanocortin pathway [189]. 
In addition to its expression in CNS, POMC is predominantly expressed in the anterior pituitary 
(corticotrope cells) where its cleavage product adrenocorticotropic hormone (ACTH) binds with 
the MC2R in the adrenal cortex to stimulate adrenal glucocorticoid synthesis and secretion. [190].  
Homozygous or compound heterozygous pathogenic mutations that result in complete POMC 
deficiency are rare and have so far been reported in only eight cases [133, 191-194]. Patients with 
pathogenic POMC mutations present hyperphagia and obesity due to lack of αMSH and thereby 
an inactivation of its receptor, MC4R, in the hypothalamus and hypocortisolemia which is 
secondary to ACTH deficiency. In some of these investigations heterozygous carriers of POMC 
mutations also showed a high risk of obesity or being overweight [195, 196], suggesting that the 
defective allele in the heterozygous state can sufficiently interfere with the central melanocortin 
signalling to increase susceptibility to obesity. POMC deficiency, both in humans and rodents is 
also associated with pale skin and red hair consistent with the lack of MC1R receptor signalling in 
the absence of POMC derived αMSH. MC1R signalling is necessary to maintain phaeomelanin 
(yellow ⁄ red pigment) to eumelanin (brown ⁄ black pigment) ratio in the mammalian skin and hair 
colour [197, 198] and a disruption of which causes an increase of phaeomelanin. 
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Figure 1.2 Processing of POMC precursor protein. 
Proopiomelanocortin is post-translationally processed to produce several biologically active peptides, 
including adrenocorticotropin (ACTH) and α-, β- and γ-melanocyte-stimulating hormone (MSH). Arrows 
indicate the cleavage sites.  
 
Melanocortin-4 receptor (MC4R) 
MC4R, a G-protein coupled receptor activated by its ligand α-MSH, is highly expressed in the 
hypothalamic part of the brain and plays a significant role in melanocortin signalling and 
regulation of appetite and energy balance [121]. Compared to other rare single gene variants 
associated with obesity, mutations in the MC4R gene appear to be the more prevalent form of 
monogenic obesity. Studies regarding the frequency of MC4R mutations associated with human 
obesity estimate up to 6% of obese subjects and 1 in 1000 of UK population [199] although the 
prevalence may vary in different populations. The functional relevance of MC4R mutation to 
human obesity was first established in 1998 with a report of heterozygous frameshift mutation 
by two groups [138, 200]. Until 2000, 21 different mutations had been identified in this gene and 
associated with obesity. Of these 20 are reported in the heterozygous form while only one, 
p.Asn62Ser, was reported in the homozygous state in a subject from a consanguineous  family of 
Pakistani origin [41]. By  2013, 166 autosomal dominant and recessive loss of function variations 
in the single coding exon (encodes for 322 AA) of MC4R gene have been described [201].  
Most of the studies carried out on families indicate a co-dominant mode of inheritance with 
heterozygous subjects having a less severe obesity phenotype than homozygous carriers and with 
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a variable expression and penetrance [202-204]. In a French multigenerational familial study on 
MC4R mutation carriers an age and generation related effect on the penetrance of obesity has 
been demonstrated. This study shows that in older French generations (>52 years of age), the 
penetrance of heterozygous loss-of-function MC4R mutations was not more than 40%, and only 
a small minority of these individuals were self-reported to be obese (BMI>30) at the age of 20 
years [202]. These observation suggest that the penetrance of MC4R mutations is variable and to 
a certain extent dependent on environmental and other factors. 
The relatively high frequency of mutations in the MC4R gene urged scientists to carry out 
functional characterization to understand the underlying molecular mechanisms. Such studies 
have provided insights into different components of MC4R signalling including trafficking of 
receptor to the cell, ligand binding, activation and downstream signalling. A careful 
characterization of these defects has helped to identify mechanisms by which a specific receptor 
dysfunction could contribute to an increase in adiposity [203, 205, 206]. Most importantly such 
studies could also lead to development of therapeutic agents such as the use of small molecules 
that could act as pharmacological chaperones to rescue intracellular retained mutant MC4R 
receptor proteins [205]. 
Single-minded 1 (SIM1) 
More recently, mutations in single-minded homolog 1 gene (SIM1) have been associated with 
severe obesity. SIM1 encodes for its protein, SIM1, also known as Class E protein basic helix-loop-
helix 14 (bHLHe14), a transcription factor, known to be involved in the development and function 
of the paraventricular nucleus (PVN) [207]. Mice with complete knockout of sim1 (Sim1–/–) die 
perinatally due to lack of PVN development [208]. Whereas haploinsufficiency of SIM1 leads to 
obesity [208, 209], its over expression has been shown to protect against diet-induced obesity in 
rodents [210], indicating a possible involvement of SIM1 in energy balance. In spite of being 
hyperphagic and obese, Sim1+/- mice undergo increased linear growth resembling mc4r mutants 
in appearance [144]. Also, Sim1+/– mice are reported to have significantly reduced levels of Mc4r 
mRNA in the PVN [144]. Sim1 overexpression observed in agouti yellow mice in which 
melanocortin signalling is impaired resulted in amelioration of hyperphagia and decrement of 
adiposity thus compensating for the defective Mc4r signalling [210]. The foregoing observations 
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support the notion of a physiological role of SIM1 in regulation of food intake and body weight 
through a modulation of downstream pathway of leptin-melanocortin signalling.  
Human SIM1 deficiency was first reported by Holder and colleagues who described a de novo 
translocation between chromosomes 1p22.1 and 6q16.2 [211]. Subsequently, in patients with a 
Prader-Willi-like (PWL) phenotype, deletion of the 6q16.2-6q16.3 region that includes SIM1 gene 
was also reported [212-214] suggesting its role in the development of PWL syndrome [215]. 
Further support to the involvement of SIM1 in human obesity came with the identification of 
point mutations in this gene associated with severe obesity and PWL syndrome. In four recent 
investigations, screening of SIM1 gene in obese and PWL syndrome cases, revealed 27 different 
mutations, 16 of which were accompanied by a significantly decreased expression of SIM1 mRNA 
[141, 142, 216, 217] resulting in a spectrum of severity in obesity and of neurobehavioral 
anomalies. These findings also indicate a variable penetrance of SIM1 mutations in a manner 
similar to those MC4R pathogenic variants and raise the possibility of environmental contribution 
in determining the severity of the condition in subjects carrying these mutations [141]. 
Brain-derived neurotrophic factor (BDNF) and tyrosine kinase B receptor (TrkB) 
The brain-derived neurotrophic factor (BDNF) is a neural growth factor or neurotropin which 
exerts its effect via the tyrosine kinase B receptor (TrkB). The BDNF by activating its receptor 
regulates neuronal proliferation, survival, and differentiation during development and affects 
synaptic plasticity in the adult brain [218, 219]. BDNF expression is also required for normal 
neuronal development and plasticity in the hypothalamic part of brain thus linking its role as a 
modulator of energy homeostasis [220].  
The first direct evidence of BDNF involvement in energy homeostasis came when reduction in 
body weight, food intake and a reversion to normoglycemia were observed following intra-
cerebroventricular injection of BDNF in genetically determined severely obese mice (db/db) [221]. 
Subsequent experiments on mice either heterozygous for the BDNF mutation or with conditional 
post-natal deletion of the gene in the brain region, resulted in the hyperphagic obese phenotype 
[222-224], suggesting that this neurotrophin may contribute in differentiation/regulation of 
central circuits of energy balance. It has also been indicated that BDNF/TrkB signalling exerts 
anorexigenic effect downstream of the MC4R [143, 223].  
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Indication that defective BDNF/TrkB signalling is associated with weight regulation and appetite 
control in the human was provided by a report of a de novo heterozygous mutation in NTRK2 
associated with severe obesity, impaired short-term memory and other developmental anomalies 
[140]. Further support to this observation was provided by identification of a BDNF-
haploinsufficient child due to a paracentric inversion in the region encompassing the BDNF gene. 
In addition to severe obesity and hyperphagia, the patient also presented impaired cognitive 
function and hyperactive behaviour [61]. Altogether, these observations provide evidence of a 
significant involvement of BDNF/TrKB signalling in control of energy balance.  
Proprotein convertase subtilisin/kexin type 1 (PCSK1/3) 
PCSK1/3 formally known as PC1/3, is a member of serine endoproteases family involved in 
processing of inactive hormone and neuropeptide precursors into their biologically active form. 
PCSK1/3 expressed selectively in the neuroendocrine tissues, cleaves a number of precursor 
proteins including proinsulin, proglucagon, POMC and pro-neuropeptides, amongst others [225].  
Pathogenic mutations of PCSK1/3 that act in recessive form and cause complete lack of the 
encoded protein, are strongly linked to obesity [135, 226-228]. Congenital loss of PCSK1 protein 
in the human leads not only to obesity but to a number of other clinical phenotypes including 
intestinal dysfunction, hypocortisolemia, disruption of glucose homeostasis and endocrine 
dysfunctions due to defective processing of hormone precursors such as proglucagon, ACTH, 
proinsulin, pro-TRH and pro-GHRH. In another study partial PCSK1 deficiency due to heterozygous 
loss of function mutations have been associated with an 8.7-fold increased risk to develop obesity 
[60]. More recently, a unique dominant nonsense mutation in PCSK1 gene (p.Arg80*) has been 
associated with obesity and glucose intolerance [229]. This mutation was found to co-segregate 
with obesity in a multi-generation family. Functional analysis revealed that the variant abolished 
PCSK1 enzyme activity. 
Unexpectedly, Pcsk1 null mice do not display an obesity phenotype but undergo a blunted growth 
accompanied by various neuroendocrine disorders [230]. However, the PC1/3N222D mutant mouse 
represents a singular case leading to the obese phenotype [231]. This mutation resulted in lower 
levels of α-MSH and defective POMC processing.  
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Other putative monogenic obesity associated genes 
To date, almost all genes that have been implicated in the development of obesity appear to 
modulate adiposity either by regulating appetite and energy homeostasis or influencing 
neurogenesis of brain areas that are crucial in energy balance. Recent efforts to identify new 
obesity associated genes influencing the leptin melanocortin domain have resulted in 
identification of melanocortin receptor accessory protein 2 (MRAP2) with a suggested role in 
modulation of MC4R signalling and consequent development of obesity in rodents and humans 
[232]. Mrap2 knockout mice have been shown to develop obesity at an early age [232]. Moreover 
mutations related to  KSR2 – a scaffolding protein involved in Ras-Raf-MEK signalling pathway 
have been shown to have an effect on energy balance by way of a decrement of  BMR [233], 
mimicking the phenotype observed in  Ksr2-/- mice [234]. These findings implicate MRAP2 and 
KSR2 encoded proteins as physiological regulators of energy homeostasis.  Replication and further 
elucidation of these results are needed before mutations in these two genes could be associated 
as causal factors of monogenic obesity.  
1.4.3 Syndromes associated with obesity  
In addition to monogenic form of obesity in which excessive weight gain at early stages of life is 
the main presentation, a number of syndromes have been identified where obesity is one of the 
several other anomalous phenotypic expressions. These predominantly include developmental 
and cognitive delay, mental retardation, dysmorphic features and organ-specific developmental 
abnormalities [235]. Syndromic form of obesity may arise from structural abnormalities at the 
chromosome level involving several genes or as consequence of a mutation in a single gene with 
pleiotropic effects. Here we briefly describe some of the well-investigated forms of syndromic 
obesity from each of these two categories.  
Chromosomal abnormalities - imprinting disorders: 
Prader-Willi syndrome (PWS)  
PWS is one of the more common forms of syndromic obesity. The syndrome presents infantile 
hypotonia, hypogonadism, growth hormone insufficiency, delayed development and feeding 
difficulties in early life. These symptoms are soon followed by hyperphagia leading to early onset 
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obesity. Other phenotypic characteristics include a distinctive facial appearance and short hands 
and feet [127, 236].  
This complex obesity syndrome is caused by an absence of paternally inherited allele expression 
at 15q11–13 genomic region corresponding to where the maternally inherited allele is imprinted. 
Paternal deletion, maternal uniparental disomy, and imprinting defects are the three proposed 
mechanisms that could cause absence of paternal expression and result in development of the 
PWS. The deleted region is typically a ~6 Mb or ~5.3 Mb fragment depending on the position of 
the proximal breakpoints (BP1–BP3 and BP2–BP3, respectively) [237, 238]. However, unique 
deletion(s) with specified breakpoints have been reported in a small number of cases [239]. Some 
microdeletions ranging from 187 kb to 847 kb within SNURF-SNRPN and snoRNA cluster region 
have also been observed indicating a major contribution of non-coding RNAs in this region in most 
if not all phenotypes related to PWS [240-242]. Further studies aimed at whether there is a 
functional involvement of other genes encompassing the deleted region may contribute to 
associating distinct genetic factors with specific clinical features accompanying this syndrome. 
Albright hereditary osteodystrophy (AHO) 
Phenotypic features associated with this syndrome in addition to obesity include short stature, 
round face, brachydactyly, and mental disability. All these features are collectively termed as the 
AHO. Various genetic and epigenetic events in the GNAS1 gene have been shown to determine 
these phenotypes.  
Inactivating mutations in the GNAS1 cause a decrease in expression (~50%) and thus function of 
its encoded protein-Gsα, leading to development of AHO symptoms. Gsα is a critical component 
for signal transduction by activation of adenylyl cyclase and thereby causing an increase in 
intracellular adenosine monophosphate (cAMP). A tissue specific genomic imprinting is observed 
in the GNAS1 region. Only the maternally inherited allele is expressed in tissues including renal 
tubules, thyroid and pituitary gland. The mutated maternal allele results in a resistance to 
parathyroid (PTH) whereas inactivating mutations in the paternal allele will not cause resistance 
to the hormone. Since elsewhere in the body, bi-allelic expression of GNAS1 is present, mutation 
in either allele will reduce Gsα expression to half causing AHO. Mutations in the maternally 
inherited allele cause AHO and resistance to multiple hormones. The condition is termed as 
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pseudohypoparathyroidism (PHP) [243]. Paternal Gsα-inactivating mutations lead only to the 
AHO phenotype but without hormone resistance termed as pseudopseudohypoparathyroidism 
(PPHP) [244, 245].  
Single gene defects - ciliary dysfunction 
Cilia are the hair-like structures present on all types of cells in the body and play an important role 
in various cell functions including movement, perception of sensory input and signal transduction. 
Impaired ciliary function can lead to developmental abnormalities and deformities in several 
different organ systems. Abnormal formation and function of cilium caused by ablation of genes 
encoding for components involved in cilium integrity and function, have been linked to a 
constellation of phenotypically and genetically overlapping disorders collectively known as 
ciliopathies. Consequently there is a wide range of phenotypic outcomes of ciliary dysfunction in 
mammals. Of these obesity is one of the presentations in three syndromes namely Bardet-Biedl 
(BBS), Alstrom (ALS), and Carpenter (CA) syndromes [127]. Indeed, abnormal development of the 
primary cilia suggests a link between the ciliary function and Lep-LepR signalling in the 
hypothalamic satiety centres of the brain [246, 247]. 
Bardet-Biedl syndrome (BBS) is a pleiotropic and genetically heterogeneous autosomal recessive 
disorder. This syndrome is associated with several phenotypes including obesity, renal 
malformation, polydactyly, hypogenitalism and learning disabilities. To date, 18 genes (BBS1-18) 
have been associated with this syndrome by way of ciliary malfunctioning [248]. Proteins encoded 
by BBS genes are located at the base of the cilium and play their role in trafficking of particles in 
and out of the cilium [249, 250].  
Alstrom syndrome (ALS) is rare autosomal recessive disorder typically characterized by a 
progressive neurosensory deficit, development of obesity at an early age, male hypogonadism 
and insulin resistance. Other clinical features associated with the disease include cardiomyopathy, 
hepatic triglyceridemia, short stature, fibrosis, and multiple organ failure [251, 252]. Unlike BBS, 
this disorder is reported to be genetically homogeneous since only ALMS1 gene has so far been 
reported to be associated with this syndrome. ALMS1 is widely expressed in centrosomes and 
basal bodies in  ciliated cells suggesting  the  role of this protein in function and integrity  of cilia 
[253]. The similarity in function of ALMS1 with BBS is suggested by a strong resemblance of 
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phenotypic features of the two syndromes. However, the absence of mental retardation and 
digital anomalies distinguish it from the BBS syndrome.  
Carpenter syndrome (CS) is a very rare autosomal recessive disorder presenting   truncal obesity, 
preaxial polydactyly of foot and craniosynostosis. Clinical features include hypogenitalism, 
congenital heart disease, mental retardation and dental anomalies [127, 254].  Mutations in 
RAB23 have been implicated in the pathogenesis of CS. RAB23 encodes a member of the RAB 
guanosine triphosphates (GTPase) family and is mainly involved in the intracellular membrane 
trafficking [255].  
1.4.4 Beyond single gene defects - genomic structural variations  
In addition to rare obesity associated Mendelian variants with a large effect and common variants 
with small effect, genomic copy number variations (CNV’s) have strongly been implicated in some 
forms of extreme obesity. CNV‘s occur where a segment of DNA is duplicated or deleted and are 
estimated to account for nearly 18% of the heritable variance in gene expression. The proximal 
short arm of chromosome 16 is one such region that has strongly been associated with obesity. A 
smaller 220 kb and a larger 593 kb deletion found in 16p11.2 region were found to be associated 
with a predisposition to a highly penetrant form of obesity with a 43-fold increased risk of 
developing morbid obesity.  The frequency of the 220-kb, SH2B1 inclusive, deletion in patients 
with severe obesity has been shown to be 0.51% (7/1362) [256] whereas the 593-kb deletion in 
the same chromosomal region had a frequency of 0.36% in obese individuals (15/4197) [257], 
presenting one of the more frequent genetic causes of obesity.  This deletion has been 
consistently replicated in various independent investigations [258-260]. Whereas homozygosity 
of the 600 kb deletion in the short arm of chromosome 16 has been associated with severe 
obesity, corresponding duplication(s) in the same region result in extremely low BMI of affected 
patients.  The reciprocity of deletions and duplications effects at the same locus present an 
interesting example of a ‘mirror’ effect on the phenotype [261]. 
The 220kb deleted region maps a strong candidate gene for obesity - Sarcoma (Src) homology 2 
(SH2) B adaptor protein 1 (SH2B1). SH2B1 is an adaptor protein involved in signalling downstream 
of a various receptor tyrosine kinases and cytokine receptors including leptin receptor. Targeted 
disruption of Sh2b1 in mice causes a striking leptin and insulin resistance, increased food intake 
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and severe obesity [262, 263]. SNPs within SH2B1 have also been linked to human obesity and 
BMI through several genome-wide association studies (GWAS) providing support for the 
involvement of SH2B1 in body weight regulation [99, 100, 264, 265]. Recently, several non-
synonymous mutations have been identified and associated with obesity, insulin resistance and 
some of the behavioural abnormalities [266-269]. It has also been shown that variants present in 
N-terminal region exhibit a spectrum of maladaptive behaviour in addition to affecting food intake 
and body weight [269]. Interestingly SH2B1α variant carriers were hyperinsulinemic but did not 
exhibit the behavioural phenotype observed in individuals with N-terminally located (1–631 
region) mutation [268] suggesting genetic variants that disrupt isoforms other than SH2B1β may 
be functionally significant. Taken together, these findings suggest a substantial role of copy 
number variants in susceptibility to obesity.  
1.5 Physiological basis of energy homeostasis - role of CNS 
Energy homeostasis implies a balance of energy intake with energy expenditure resulting in the 
maintenance of fat stores and body weight more or less at a set point, under normal conditions. 
Energy homeostasis like other homeostatic mechanisms is controlled and regulated by specific 
areas of the brain in relation to afferent peripheral and environmental signals interpreted and 
processed by a complex neurocircuitry, and translated into efferent signals affecting appropriate 
responses to maintain energy balance.  
The key role of hypothalamic area of the brain in the control of energy homeostasis was indicated 
as early as 1940’s by the demonstration that lesions of this part of the brain resulted in morbid 
obesity [270]. Since then a large body of morphological, physiological, genetic and 
pharmacological studies have established the importance of the hypothalamus in the regulation 
of food intake, body weight and energy homeostasis.  
The hypothalamic neurons are concentrated in a number of nuclei including the arcuate (ARC), 
ventromedial hypothalamus (VMH), dorsomedial hypothalamus (DMH), lateral hypothalamus and 
paraventricular (PVN) nuclei. These neurons are anatomically localized around the third ventricle 
and express receptors that are specific to metabolic signalling molecules originating peripherally 
as well as centrally [271]. Neurons comprising these nuclei receive multiple peripheral signals in 
the form of hormones, neuropeptides, neurotransmitters and metabolites and in turn produce 
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specific and coordinated physiological responses by inter- and intra-cellular signalling 
mechanisms to other brain regions [126, 272]. The circulating nutrient signals mostly converge to 
ARC situated ventrally and adjacent to the median eminence and the specific peptides expressed 
by its neurons play an important and well characterised role in regulating food intake and energy 
homeostasis.  
The complex network of homeostatic circuitry also includes extra hypothalamic regions of the 
CNS such as the brainstem or nucleus of the solitary tract (NTS) a critical sensor of circulating 
signals for regulating food intake. This part of the brain contains various neuropeptides and 
receptors that have their role as appetite modulators and receives vagal inputs from the 
gastrointestinal tract on information about nutrient content, and projections of the hypothalamic 
nuclei to provide nutrient related information [273]. 
Of the peripheral hormonal signals that transmit the nutritional state of the body to the 
homeostatic system, leptin and insulin are considered as long term modulators of energy balance 
while peptides produced by the gut including ghrelin, peptide YY (PYY), glucagon-like peptide 1 
(GLP-1) and cholecystokinin (CCK), along with vagal inputs are the main components of the short 
term food intake regulatory system. These hormones signal through their receptors and 
interacting by various feed-forward and feed-back mechanisms regulate appetite and energy 
balance [274].  
In addition to homeostatic control of food intake and energy homeostasis, eating behavior is 
greatly influenced by cognition, emotional and reward related responses mediated by pre-cortex 
and areas of limbic system. Evidence is also available suggesting influence of peripheral metabolic 
factors on reward system [275, 276] in addition to acting as homeostatic mediators through the 
hypothalamus. Nutrition related information from these hedonic reward centers may also 
converge to central hypothalamic part to influence food intake by modulating the sense of 
pleasure associated with eating [126, 272].  
Leptin and melanocortin pathway 
Following the pioneering discovery of the obesity gene in 1994, and its encoded protein hormone 
leptin secreted by the adipose tissue [119], a great deal of attention has been given to search 
specific signalling molecules and pathways controlling our food intake and body weight leading 
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to the current understanding of mechanisms of action of leptin and its downstream mediators 
[71, 126, 127]. As a result of studies in rodents and the human and especially through insights 
derived from monogenic obesity, the central leptin melanocortin pathway has emerged as the 
principal signalling mechanism regulating energy balance. 
The ARC is protected by the blood-brain barrier (BBB) and it is difficult for circulating molecules 
as large as leptin to access it by simple diffusion. It is generally held that leptin gets across this 
barrier that separates the ARC from the median eminence, by a ‘saturable transporter system’ 
[277]. The median eminence is provided with fenestrated capillaries, a part of the so-called 
circumventricular organs (CVO) that lie outside the BBB. It has been proposed that ARC LepRb 
bearing neurons in close vicinity to its border with median eminence may also be accessible to 
peripheral endocrine signals such as that of leptin. The border between ME and ARC is lined by 
highly modified glial cells, the tanycytes, that have been implicated in the process and mediate to 
transport leptin to the cerebrospinal fluid (tanycyte-mediated transport) [278, 279]. Moreover, 
there is evidence that some of the leptin receptor expressing neurons send projections across the 
barrier into the median eminence hence gaining direct access to the circulating hormone [280]. 
Intracellular leptin signalling - JAK2/STAT3 pathway 
LepRb is the only form of leptin receptor that possesses all domains necessary for intracellular 
signalling [178] and initiates several signal transduction pathways [152, 281-283]. Of these the 
JAK2/STAT3 pathway is the best studied and is demonstrated to play a major role in energy 
homeostasis and body weight regulation [284] Following leptin binding and receptor 
dimerization, JAK2 is autophosphorylated subsequently leading to phosphorylation of multiple 
tyrosines in LepRb (Tyr985/1107/1138) and enabling recruitment of downstream effectors. The 
phosphorylation of Y1138, provides a binding site for STAT3 protein which upon activation 
dissociates from the leptin receptor (Figure 1.3). Recently, Rho-kinase 1 (ROCK1) has also been 
reported to play a critical role in leptin signalling by phosphorylating JAK2 via a direct ROCK1-JAK2 
interaction [285]. Following dimerization, the activated STAT3 translocates to the nucleus where 
it binds to the target gene to bring about a change in transcription. The promotor region of both 
AgRP and POMC contain a domain for STAT3 binding which then activates the transcription of 
POMC whereas inhibits the transcriptional activity of AgRP [286]. 
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It was shown that mice with a targeted mutation at the tyr1138 of the LepRb (s/s mice) were 
hyperphagic and obese but unlike mice with neural STAT3 deletions had normal body growth and 
fertility [287]. Mice with selective neural deletions of STAT3 like db/db mice, not only developed 
hyperphagia and obesity but were also defective in body growth and reproduction [152, 288]. 
These investigations indicate that STAT3-independent signals may be responsible for leptin 
mediated neuroendocrine regulation. JAK2/STAT3 pathway of leptin action has also been shown 
to suppress the orixigeneic AgRP/NPY neurons [287, 289]. Disruption of JAK2/STAT3 in mice with 
mutation at Tyr1138 (s/s), results in an increased transcription of AgRP and NPY mRNA’s and 
increased weight gain [162].  
Additionally, LepRb signalling is shown to be affected by two adaptor molecules – SOCS3 and PTP-
1B. These molecules when activated induce a negative feedback regulation resulting in an 
inhibition of tyrosine phosphorylation of LepR [290, 291]. Gene expression of SOCS3 is increased 
by STAT3 mediated leptin signalling which in turn binds to Tyr985 blocking leptin signalling. Initial 
findings demonstrated the involvement of Tyr985 for recruitment of SOCS3 [284, 291]. However, 
more recent studies suggest multiple binding sites within LepR [292]. Similar to SOCS3, leptin 
signalling results in an up-regulation of PTP-1B. Deletion of either Socs3 or Ptp1b in POMC neurons 
leads to reduced adiposity, improved leptin sensitivity, and increased energy expenditure under 
HFD conditions [289, 293]. Moreover, changes in SOCS3 as well as PTP-1B expression in line with 
negative feedback mechanism of leptin signalling have been implicated in development of leptin 
resistance in relation to hyperleptinaemia observed in most cases of obesity [164, 165, 294]. 
PI3K signalling 
In addition to JAK2/STAT3 pathway, activation of LepRb stimulates the phosphatidylinositol 3-
kinase (PI3K) pathway in the hypothalamus [295].  Autophosphorylation at position Tyr813 by 
JAK2 causes binding of Src homology 2 B adapter protein 1 (SH2B1) that markedly increases JAK2 
catalytic activity thus helping in recruitment and activation of downstream insulin receptor 
substrate proteins (IRS-1, IRS-2, IRS-4) to the LEPRb- JAK2 complex  [296]. IRS’s bind to the p85 
regulatory subunit of PI3-kinase (PI3K) and activation of PI3K through a sequence of events leads 
to phosphorylation of FOXO1. Upon phosphorylation, FOXO1 leaves the nucleus to allow STAT3 
binding to enhance the expression of AgRP/NPY and suppresses the expression of POMC (Figure 
1.3) [297]. Hyperphagia accompanied with increased adiposity and hyperleptinaemia in IRS2-null 
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mice, provide evidence for a plausible participation of the IRS/PI3K cascade in leptin action [298]. 
The role of FOXO1 transcription factor in mediating IRS2/PI3K signalling to control energy balance 
may also explain the link between the downstream insulin and leptin signalling pathways [299, 
300]. Furthermore, the overlapping PI3K pathways of leptin and insulin provide a possible 
explanation of the concomitant leptin and insulin resistance encountered so often in common 
obesity [126].  
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Figure 1.3 Leptin signalling pathway in the arcuate nucleus. 
STAT3 activation and dimerization that take place after leptin’s binding to LepRb allow p‐STAT3 to enter in 
nucleus and bind to promotor regions of Pomc and Agrp to stimulate Pomc and inhibit Agrp expression. 
Activation of PI3K by leptin facilitates activation of phosphatidylinositol-3,4,5-triphosphate (PIP3) which in 
turn leads to the activation of  downstream targets such as Akt mediated by phosphoinositide-dependent 
kinase 1 (PDK1). Akt activation finally phosphorylates the transcription factor forkhead box protein O1 
(FOXO1) and makes it depart from the nucleus and allows STAT3 to bind to Pomc and Agrp promoters. 
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Within the hypothalamic arcuate nucleus (ARC), leptin acts on two functionally opposing 
populations of neurons. One population of neurons synthesizes and releases three orexigenic 
neuropeptides: the agouti-related peptide (AgRP), the neuropeptide Y (NPY) and GABA [162, 287, 
289]. The other set of neurons expresses genes that encode the POMC which is post-
translationally cleaved to produce α- and β-melanocyte-stimulating hormone (α- and β-MSH). α-
MSH acts as an anorexigenic signal and promotes energy expenditure by activation of 
melanocortin-4 receptor (MC4R) and to a lesser extent the melanocortin-3 receptor (MC3R) [301, 
302]. POMC producing neurons also express cocaine and amphetamine-related transcript (CART). 
Both subsets of neurones in ARC are reciprocally regulated by leptin and make numerous 
connections with other hypothalamic nuclei, including the LH, PVN, VMN and DMN [189, 272]. 
Thus, the leptin-driven regulation of food intake results through a suppression of orexigenic and 
an induction of anorexigenic neuropeptides. Leptin exerts most of its effects on energy 
homeostasis through its long-form of receptor, LepRb, which is highly expressed in hypothalamic 
nuclei and other CNS regions involved in the control of energy balance [282]. In mice, ablation of 
LepRb in either POMC, AgRP, or both populations of neurons results in increased adiposity 
indicating the importance of leptin signalling in these neurones [303, 304]. However, the extent 
of adiposity observed is less than that observed in mice with global ablation of the receptor, 
demonstrating the involvement of other populations of LepR expressing neurons in the brain and 
indicating that leptin may act through different and independent neural systems to influence body 
weight and energy balance [287].  
PVN has been shown to be a key site for LEP/LEPR signalling for regulation of food intake and 
energy balance. Electrolytic lesions in this part of the brain are accompanied by hyperphagic 
obesity. Release of α-MSH by POMC neurons, promotes satiety by binding to these melanocortin 
4 receptors (MC4Rs) whereas inverse agonist of MC4R, AgRP, stimulates feeding. Expression of 
the transcription factor, SIM1, is shown to be necessary for normal PVN development and 
function. Partial deletion in the SIM1 evokes decreased cellularity of PVN [305] and is associated 
with obesity due to increased food intake and neurobehavioral abnormalities. 
Apart from well researched leptin driven melanocortin pathway in the hypothalamic area of the 
brain, evidence has been derived in the recent past of the existence of a leptin-independent 
melanocortin activation. Monogenic mutations and genetic manipulations influencing the brain-
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derived neurotrophic factor (BDNF) and 5-hydoxytrytamine (5-HT) systems that result in obesity, 
indicate their involvement in energy homeostasis and body weight regulation [273]. Several lines 
of evidence are available linking BDNF signalling to energy balance in humans and rodents through 
its functional interactions with central as well as brainstem anorexigenic pathway. BDNF mainly 
expressed in VMH neurons acts as a downstream metabolic effector of MC4R signalling to 
mediate its role in the homeostatic control of food intake and body weight [223] [306]. Recent 
investigations also nominate 5-HT in regulation of energy homeostasis by activation of its specific 
receptors on POMC and AgRP neurons. BDNF-5HT signalling similar to that of leptin may, 
therefore, be regarded as a component of the central melanocortin system (Figure 1.4) [273].  
Nonetheless, leptin undoubtedly appears to play the dominant role in driving the melanocortin 
signalling pathway, as its deficiency or that of its receptor, leads to one of the most severe types 
of obesity and hyperphagia, at a very early age.  
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Figure 1.4 Neurocircuitry involved in energy homeostasis. 
Neurones present in hypothalamic arcuate nucleus as well as in NTS are major respondents of peripheral 
signals such as leptin. In the state of positive energy balance, leptin activates anorexigenic (POMC) 
neurones and inhibits orexigenic (AGRP) neurones. Activated POMC neurones after cleavage and 
processing by PCSK1 give rise to MSH (not shown) that in turns serves as ligand for MC4R in PVN. Neurones 
in PVN such as oxytocin after activation inhibit feeding. Also VMH (not shown), which is a key site of BDNF 
expression, mediates downstream MC4R signalling to reduce food intake. Leptin responsive GABAergic 
neurones also mediate reduction in food intake though inhibiting downstream neural circuit that drive 
feeding. Collective effect from all these nuclei in conveyed to reward centre to modulate food intake (From 
Morton, Meek et al 2014 [307]). 
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1.6 Molecular approaches for diagnosis of obesity 
1.6.1 Mutation screening from Sanger to next-generation sequencing 
In 1976-77 Fredrick Sanger and his colleagues developed a nucleic acid sequencing technique that 
would be a watershed moment in the field of genetic analysis. The technique now generally 
known as Sanger sequencing was originally referred to as the ‘dideoxy sequencing’ or ‘chain 
termination sequencing’ [308]. The technique is based on chain termination chemistry—namely 
the dideoxynucleotides that contain hydrogen on the 3’ carbon instead of a hydroxyl group (OH) 
when integrated stop phosphodiester bonding between the dideoxynucleotide and the next 
nucleotide sequentially, and prevent further chain extension. Sanger sequencing undoubtedly 
proved a trailblazer for today’s innovative advancements in rapid and high-throughput 
sequencing techniques. Four decades after its discovery, Sanger sequencing is still considered the 
gold standard for nucleic acid sequencing and remains an important method for molecular genetic 
testing and validation for next generation sequencing results in most of the laboratories around 
the globe.  
In 2003, the entire human genome was successfully sequenced unlocking the code of human life. 
The accomplishment of the ‘Human Genome Project” marks it as one of the greatest feats in the 
history of human endeavour. Nucleotide analysis of the entire genome was carried out by using 
conventional (Sanger) sequencing and the first capillary-based automated sequencing 
instrument. Accurate and longer read lengths made possible by this procedure were of significant 
advantage in the absence of a template or reference sequence at that time. However, this first 
generation sequencing method used in the human genome sequencing, proved cost intensive and 
time consuming particularly for large scale genetic screenings. Since then efforts have been made 
to develop high throughput and cost effective sequencing technologies that offer technical and 
economic advantages over previous screening methods and could provide faster ways to identify 
genes and genetic variants of pathogenic significance. The advent of massively parallel sequencing 
(MPS) technologies developed in recent years have indeed made it possible to generate large 
amounts of sequence data rapidly and bring it down to a single-base resolution in a short time 
period at the scale of the whole human genome [309]. In principle, these newer technologies 
follow the same general concept as that of Sanger chemistry and CE sequencing. The main 
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difference lies in that newer technologies allow sequencing of millions of fragments in a massively 
parallel way as compared to sequencing of single DNA fragments as seen in CE. MPS has 
undoubtedly revolutionized the sequencing capabilities and has led to the development of next-
generation sequencing (NGS) technologies [310].  
Rapid advancements in terms of efficiency and cost effectiveness in NGS sequencing technologies 
is obvious from the fact that a single base sequencing run rate has climbed to one gigabase in 
2005 and to 1.8 terabases in 2014 and has drastically reduced the cost of sequencing in terms of 
both money and time. NGS has enabled sequencing at population level and expedited discovery 
of genes and genetic variants associated with disease and to gain insights into the etiology of 
disease susceptibility [311]. 
Whole Genome Sequencing (WGS) is a powerful sequencing approach that enables 
characterisation of all protein coding and noncoding variations spanning across the genome. This 
technique has the capacity to identify genetic variations associated with a vast number of 
diseases, yet relatively high costs involved have restricted its wider use. As the cost of sequencing 
continues to drop with time it is hoped WGS will become a method of choice in the foreseeable 
future. 
Whole Exome Sequencing (WES) technique is used to sequence all protein-coding regions in the 
whole genome (exome capture) and is now in fairly wide use. Since less than 2% of human 
genome contains majority (~85%) of the disease causing genes, WES, therefore, provides a cost-
effective alternative to WGS, to identify candidate genes and mutations associated with various 
disease conditions [312] especially those that follow Mendelian inheritance. WES, has recently 
emerged as a useful diagnostic tool for disease gene identification [313-315]. In the recent past 
use of whole exome analysis in subjects carrying Mendelian mutations, has identified more than 
100 causative genes [311, 316, 317] thus establishing the sensitivity and accuracy of the technique 
as well as its utility in clinical settings [318, 319]. 
Sequencing of targeted regions involves sequencing a subset of genes or genomic region of 
interest, enabling cost-effective and efficient detection of variants. This approach permits 
researchers to achieve excellent coverage (100x or higher) and thus allows identification of 
rare/novel variants that could be missed by WES and WGS. This method has already proven its 
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usefulness in clinical diagnostic testing by targeting selected genes to accommodate specific 
clinical needs. 
A wide range of kits for targeted sequencing (including WES - since in principle it also comes under 
the category of targeted sequencing) are commercially available. These kits support one of the 
two main methods for DNA isolation and enrichment of targeted sequence from the human 
genome namely those that are hybridization based or those that are amplicon/multiplex PCR 
based. 
Target enrichment through hybridization allows capturing a region of interest by hybridization 
to bionylated probes followed by magnetic pulldown. There are several commercially available 
enrichment systems that follow this principle. SureSelect and HaloPlex Target Enrichment 
provided by Agilent Technologies and Nextera Rapid Capture Custom Enrichment Kit offered by 
Illimina are highlighted amongst others. 
Enrichment through amplicon generation allows enrichment of desired genes/regions by primer 
based PCR amplification. In most of the cases highly multiplexed PCR oligo sets are used to obtain 
amplicons of interest for subsequent MPS. There are several commercially available amplicon-
based kits in the market, including Ion AmpliSeq (Life Technology, Carlsbad, CA, USA), TruSeq 
(Illumina, San Diego, CA, USA), Microdroplet PCR (RainDance Technology, Billerica, MA, USA) and 
Access Array (Fluidigm, San Francisco, CA, USA). 
Microdroplet PCR (RainDance Technologies Inc., Billerica, MA, USA) implies microdroplet-based 
multiplex polymerase chain reaction (PCR) technology (RainDance). This technique provides for 
amplification of a large number of targeted regions in a cost/time effective manner and is 
considered ideally suited for identification of monogenic/rare mutations. Here primer library is 
combined with each sheared genomic DNA sample into droplets on a RDT1000 platform. Droplets 
are collected and amplified through PCR. Amplification products are recovered by breaking the 
emulsion (Figure 1.5). The Access Array system developed by Fluidigm, on the other hand, uses 
an integrated fluidic circuit (IFCs) and controllers to process samples. Before PCR is performed, 
the samples and primers are combined in the pre-PCR IFC Controller AX, which is then placed into 
the FC1 Cycler for amplification. Ion AmpliSeq and TruSeq use a highly multiplex PCR method to 
amplify regions of interest.  
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Likewise there are several different next generation sequencing platforms available in the market. 
Each one employs a different sequencing chemistry such as pyrosequencing by Roche 454, 
reversible dye terminator chemistry by Illumina/Solexa and sequencing by ligation that has been 
introduced by Life Technologies. Demand of highly efficient and low cost technologies has   
resulted in development of several novel technologies leading to an era of third generation 
sequencing. As expected, the third generation sequencing platforms are characterised by new 
chemistry allowing less operation time and low cost. There are three noticeable third-generation 
sequencers in use: the Pacific Biosciences’ realtime single molecule sequencing (PacBioRS) [320, 
321], Complete Genomics’ proanchor hybridization and ligation (cPAL) [322, 323], and Ion Torrent 
of Life Technologies Inc [324]. Recently, Oxford nanopore technology has employed a totally 
different sequencing approach where alterations in conductivity across the nanopore are 
measured as single DNA molecules pass through the membrane. In short, there has been an 
exponential improvement in the NGS technologies over the past few years in terms of efficiency 
and cost. 
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Figure 1.5 Microdroplet PCR-based target enrichment (RainDance technology) workflow. 
 
 (A) Primer library (forward and reverse primers) for each genes/regions of interest is designed using a 
proprietary pipeline. (B) Genomic DNA is fragmented, purified and end-repaired. (C) Purified genomic DNA 
droplets and primer pair droplets coated flow through the designated channels of the microfluidic chip of 
RDT1000 platform and reach the merge area where an induced electric field make two discrete droplets to 
combine to make a  PCR droplet. (D) PCR droplets directly collected into a PCR tube are amplified on 
standard thermal cycler followed by emulsion breaking to release the PCR amplicons followed by 
purification and NGS sequencing. (From Tewhey, Warner et al. 2009 [325]). 
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1.6.2  CNV detection and validation  
Copy number change at genome wide level can be inferred by employing array based techniques 
such as array competitive genome hybridization (aCGH) or genome wide SNP array. CNV’s from 
targeted region of interest can also be detected by using multiplex ligation-dependent probe 
amplification (MLPA) or quantitative real-time PCR assays. Both techniques offer non-array based 
procedures for CNV detection. 
1.6.2.1   Array based techniques 
Array based methods such as array comparative genomic hybridization (aCGH) as well as SNP 
microarrays technologies infer copy number changes by comparing the test sample to an 
appropriate reference sample or population.  
Array competitive genome hybridization (aCGH) 
Platforms for this assay rely on the principle of comparative hybridization of test and reference 
samples. The signal ratio of both reference and test samples is normalised and is used to infer 
changes in copy number in the test sample. An increase in this ratio at any region will represent 
an increase in copy number in the test sample compared with the reference and similarly a 
decrease would signal a loss in copy number. Obviously use of well characterized reference 
sample is very crucial for accurate interpretation of data generated by array CGH [326].  
SNP microarrays technologies  
SNP arrays also follow hybridization method but unlike aCGH, these are performed on a single 
sample per array. In SNP genotyping arrays, highly specific probes are designed complementary 
to the test DNA with a difference in one nucleotide. The bases of interest are detected by single 
base extension method (Illumina) or by differential hybridization (Affymetrix). Since the 
genotyping data presented in this thesis have been generated on the Illumina platform a brief 
introduction to the Illumina workflow and data output is given as follows. 
Illumina utilizes the proprietary beadchip technology. An individual infinium bead assay 
genotypes a locus using two colors read system where one colour represents each allele. More 
than 5 million genotypes for a single individual can be assayed simultaneously on the surface of 
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each bead chip. These silica beads housed in with carefully framed micro wells are coated with 
oligonucleotides probes that target a particular locus in the genome. Sample DNA fragments are 
allowed to hybridize with the probes attached to bead chip and each probe would bind to a 
complimentary sequence in the sample on a location one base prior to the locus of interest. Allele 
specificity is conferred by a single base extension that incorporates one of the four labeled 
nucleotides followed by fluorescent staining. Once laser excites the nucleotide, the labels emit a 
signal that is detected by illumina scanner. Intensity value of each color conveys information of 
the allelic ratio. Data can then be analysed by GenomeStudio software to call genotypes and 
evaluate copy number variations across the genome (Figure 1.6). 
 
 
 
 
 Figure 1.6 Schematic representation of the Illumina Infinium assay genome-wide SNP genotyping 
workflow. (From www.Illumina.com). 
  
 
 S Saeed 
 
 
  
67 
 
 
  
 
For each SNP the two color-read out system gives an intensity value corresponding to each color. 
Polar transformation of these intensity values provides us the normalized intensity value (R), and 
allele intensity ratio (θ). Using these parameters on genoplot, LogR ratio and B Allele frequencies 
can be determined. 
Log R ratio (logged ratio of the observed R) representing ratio of the sum of normalized signal 
intensity at each locus to the expected, is a matrix that normalises the signal intensities for CNV 
analysis. Expected allele frequency is computed by linear interpolation of the observed allelle 
intensity ratio (θ) with respect to three canonical genotype clusters (genotypes AA, AB, and BB) 
from normal population data. A log base 2 transformation of this ratio yields the log R ratio: 
Log R Ratio= log2(R observed/R expected) 
The BAF represents the frequency at which the B allele is called at a SNP, interpolated from the 
θ, by using the formula given below: 
 
Eq no.  Sample Ɵ is B Allele Freq 
1 <mean Ɵ of AA cluster 0 
2 between AA and AB 0.5(θSNP - θAA)/( θAB- θAA) 
3 between AB and BB 0.5 + 0.5(θSNP - θAB)/( θBB- θAB) 
4 >mean Ɵ of BB cluster 1 
 
Generally, both BAF and LRR are taken into account to determine CNV’s. For BAF, deviation from 
0, 0.5, or 1 (alleles AA, AB, and BB, respectively) may suggest the presence of an imbalance of 
copy number whereas, deviation of the LRR from an average of 0 suggests a higher or lower signal 
intensity than expected in the two chromosome copies (Figure 1.7). 
Various statistical tools have been developed and used to analyse genotyping array data to infer 
copy number. These software packages/tools employ a range of statistical modelling approaches. 
An often used model for such analytical softwares is the Hidden Markov Model (HMM) that 
integrates data from multiple sources to infer CNV calls. Thus this model is designed to detect 
CNV by determining the hidden sequence of copy number state from observed LRRs and BAFs. 
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The software tools for CNV that implement HMM  include QuantiSNP [327], PennCNV [328] and 
GenoCN [329]. Among these, PennCNV is more efficient in identifying large CNVs and  generally 
has  the lowest false discovery rate as compared to other similar tools [330]. 
 
 
Figure 1.7 Derivation of the Log R Ratio (LRR) and B allele frequency (BAF) signal intensity measures by 
Illumina's GenomeStudio Algorithm. 
The BAF is calculated using the subject theta value and a linear interpolation of the cluster defined B-allele 
frequencies assigned to each cluster (0.0, 0.5.1.0). LogR ratio (log2 R ratio) is calculated as a ratio of 
observed normalised subject intensity to expected intensity. Where expected, intensity is calculated from 
observed allelic ratio with respect to linear interpolation of canonical genotype clusters AA, AB and BB. 
(Modified from Peiffer, Le et al. 2006 [331]). 
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1.6.2.2 Non-array based techniques  
Multiplex Ligation-dependent Probe Amplification (MLPA) 
Multiplex ligation-dependent probe amplification (MLPA) is a multiplex polymerase chain 
reaction-based method to infer copy number change in the desired regions. It is most frequently 
used non-array based method that provides a rapid and cost-effective procedure for copy number 
quantitation. Frequent use of this technique is also seen for validation of CNV detected by 
sequencing and genotyping data [256, 257]. Methylation-specific MLPA (MS-MLPA) has also been 
employed to detect changes in both DNA copy number and DNA methylation [332]. This 
technique has proved its usefulness for detecting disease related to imprinting disorders [333] . 
A notable feature of MPLA that distinguishes it from other non-array based CNV detection 
methods is that in MLPA assay the probes attached to target sequence are amplified. The resulting 
products are fragments of different length (130 - 480 nt in length) that can be detected and 
analysed by capillary electrophoresis (Figure 1.8). Analysis of data includes normalizing peak 
values and comparisons with peak patterns obtained from reference samples to identify change 
in copy numbers. Analysis of MLPA can be performed by MLPA analysis software such as 
coffalyser.net (developed at MRC-Holland). 
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Figure 1.8  Multiplex Ligation-dependent Probe Amplification (MLPA). 
Each probe set contains two specific oligonucleotides – short and long. The long probe neucleotide has 
stuffer seuence of variable length. In the first step the probes are hybridized with genomic DNA. Single 
base PCR reaction with one primer pair performs ligation reaction that is followed by PCR amplification 
with fluorescent labelled universal primer pair. High resolution capillary electrophoresis enables separation 
of PCR prodeucts in the form of electropherograms that are then normalised to infer copy number change 
in the test sample. (From www.mlpa.com). 
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Quantitative real-time PCR or real-time PCR (RT-PCR) is a refined version of the conventional PCR. 
It is used to amplify a targeted DNA segment and to simultaneously quantify the amplified product 
by monitoring the increase in fluorescence dye as the reaction progresses and the PCR product 
accumulates.  
Conventionally qPCR is carried out by binding of a dye (such as SYBR Green) to the double 
stranded DNA [334], and each PCR cycle results in an increase in fluorescent intensity that is 
measured with a detector [335]. The method provides low cost and rapid detection of any change 
in DNA. Real time qPCR method was improved by employing a labelled probe complementary to 
the target DNA sequence such as in qPCR assays based on TaqMan chemistry (Applied Biosystems) 
[336]. These fluorogenic probes eliminate chances of any non-specific binding. qPCR can be used 
with advantage 
 for amplification of a region of interest with unknown copy number and a reference locus with 
known copy number using equal quantities of total starting DNA of each of the samples.  
Other widely applied techniques for copy number detection include conventional karyotyping and 
fluorescent in situ hybridization (FISH) [337] and digital PCR (dPCR). The latter technique has 
greatly improved the limit of detection for copy number change and has been regarded to have a 
high level of accuracy for CNV analysis [338, 339]. 
1.6.2.3  Additional approaches for identification of highly penetrant or Mendelian 
mutations 
Identification of a causative genetic variant for a disease that follows Mendelian inheritance 
seems to be less laborious compared to conditions that arise due to multigene effects. 
Nonetheless, investigating monogenic variants causing human disease still remains a major 
challenge.  
Among the different approaches that have been adopted to identify causative mutations in 
monogenic disease, position mapping is a significant procedure that has resulted in determining 
a large number of genes associated with Mendelian diseases [340]. Position mapping identifies 
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physical locus of the gene in the human genome in a hypothesis free manner. There are two main 
methods through which position mapping can be achieved – linkage analysis and autozygosity 
mapping.  
Positional mapping approach initially relied on genotyping of highly polymorphic microsatellites 
markers (STR) to pin down potentially causative intervals by a rather laborious process. The use 
of microsatellite markers has now been replaced by high-density genome-wide single nucleotide 
polymorphism (SNP) array offering a rapid and relatively accurate identification of chromosomal 
regions. The present era of  NGS technologies has once again revived interest in  genetic mapping 
to identify disease genes [341].  
Several groups are taking advantage of the power of linkage analysis and homozygosity mapping 
and performing NGS experiments in parallel with these positional mapping techniques for the 
identification of disease genes. More recently attempts have been made to infer mapping from 
sequencing data [342]. 
Linkage analysis 
Linkage analysis involves the mapping of those genomic regions that have a tendency to be 
transmitted together to the next generation without undergoing recombination during the 
meiosis event. The technique has been widely in use for many years as a first step in identifying 
the location of rare variants associated with a disease that follows Mendelian inheritance. It 
permits assigning numerical values to these regions in the form of LOD (logarithm of odds), which 
is a statistical presentation of a likelihood of that region being linked hence inherited together, 
and also reflects the probability of a certain region encompassing the disease gene. LOD score of 
3 (or sometimes 3.3) is conventionally used as a cut-off that corresponds to a sample significance 
level of 0.0001 [343, 344]. However, large pedigrees with multiple affected individuals are needed 
to efficiently perform such an analysis.  
Although this approach did not seem much useful for identifying recurrent genomic regions that 
accounts for milder form of obesity [345] as described above in the polygenic obesity section, it 
has been a highly effective strategy for identifying rare loci that carry variation exhibiting large 
effect. More recently cost effective availability of NGS has revived the interest in utililising this 
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approach to attain causative variant identification so that linkage analysis is once again in the 
forefront of studies on familial genetics [341].  
Homozygosity mapping 
In the context of autosomal recessive disorders, consanguinity offers a powerful approach/tool 
for disease gene mapping called homozygosity mapping  [346].  Homozygosity mapping is a 
variation on linkage analysis that relies on the fact that the affected individuals from a 
consanguineous parentage are expected to be homozygous for causative alleles identical by 
descent (IBD). Homozygosity is not only confined to the specific disease locus but extends to the 
region spanning the disease locus. Searching for such blocks of homozygosity (regions of IBD) that 
are exclusively shared by the affected individual/s are expected to provide a powerful way to infer 
the candidate regions that include the associated allele/variant.  
High-density single nucleotide polymorphism (SNP) array data can now be used to infer genome-
wide homozygosity directly, by detecting contiguous homozygous segments in the genome 
referred to as genomic runs of homozygosity (ROH). Such ROH regions that are common in human 
population are assumed to be homozygous-by-descent [347] and can be inferred by publically 
available packages such as Plink [348]. 
In this era of next generation sequencing, this approach has been further revamped by pairing 
with WES or WGS experiment. This powerful approach of homozygosity mapping has provided us 
with additional evidence in our attempt to identify causative genetic variant in recessive disease 
aiming to narrow down the list of variants and to allow us to focus on only those genetic variants 
that lie in a critical locus homozygous in the affected subject. This provides a useful lead in the 
quest to identify the causal variant thus warranting their identification in inbred families as 
exemplified by Schrader et al [349], Puffenberger et al [350] and Wang et al [351] amongst several 
others. 
Inbreeding and inbreeding depression 
Inbreeding may be defined as ‘production of offspring from the mating of individuals related by 
lineage’. Charles Darwin who published his theory of evolution, in ‘Origin of Species’ in 1859, was 
perhaps the first person to point out and document the harmful effects of inbreeding. In the same 
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era (late 19th century) the investigation of genetic transmission of characters or disease had also 
begun to emerge through the work performed by Gregory Mendel mainly through his breeding 
experiments on pea plants. Mendel, by taking into account the characteristics of the progeny, 
determined the inheritance of single traits as transmitted from parents to the offspring that are 
now referred to as the laws of Mendelian inheritance. The negative effects on fitness traits due 
to inbreeding can now be explained on the basis of increased chances of holding two mutated 
copies of an ancestral allele and an increase in homozygosity of such deleterious mutations leads 
to what is generally termed as inbreeding depression. 
1.7 Global distribution of known consanguineous populations and major 
communities  
The risk of carrying congenital abnormalities has been estimated to be ~2 times greater in 
offspring of consanguineous parents than those of unrelated parents [352, 353]. Moreover, 
consanguinity/inbreeding is considered to be the single most common cause of genetically related 
mortality due to increased chances of homozygosity of deleterious recessive mutations [354]. 
Regardless of the knowledge that inbreeding increases the risk of serious recessive disease, 
consanguineous marriages are the norm in 10 percent of the population and are widespread in 
many parts of the world [355]. The most predominant form of consanguinity is the first cousin 
union. 
Presently, consanguineous unions are frequent in countries of Asia, Africa and the Middle East 
and in many smaller populations confined to certain geographical isolates [354, 356]. While these 
marriages are considered rather unusual in modern Western culture, consanguinity was not 
uncommon in the West until the latter half of the 19th century [357]. Although there is no 
religious restriction in most of the religions, consanguineous marriages are predominantly 
common in Muslim majority countries [358]. Whereas a decline in the practice has been observed 
in parts of Asia, Africa and the Indian subcontinent during the past years, there has only been a 
slight drop of consanguinity in the Muslim countries [6, 352, 359, 360]. Preference for 
consanguineous marriage amongst Muslim communities appears to be due to social and cultural 
traditions, rather than religious considerations. 
 S Saeed 
 
 
  
75 
 
 
  
 
 
 
 
Figure 1.9 prevalence of consanguinity in countries around the world. 
Pakistan (by arrow) has >50% frequency of consanguineous marriages. (From Romeo and Bittles 2014 
[361]). 
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Pakistan, a South Asian country, has one of the highest rates of inbreeding and prevalence of 
marriages between cousins or close relatives has been estimated to be between 60-70% cases 
[362, 363] (Figure 1.9). The practice is more predominant in rural areas and village isolates [354] 
and has been preferred over generations due to social and economic advantages such as 
protection of wealth, land and property and preservation of family norms and traditions [364]. 
Pakistan's population comprises many ethnic groups as a result of successive waves of migration 
from its neighbouring countries, mainly Iran, Afghanistan and India, during its history. The major 
ethnic groups include Punjabi, Sindhi, Pashtun, Baluchi and Mohajirs [354]. This ethnic 
composition also corresponds to the linguistic and to a large extent regional distribution. These 
major ethnic groups are composed of castes or sub-ethnic groups [356, 365]. 
Studies in UK showed that incidence of congenital anomalies and rates of infant deaths are 
markedly higher in children of Pakistani origin as compared to those of British and other 
ethnicities [353, 366]. A large study to estimate the incidence of congenital abnormalities in 
different ethnic groups was conducted in Bradford on pregnant mothers and babies born between 
2007-2011 (the Born in Bradford Study) [353]. In this investigation, of 5127 babies born to 
mothers of Pakistani origin, 1922 (37%) were the outcome of first cousin unions. The study 
reported mortality in 9.7 per 1000 children of Pakistani origin as compared with a national rate of 
5 in 1000. Majority of the deaths in Pakistani children were ascribed to chromosomal, genetic and 
congenital anomalies [367]. The study concluded that consanguinity doubles the risk of incidence 
of congenital anomalies. Consanguinity has also been accounted as the major risk factor of 
heritable anomalies irrespective of the social and economic status or life style [353]. 
In a separate investigation Morton et al [368] reported a significantly higher incidence of severe 
disabilities including hearing loss, learning disability and visual impairment in Pakistani children 
from Derbyshire. The incidence of these disabilities was shown to be 2% in children of Pakistani 
origin as compared to 0.56 to 0.87% in children of other nationalities [368]. 
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1.8 Rationale and objectives of the study 
Although recent technological advancements have evidently accelerated the pace of disease gene 
identification, yet we are still way off to narrow down the gap of missing or unexplained 
heritability of obesity [43, 102]. In recent years, a large part of the successes in unravelling the 
genetic basis of obesity has been derived from studies of the extreme phenotype caused by a 
disruption of the neuroendocrine pathways controlling appetite and energy homeostasis [71]. 
Inbred human populations offer a unique background for the discovery of genetic factors 
underlying many of the heritable anomalies including obesity. Indeed the first direct evidence of 
a homozygous recessive mutation in a gene (LEP) associated with severe obesity in human came 
from a consanguineous family of Pakistani origin [125]. Chances of occurrence of a deleterious 
recessive mutation in an individual in the homozygous state depend largely upon the level of 
inbreeding.  Study of homozygosity in individuals with a long history of consanguinity, has shown 
that 11% of their genome may be homozygous resulting in a high risk of incidence of autosomal 
recessive disease [363]. Indeed, cousin marriages cause union of genomes, 1/8th of which is 
similar, leading to an increase in the coefficient of inbreeding (percentage of genome that is 
homozygous or identical by descent) and greater chances in incidence of recessive disorders in 
the offspring [369]. It is expected that genetic analysis of consanguineous families that has led to 
the identification of a number of rare variants with large effect could also be helpful in revealing 
recessive variants with a small or subtler effect size. 
No systematic analysis to elucidate genetic causality of severe obesity has so far been carried out 
in specific predominantly consanguineous populations. Previously only 4-6% of randomly selected 
severely obese patients have been identified with monogenic obesity. Undertaking an intensive 
search to identify the genetic basis of severe obesity in a consanguineous population like that of 
Pakistan, therefore, appears in order to not only in furthering our knowledge of the genetic basis 
of obesity, but also to possibly bring in focus potential molecular targets in the perspective of an 
emerging era of personalised medicine.  
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In the context of aforementioned the main objectives of the study are summarised, as follows 
 Estimate the proportion of monogenic forms of disease among cases of early onset severe 
obesity from a consanguineous population of Pakistan. 
 Identify known and novel genetic variants in previously identified candidate genes for 
monogenic obesity. 
 Elucidate the contribution of genomic structural variations in severe obesity.  
 Identify novel genes that have not previously been associated with severe obesity in the 
human. 
 Develop a rapid and cost-effective molecular diagnostics for severe obesity. 
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2. Chapter two 
 
 
Materials and Methods 
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2.1 Study subjects 
This investigation is based on 175 unrelated probands with early onset severe obesity with a BMI 
SDS for age ≥3 from consanguineous families. In addition, 380 family members were also included 
in the study. The subjects were mainly recruited from the Children’s Hospital Lahore, Mayo 
Hospital, Lahore, and Allied Hospital, Faisalabad, Pakistan, following patient/parent written 
informed consent. The study protocol was approved by the institutional ethical committees. 
During the period under review, I visited Pakistan at four occasions to work with physicians and 
collaborators where I made regular visits to outdoor paediatrics clinics to recruit new subjects. 
Moreover, field visits were arranged to get samples from the patients and/or their family 
members. Probands and/or their parents were interviewed to obtain their family and medical 
history and to construct pedigrees spanning at least 3 generations. Anthropomorphic 
measurements and physical examination were carried out and blood samples were obtained in 
each case for subsequent DNA extraction and hormone estimations.  
2.2 DNA extraction and quantification 
Initially extraction of genomic DNA from peripheral blood leukocytes of 82 probands and 184 
family members was carried out by myself using Gentra Puregene Blood Kit (Qiagen, Crawley, UK) 
as per instructions of the manufacturer. Subsequently I quantified the extracted DNA by 
NanoDrop (2000c, Thermo Scientific, Wilmington, DE, USA) and by qubit system. For DNA 
extraction of rest of the samples of 93 probands and 196 family members, DNA extraction facility 
from LGC genomic service (LGC Middlesex, UK) was used.  
 
 
2.3 Genetic analysis 
2.3.1 Screening of LEP and MC4R mutations 
At the first step of genetic analysis, I performed genetic screening for LEP and MC4R genes. Coding 
exons of both genes were amplified followed by Sanger sequencing using BigDye terminator kit 
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(Applied Biosystems, Foster City, CA, USA) on an ABI 3730xl DNA sequencer. Exons 2 and 3 of LEP 
were amplified using 2 sets of primers. Exon 2 forward primer, 5′-
GATGCATTTCATTAATACATATGTAG-3′ and reverse primer, 5′-
GTTTCTTGGACTATCTGGGTCCAGTGC-3′; exon 3 forward primer, 5′-GCACTTGTTCTCCCTCTTCCT-3′ 
and reverse primer, 5′-GTTCCTTCCCTTAACGTAGTCCT-3′. For exon 2, PCR was performed using 
AmpliTaq Gold (Applied Biosystems, Foster City, CA, USA), under the following conditions: 95° C 
8 min, followed by 39 cycles of 95° C 30 s, 56° C 40 s, 72° C 1 min 10 s, followed by 72° C 10 min. 
Amplification of exon 3 of leptin gene was performed by using Clontech (Clontech Laboratories 
Inc, Mountain View, CA, USA) under the following conditions: 95° C 1 min, followed by 30 cycles 
of 95° C 30 s, 68° C 1 min, followed by 68° C 3 min. Coding region of the MC4R was amplified using 
the forward primer 5′-GTGAGCATGTGCGCACAGATTC −3′ and the reverse primer 5′-
GATATTCTCAACCAGTACCCTACA −3′. PCR was carried out using BioTaq (Bioline, London, UK) 
under the following conditions: 95° C 2 min, followed by 35 cycles of 95° C 40 s, 56° C40 s and 72° 
C 1 m 20 s. PCR products were sequenced using BigDye Terminator kit (Applied Biosystems) and 
analysed on ABI 3730xl DNA sequencer. The sequencing reads were assembled and analysed by 
Mutation Surveyor DNA Variant Analysis software (SoftGenetics, State College, PA).  
2.3.2 Microdroplet PCR-based enrichment and next generation sequencing (NGS).  
To identify rare and novel variants in 27 genes associated with obesity, subjects that were found 
negative for LEP and MC4R mutations were further investigated by using PCR based microdroplet 
enrichment (RainDance Technologies) followed by NGS. The experiment was performed during 
my visit to CNRS UMR8199, Lille, France. 
2.3.2.1   Primer Library Design 
We selected 27 susceptible genes for monogenic and syndromic form of obesity from published 
material for this experiment. Table 2.1 provided the list of these genes. Subsequent to selection 
of genes, we designed the Primers for coding regions of all 27 genes included in the experiment 
using proprietary pipeline developed by RainDance Technologies (Lexington, MA). Moreover, 40 
bp of flanking region of each exon and 1000 base upstream and downstream of first and last exon 
respectively were also included. For primer designing following criteria were used: primer length 
between 15 and 33 bp; namely guanine-cytosine content between 25 and 80%; melting 
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temperature between 56 and 60 C; amplicon length between 200 and 600 bp. The 355 targeted 
exons from 27 obesity associated genes were covered by 664 primer pairs that were encapsulated 
into microfluidic droplets via RainDance Technologies. 
Laboratory work subsequent to primer designing that involved PCR enrichment and library 
preparation was performed during my visit to CNRS. Lille, France.  
2.3.2.2   Microdroplet-Based PCR Enrichment 
Three µg of DNA was fragmented to attain a length of 2–4 kb by sonication (Bioruptor NGS; 
Diagenode, Liege, Belgium) and purified using the MinElute system (Qiagen, Valencia, CA). The 
fragmented and purified DNA was assessed for quality and quantity by using the 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA) and ends were repaired. Subsequently, the primer library 
was combined with each sheared genomic DNA sample on the RDT1000 (RainDance 
Technologies), according to the manufacturer’s protocol. A microdroplet-based PCR of 664 primer 
pairs encompassing 355 coding exons was performed. To release the PCR product, destabilizer 
reagent (RainDance Technologies) was added that resulted in the degradation of the emulsion. 
This was centrifuged briefly to separate oil from PCR product, which was then subjected to 
purification using MinElute columns (Qiagen). Final assessment of both quality and expected 
amplification profile was assessed on the 2100 Bioanalyzer (Agilent Technologies). 
All samples enriched with targeted amplicons were sequenced on a HiSeq2000 (Illumina) in 
paired-ends. Reads were aligned to the Human Genome (hg19/GRC37) using the Burrows-
Wheeler Aligner. 
2.3.2.3   Library preparation and next generation sequencing 
End repairment and concatenation of PCR product in order to get blunt ends was performed by 
NEB Quick blunting kit and the NEB Quick ligation kit (New England Biolabs, Ipswich, MA). The 
samples were purified using Agencourt AMPure XP beads (Beckman Coulter, Fullerton, CA) and 
sonicated to achieve 200 bp fragments (Bioruptor NGS; Diagenode). Adaptors were ligated to the 
fragments by using NEBNext Multiplex Oligos for Illumina (New England Biolabs). Finally, the 
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amplicon-enriched samples were sequenced on the HiSeq2000 (Illumina, San Diego, CA) in 76-bp 
paired-end reads by multiplexing 12 samples per lane. 
2.3.2.4   Data Analysis 
Bioinformatics expertise at Lille (CNRS UMR8199) was used for data analysis sequence. Briefly 
demultiplexing of sequence data were performed with CASAVA (version 1.8.2). Reads were 
aligned to the Human Genome (hg19/GRC37) using the Burrows-Wheeler Aligner (BWA-SW, 
version 0.6.1). SAMtools (version 0.1.18; algorithm "pileup” was employed for the variant calling.  
2.3.2.5   Variant Prioritization 
Following detection of all variants in the targeted regions, I carried out the filtration steps focusing 
on novel, nonsynonymous and homozygous variations. Also, novel variants present in splice 
donor and acceptor site were considered. Furthermore, I focused on heterozygous variants on 
those genes that are reported to show dominant models and show their effect in heterozygous 
state as well. 
Any novel mutations identified by microdroplet-based PCR target enrichment and next generation 
sequencing were subsequently confirmed by me using conventional Sanger sequencing. 
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Table 2.1: List of genes for targeted sequencing using microdroplet PCR enrichment 
 
No Gene  Gene location 
No of 
amplicons 
Target size 
(bp) 
1 LEP 7q31.3 13 5,577 
2 LEPR 1p31 41 13,803 
3 MC4R 18q22 7 3,488 
4 MKKS 20p12 16 6,123 
5 MKS1 17q22 23 5,440 
6 NTRK2 9q22.1 59 22,705 
7 PCSK1 5q15-q21 29 9,761 
8 POMC 2p23.3 9 3,495 
9 SDCCAG8 1q43 22 5,517 
10 SIM1 6q16.3-q21 19 6,545 
11 TRIM32 9q33.1 13 5,819 
12 TTC8 14q31.3 20 4,953 
13 WDPCP 2p15 25 6,209 
14 ALMS1 2p13 45 16,072 
15 ARL6 3q11.2 15 3,953 
16 BBS1 11q13 24 6,123 
17 BBS2 16q21 22 5,664 
18 BBS4 15q22.3-q23 22 5,292 
19 BBS5 2q31.1 22 5,583 
20 BBS7 4q27 29 8,232 
21 BBS9 7p14 29 7,169 
22 BBS10 12q21.2 12 5,683 
23 BBS12 4q27 13 5,582 
24 BDNF 11p13 31 14,038 
25 CEP290 12q21.32 59 12,517 
26 GNAS 20q13.3 35 11,439 
27 SH2B1 16p11.2 10 6,692 
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2.3.3 Whole Exome Sequencing (WES) 
2.3.3.1   Target enrichment and library preparation 
A subset of probands and their family members that has previously been screened for 27 obesity 
associated genes by Sanger sequencing and RainDance targeted sequencing techniques was 
selected for WES. For target enrichment and subsequent library preparation, instructions 
provided in user manual were followed. First experiment for target enrichment and library 
preparation on 4 samples for WES experiment was performed by me in our laboratory of 
Genomics of Common Disease. Briefly, the genomic DNA samples were fragmented to 
approximately 200 bp fragments by sonication. Ends were repaired and adenine bases were 
added to the 3' end of the DNA fragments. Following this, we ligated the indexing-specific paired-
end adapter and amplified the adapter-ligated library. Hybridization: Following quality control, 
the prepared library was hybridized using SureSelect Human All Exon kit (Agilent Technologies 
Inc, Santa Clara, CA, USA). After hybridization in solution and capture on streptavidin-coated 
magnetic beads, the hybrid-selected DNA targets were purified by Dynal MyOne Streptavidin T1 
(Invitrogen, Life Technologies Ltd, UK) and PCR-amplified to add index barcode tags for 
multiplexing. Samples were pooled for paired-end sequencing spread across 8 lanes of flow cell 
(multiplexed). For rest of the 36 probands and 59 family members, the target enrichment and 
library preparation through the same procedure, was performed in Lille using Bravo automated 
liquid handling platform (Agilent Technologies). 
Bioinformatics expertise at Lille (CNRS UMR8199 & Institut de Biologie de Lille) was utilized for 
the analysis of the raw data. Briefly the reads were aligned to human genome build hg19 with 
CASAVA 1.8.2, variants were called using CASAVA 1.8.2 and GATK 2.5 and annotated with Ensembl 
v71 and dbNSFP 2.0.  
2.3.3.2   Variant Prioritization 
After variant calling and annotation, I implemented the subsequent filtering and bioinformatics 
variant analyses in order to identify causative mutations. Variants from each family were filtered 
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independently to identify specific homozygous mutation in that affected individual. For this the 
filtration steps mentioned in Figure 2.1 were performed (as described in chapter 6 section 6.3). 
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Figure 2.1 Step-wise filtration procedure carried out to identify causative variants. 
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2.3.4 SNP genotyping  
Genome-wide high-density genotyping was performed by us in our lab facility, by using the 
HumanOmni 2.5S BeadChip KIT (Illumina Inc., San Diego, CA, USA) that contains over 2.5 million 
variants with capture capacity down to MAF 2.5%. The experiment was performed following 
instructions provided by the supplier. Briefly, the samples were denatured and whole genome 
amplified up to 1000-fold. Fragmentation step was carried out to cleave DNA into segments of 
300-600 bp. DNA samples were purified and re-suspended prior to hybridization on bead chips 
followed by extension and staining (Xstaining). This procedure involves single base extension 
reaction using chain terminating dideoxynucleptides followed by the staining step. Subsequently, 
the beadchips were scanned and viewed on Illumina scanner to measure fluorescent intensity to 
enable genotype calls. 
2.3.4.1  Creating genotyping project in genome studio and subsequent genotype calling 
I created a genotyping project in the GenomeStudio using the standard cluster file and the 
genotypes were assigned to each SNP based on the florescent intensity data. One individual with 
less than 99% call rate was excluded from the study (Figure 2.2). Reproducibility and heritability 
report was also generated to make sure that parent to child heritability frequency (P-C Heritability 
Freq) is 0.99 or above. Finally the cluster file was exported and reports were generated for 
subsequent calling of runs of homozygosity as well as the CNV analysis. 
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Figure 2.2 Scatter plot of call rate against 10% GenCall score 
 Cluster at the right top corner depicts pattern of samples behaviour. Better value of p10 GC depicts high 
quality of the reads. 
 
 
2.3.4.1   Calling runs of homozygosity  
As mentioned in introduction (section 1.6.2.3), linkage analysis or ROH are used to perform 
positional mapping. However, linkage analysis presents its usefulness when performed on a 
relatively large family with 2 or more affected individuals. Among all the families that have been 
included in WES analysis, only one family had more than one affected individuals. Therefore, 
homozygosity mapping was performed in the present case. This procedure consists of searching 
for a region of the genome that is autozygous in the inbred affected individuals. I performed the 
mapping of homozygosity using Plink open source whole genome association analysis toolset. The 
genotyping data were subjected to quality control so as to a) remove individuals missing more 
than 5% genotype data; b) exclude SNPs minor allele frequency (MAF=0.05); c) exclude markers 
that fail to comply with the Hardy-Weinberg test at a specified significance threshold (HWE= 
0.001) and d) exclude individuals and/or markers, on the basis of Mendel error rate (ME=0.05 
0.1). Runs of homozygosity function (ROH) in Plink was utilized to identify regions where affected 
individuals were likely to have received twice the same ancestral ROH.  
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2.3.4.2   Copy number variation analysis by genotyping data 
For the copy number analysis, I exported the called genotypes, B allele frequency (BAF) and log R 
ratio from GenomeStudio using default clustering files for each SNP. PFB (population frequency 
of B allele) was calculated based on the BAF of each marker. Identification of CNVs in this data set 
was carried out by me using PennCNV, an algorithm which employs a hidden Markov model for 
CNV prediction [328]. The Perl script Clean_cnv.pl, also developed by PennCNV, was used to 
merge adjacent CNVs automatically in order to get large CNVs. CNVs identified by PennCNV were 
also checked for the presence using CNV Partition plug-in provided by illumina.  
2.4 Methods related to chapter 3 
2.4.1 Sanger sequencing to confirm mutation in LEPR  
Following identification of potential causative variants identified by targeted NGS sequencing, I 
confirmed the mutations for their presence by Sanger sequencing via the 3730 × l DNA Analyzer 
(Life Technologies, Carlsbad, CA, USA). Primers, encompassing region of interest were designed 
using primer 3 software (Table 2.2).  
 
 
Table 2.2: primers used to amplify LEPR regions of interest 
 
LEPR primers   
c.1675G>A  
Forward primer sequence - Exon 10 GATATTGCTTGATGAATACAGATG 
Reverse primer sequence - Exon 10 TCTAATGCAATTAAACTCTTACATATT 
c.1810T>A  
Forward primer sequence - Exon 11  TGTACTTCAGGGCCCTTTAGA 
Reverse primer sequence - Exon 11 GAAGCACACACTTATGCAC 
c.2396-1G>T  
Forward primer sequence - Exon 15 CTATTGTCATGACTAGATAATTAG 
Reverse primer sequence - Exon 15 CAATATTACTGCAAACAAATTAGGCAC 
c.40G>A  
Forward primer sequence - Exon 1 GAGACTTATCTATAATCCCTTTCC 
Reverse primer sequence - Exon 1 TTAGGAGGTTGGGAAGGGTTTT 
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Amplifications of LEPR exon 10 and exon 15 to confirm c.1675G>A and c.2396-1G>T mutations, 
respectively, were performed by using BioTaq (Bioline, London, UK). A 30 cycle PCR program was 
performed with denaturation at 95 °C for 30 sec, annealing at 56 °C for 40s and extention at 72 
°C for 90 sec. Finally elongation was performed at 72 °C for 10 min. While for confirmation of 
c.1810T>A mutation in exon 11 of LEPR gene and c.40G>A in exon1, amplification was performed 
using Clontech (Clontech Laboratories Inc, Mountain View, CA, USA) under the following 
conditions: 95 °C 1 min, followed by 30 cycles of 95°C 30 sec, 68°C 1 min, followed by 68°C 3 min. 
Sequencing reads were assembled and analysed for the presence of the variant using Mutation 
Surveyor DNA Variant Analysis software (SoftGenetics, LLC, USA).  
2.4.2 Characterization of 42 bp deletion mutation (c.1-2del42) in LEP 
To further characterise a 42 bp deletion in LEP, identified in one of the family through Sanger 
sequencing, 2 ml of blood was drawn in PAXgene Blood RNA tube and was shipped to me, under 
dry ice. I extracted the RNA from blood cells of the proband, his parents and sibling using PAXgene 
RNA Blood kit (Qiagen, Germany) in accordance with the manufacturer instructions. Following 
RNA extraction, I characterized the deletion mutation. Reverse transcription polymerase reaction 
(TR-PCR) was carried out to acquire full length cDNA fragments containing the coding regions of 
the LEP, using random 6-mers primer (2.5Um) and dNTP mix (10mM each; provided PrimerScript 
RT-PCR kit (TaKaRa, Ohtsu, Shiga, Japan) added to 1 µg of the template RNA and making up the 
volume to 10 µl. Denaturation/annealing was carried out at 65°C for 5min. A reaction mixture 
containing 4 µl of PrimerScript buffer (5x), 0.5 ul of RNAase inhibitor, and 0.5 ul of PrimerScript 
RTase and 5 µl of RNAase free water was added to 10 µl of denatured product. The condition of 
RT-PCR were set as follows: 30°C for 10 min, 42°C for 25 min followed by 95°C for 5 min. The 
synthesized cDNA was amplified using the following conditions: 94°C for 1 min; 45 cycles of 94°C 
for 30 sec, 65°C for 35 sec, and 72°C for 1 min.  
Gel electrophoresis, with 1% agarose gel, of the amplified product from heterozygous parents 
resulted in two bands corresponding to the mutated whereas one band was found in the sample 
from unaffected control subject. The bands from 3% agarose gel were excised using sharp scalpel 
and were purified by QIAquick Gel Extraction Kit (Qiagen, Germany) according to manufacturer’s 
protocol and followed by direct sequencing using primers as given in Table 2.3. 
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Table 2.3: PCR primers used to amplify cDNA of LEP. 
 
Primers to amplify cDNA  
 
5’ Primer Sequence - Exon 1 
 
CGCAGCGCCAGCGGTTGCAA 
 
3’ Primer Sequence - Exon3 GCTGCCACAGCATGTCCTGC 
 
2.4.3 Deletion mapping ~59 kb homozygous region in LEPR 
In this experiment I performed mapping of deletion break points. Long range PCR amplicon was 
generated using SequalPrep Long range PCR Kit (Invitrogen, Carlsbad, CA). PCR amplification was 
performed with following PCR conditions: 4µl of SequalPrep10X Reaction Buffer (including 
dNTPs), 2 µl of SequalPrep PCR Enhancer A, 0.8 µl of dimethyl sulfoxide and 0.4 µl of SequalPrep 
Long Polymerase. All were mixed and added to 1 µl of a 2.5 µmol/l of primer and reverse primers 
and 100 ng of genomic DNA. Thermal cycling was performed under following conditions: 94°C for 
2 minutes for activation followed by 10 cycles of 94°C for 10 sec, 66°C for 30 sec and extension at 
68°C for 3 min. This was followed by 25 cycles of 94°C for 10 sec, 64°C for 30 sec and 68°C for 3 
min with 20 sec increase in time every cycle, 72°C for 5 minutes and hold at 4°C. The amplicon 
was purified with ExoSAP-IT (USB) and sequenced using BigDye Terminator Cycle Sequencing kit 
(BigDye terminator kit Applied Biosystems, Foster City, CA). To identify deletion breakpoints, 
starting from last known undeleted region on the flanking side of the breakpoints, as identified 
by genotyping array (Figure 2.3), primers were designed using primer 3 (Table 2.4) and direct 
sequencing of amplified product was made. Breakpoints were detected by reading sequences 
using Mutation Surveyor DNA Variant Analysis software (SoftGenetics, LLC, USA). 
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Figure 2.3 Primer spanning and within deleted region 
Position of paired primers spanning and within the deleted region of the LEPR gene to  
identify deletions breakpoints.  
 
 
 
 
 
 
Table 2.4: Primers used to check for deletion breakpoints of 1.3 Mb and 5.8 Mb homozygous deletions. 
 
LEPR deletion primers   
  
Forward primer sequence 1 AGAGTTTGCTGATCCCAAGCTTAGAAC 
Reverse primer sequence 2  CTAGCATATATATGAGCATCCAG 
  
Forward primer sequence 3  CATTAAAGCCATGCAAATGTTGTTTC 
Reverse primer sequence  4 AAGATGTTTAGGATCTGCACATTG 
  
Forward primer sequence 5 GTCTTTACCACTTAAGGGGAGGGTAA 
Reverse primer sequence  6 GTTTAACAGCAGTATATATTTACTTG 
  
Forward primer sequence 7 TAAAATGCACAAGCCTTCGGTAT 
Reverse primer sequence  8 GAAAATTCTCTATCCACAGATAG 
  
Forward primer sequence 9 GCTTCCTCTTCACCTTCCATTG 
Reverse primer sequence  10 AGAACATCAATTCGGTATAATAAG 
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2.5 Methods related to Chapter 4 
2.5.1 Sanger sequencing 
The potential causative variants in BBS genes that were initially identified by droplet based 
targeted sequencing, were confirmed for their presence by Sanger sequencing by myself. Primers, 
encompassing region of interest were designed using primer 3 software (Figure 2.5) and 3730 × l 
DNA Analyzer (Life Technologies, Carlsbad, CA, USA) was used to get sequence reads.  
 
Table 2.5: Primers used to amplify BBS regions of interest. 
 
BBS2 primers   
c.406insG  
Forward primer sequence  GGGCCTGCATATTATCGTGTC 
Reverse primer sequence  GAATTAACATTGTCTCCAGTAACC 
BBS10 primers  
c.271insT  
Forward primer sequence  GTGTCTGAAACGTTAGGAGAGC 
Reverse primer sequence  TAAGATGTGGGAAGCCAGCC 
 
Amplifications of BBS2 to confirm c.406insG mutation was performed by using Clontech (Clontech 
Laboratories Inc, Mountain View, CA, USA) under the following conditions: 95°C 1 min, followed 
by 30 cycles of 95°C 30 sec, 68°C 1 min, followed by 68°C 3 min. Sequencing reads were assembled 
and analyzed for the presence of the variant using Mutation Surveyor DNA Variant Analysis 
software (SoftGenetics, LLC, USA). While for confirmation c.271insT in BBS10 same enzyme was 
used but the PCR programme performed was by using BioTaq (Bioline, London, UK). A 30 cycle 
PCR program was performed with denaturation at 95°C for 30 sec, annealing at 56°C for 40s and 
extention at 72°C for 90 sec. Finally elongation was performed at 72°C for 10 min. While for 
confirmation of c.1810T>A mutation in exon 11 of LEPR gene and c.40G>A in exon1, amplification 
was performed 95 °C 3 min, followed by 35 cycles with denaturation at 95°C for 30 sec, annealing 
at 68°C for 45 sec and extention at 72 for 60 sec. Finally elongation was performed at 72°C for 10 
min. 
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2.5.2 Multiplex Ligation-Dependent Probe Amplification  
Subjects showing apparent heterozygous deletion 15q11-13 region were analysed using MLPA 
technique.  
2.5.2.1  MLPA analysis using 343 probemix to confirm deletions/duplications in 15q11-13 
region associated with Prader-Willi syndrome (PWS) and Angelman syndrome (AS) 
I carried out the multiplex ligation-dependent probe amplification (MLPA) assay using P343 
Autism-1 probemix (MRC Holland, Amsterdam, The Netherlands) to detect deletions/duplications 
in 15q11-13. These regions have previously been associated with autism and/or obesity.  
Principally MLPA is a relative technique and no conclusions regarding copy number change can 
be drawn from a single MLPA reaction of patient sample unless reference DNA samples are 
analysed simultaneously. 
Purified DNA samples from two normal subjects were selected as reference samples as per 
manufacturer’s instructions. Briefly, the procedure consisted of the following steps:  5ul of 150 
ng genomic DNA rehydrated in DNA hydration solution (Qiagen, Crawley, UK), was denatured for 
5 min at 98°C.  After denaturation step, 1.5 µl of SALSA MLPA buffer and 1.5 µl of MLPA P343 
probemix were added into each sample. The probes were allowed to hybridize to their targets for 
20 h at 65°C. Following hybridization, 32µl of ligase-65 master mix (25 µl of dH2O + 3 µl of ligase 
buffer A + 3 ul of ligase buffer B + 1ul of Ligase-65 enzyme) was added to each hybridized sample 
while samples were kept at 54°C and ligation reaction was performed (15 min at 54°C, 5 min at 
98°C and paused at 20°C). Lastly, PCR mix (7.5 μl dH2O + 2 μl SALSA PCR primer mix + 0.5 μl SALSA 
Polymerase) was added to ligation products that were amplified by PCR (35 cycles of 95°C for 30 
sec,  60°C 30 sec, 72°C 60 sec followed by elongation step at 72°C for 20 min). PCR products were 
serially diluted (undiluted, 4x and 16x diluted) and taken forward for analysis. 0.7 µl PCR products 
from each tube were mixed with 0.3 µl of size standard (Rox-500 Genescan; Applied Biosystems, 
Foster City, CA) and 9 µl of deionized formamide. PCR products were analysed on a fluorescent 
capillary sequencer, Genescan (ABI 3730, Applied Biosystems, Darmstadt, Germany). Data 
generated by 26 probes in 15q region (Table 2.6) were normalised by Coffalyser (MLPA analysis 
tool developed at MRC-Holland). 
 S Saeed 
 
 
  
96 
 
 
  
 
 
 
Table 2.6: Probes in the MRC Holland P343-C1 AUTISM-1 kit within the 15q11-13 region. 
  
No gene Map view Chr. pos. 
1 SNRPN-HB2-85 15-022,848294 15q11.2 
2 SNRPN-HB2-85 15-022,858473 15q11.2 
3 UBE3A 15-023,136395 15q11.2 
4 UBE3A 15-023,150555 15q11.2 
5 UBE3A 15-023,152935 15q11.2 
6 UBE3A 15-023,167740 15q11.2 
7 UBE3A 15-023,171919 15q11.2 
8 ATP10A 15-023,484000 15q12 
9 ATP10A 15-023,659036 15q12 
10 GABRB3 15-024,344242 15q12 
11 GABRB3 15-024,357380 15q12 
12 GABRB3 15-024,363881 15q12 
13 GABRB3 15-024,376510 15q12 
14 GABRB3 15-024,379640 15q12 
15 GABRB3 15-024,417665 15q12 
16 GABRB3 15-024,568655 15q12 
17 OCA2 15-025,770116 15q12 
18 OCA2 15-026,017939 15q13.1 
19 APBA2 15-027,196749 15q13.1 
20 NDNL2 15-027,348739 15q13.1 
21 TJP1 15-027,900944 15q13.1 
22 TRPM1 15-029,081415 15q13.3 
23 KLF13 15-029,452013 15q13.3 
24 CHRNA7 15-030,191319 15q13.3 
25 SCG5 15-030,759311 15q13.3 
26 SCG5 15-030,776133 15q13.3 
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2.5.2.2  MS-MLPA to check for deletion breakpoints and methylation status in 
chromosome 15q11  
In order to detect deletion breakpoints in PWS/AS region (initially identified by MLPA P343 Autism 
kit) and to analyse CpG island methylation of the 15q11 region, I performed the multiplex ligation-
dependent probe amplification (MS-MLPA: ME028-B2 Prader Willi/Angelman probemix). The list 
of probes is provided in Table 2.7. 
Denaturation and probe hybridization steps were similar to that of simple MLPA. Following 
hybridization, the product was diluted with 10 µl water and 3 ul of ligase buffer A, mixed well, and 
10 ul of mixture was added in a second tube. Two ligase mixtures were prepared, a ligation 
mixture (8.25 μl dH2O + 1.5 μl ligase buffer B + 0.25 μl ligase-65 enzyme) for copy number 
detection and a ligation-digestion mixture (7.75 μl dH2O + 1.5 μl ligase buffer B +  0.25 μl Ligase-
65 enzyme and 0.5 µl HhaI enzyme-Promega R6441, 10 units /μl) for methylation detection. At 
49°C, 10 µl of each mixture were added in respective tubes and ligation and digestion step were 
carried through at 49° C for 30 min, followed by 5 min of heat inactivation of the enzymes at 98°C. 
Following ligation/digestion, 5ul of PCR reaction mix (3.75 μl dH2O + 1μl SALSA PCR primer mix  + 
0.25 μl SALSA Polymerase) was prepared per sample and PCR was performed (35 cycles: 95°C 30 
sec, 60°C 30 sec, 72°C 60 sec). PCR products were analysed in an identical manner as described in 
the previous section (2.5.2.1). 
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Table 2.7: Probes in the MRC Holland ME028-B2 Prader Willi/Angelman probemix  
within the 15q11-13 region.  
 
No Gene Map view Chr 
position 
2 TUBGCP5 15-020.398303 15q11.2 
31 NIPA1 15-020.612289 15q11.2 
4 MKRN3 15-021.362818 15q11.2 
29 MAGEL2 15-021.440355 15q11.2 
32 NDN 15-021.482381 15q11.2 
30 NDN 15-021.483412 15q11.2 
18 SNRPN 15-022.619902 15q11.2 
13 SNRPN 15-022.626072 15q11.2 
17 SNRPN 15-022.690980 15q11.2 
16 SNRPN 15-022.703328 15q11.2 
15 SNRPN 15-022.716714 15q11.2 
27 SNRPN 15-022.717321 15q11.2 
14 SNRPN 15-022.751105 15q11.2 
5 SNRPN 15-022.751214 15q11.2 
7 SNRPN 15-022.751480 15q11.2 
1 SNRPN 15-022.751773 15q11.2 
19 SNRPN 15-022.764248 15q11.2 
28 SNRPN 15-022.772555 15q11.2 
10 SNRPN-HB2-85 15-022.848250 15q11.2 
33 SNRPN-HB2-85 15-022.872658 15q11.2 
21 SNRPN-HB2-85 15-022.888662 15q11.2 
23 UBE3A 15-023.136395 15q11.2 
20 UBE3A 15-023.156677 15q11.2 
3 UBE3A 15-023.167740 15q11.2 
8 UBE3A 15-023.171919 15q11.2 
25 UBE3A 15-023.201674 15q11.2 
6 UBE3A 15-023.235184 15q11.2 
24 ATP10A 15-023.522207 15q12 
12 ATP10A 15-023.659906 15q12 
11 GABRB3 15-024.344242 15q12 
26 GABRB3 15-024.363881 15q12 
9 APBA2 15-027.196749 15q13.1 
22 BLM 15-089.061432 15q26.1 
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2.5.2.3   MS-MLPA to confirm deletion and methylation status in chromosome 20q13.32 
GNAS region 
For the proband suspected to carry Albright hereditary osteodystrophy, I performed the MS-
MLPA experiment using ME031 –GNAS probemix (MRC Holland, Amsterdam, The Netherlands; 
Table 2.8), in an identical manner as described in the previous sections 2.5.2.1 & 2.5.2.2. 
 
Table 2.8: Probes in the MRC Holland ME031 –GNAS probemix  
within the 20q region.  
 
No Gene Map view Chr.pos. 
1 NESPAS 20-056.850598 20q13.32 
2 STX16 20-056.659882 20q13.32 
3 GNASXL 20-056.862683 20q13.32 
4 NESPAS 20-056.859205 20q13.32 
5 STX16 20-056.675969 20q13.32 
6 TH1L 20-056.989740 20q13.32 
7 NESP55 20-056.848143 20q13.32 
8 GNAS 20-056.917978 20q13.32 
9 GNAS 20-056.900224 20q13.32 
10 STX16 20-056.676511 20q13.32 
11 GNAS 20-056.897495 20q13.32 
12 STX16 20-056.679054 20q13.32 
13 NESPAS 20-056.859408 20q13.32 
14 NESP55 20-056.848321 20q13.32 
15 GNAS 20-056.919132 20q13.32 
16 GNASXL 20-056.862624 20q13.32 
17 GNAS 20-056.911972 20q13.32 
18 GNASXL 20-056.863596 20q13.32 
19 NESPAS 20-056.859298 20q13.32 
20 GNAS 20-056.918452 20q13.32 
21 STX16 20-056.685865 20q13.32 
22 GNAS 20-056.900164 20q13.32 
23 NESPAS 20-056.850853 20q13.32 
24 GNAS 20-056.913829 20q13.32 
25 GNAS 20-056.897762 20q13.32 
26 NESP55 20-056.848539 20q13.32 
27 STX16 20-056.677727 20q13.32 
28 GNAS 20-056.907400 20q13.32 
29 GNAS 20-056.917576 20q13.32 
30 GNASXL 20-056.863512 20q13.32 
31 GNASXL 20-056.864358 20q13.32 
32 GNAS 20-056.904036 20q13.32 
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2.6 Methods related to chapter 5 
2.6.1 Hormone levels in subjects with monogenic obesity 
 The endocrine profile of subjects (described in detail in chapter 4) with pathogenic mutations in 
LEP, LEPR and MC4R, was assessed by us in the Department of Biological Sciences, Forman 
Christian College, Lahore, Pakistan, by measuring serum leptin, insulin, TSH and cortisol levels. 
Serum concentrations of these hormones were measured using commercially available ELISA kits 
(leptin: Organium Laboratories, Helsinki, Finland; insulin, TSH and cortisol: Monobind Inc, Lake 
Forest, CA, USA). Samples were assayed in duplicate. The intra- and inter-assay variations were < 
11% for each assay. 
2.6.2 Fasting and postprandial levels of gut hormones 
The subjects for this study were drawn from two unrelated consanguineous Pakistani families 
with leptin deficient members that were previously screened for mutations in the coding region 
of LEP.  Of the 13 family members included in this study, 5 individuals were homozygous (Group1: 
-/-) and 8 were heterozygous (Group 2: -/+) for the c.398delG mutation in the leptin gene. 
Additionally, 10 unrelated lean subjects with a wild type LEP sequence (Group 3: +/+), served as 
the control group. The study was approved by the institutional ethical committee and written 
informed consent was obtained in all cases from participants or their parents/guardians. The 
study was carried out in accordance with the principles of Declaration of Helsinki.  
The subjects were presented in the morning after an overnight (10 h) fast. Anthropomorphic 
measurements and physical examination were made followed by measurement of blood glucose 
levels. None of the subjects were on regular medication. The subjects were presented with a 
mixed meal, ad libitum. Three to 5 ml venous blood was drawn 15 min before serving the meal 
and 60 min after its termination in each subject. The samples were collected in EDTA tubes kept 
on ice. The samples were centrifuged to separate plasma stored at -80oC until analysed.  
Assessment of gut hormone levels was carried out by Paul R. Bech from the department of 
Medicine, Imperial College London and by myself. All plasma samples were analysed in duplicate. 
For PYY and GLP-1 measurements an established in-house RIA was used [370, 371]. The GLP-1 and 
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PYY assays had a sensitivity of 6 pmol/L and 18 pmol/L respectively. The coefficient of variation 
(CV) for both assay QCs were less than 10%. Total ghrelin concentrations were measured using a 
commercially available ELISA kit (Merck Millipore, Billerica, MA, USA). Samples were processed 
and analysed following the manufacture’s recommendations. The intra- and inter-assay variations 
for these hormones were less than 10% for each assay.  
2.6.3 Statistical analysis 
Student’s t test was used to assess differences between 2 groups.  Comparisons between more 
than 2 groups were made by ANOVA followed by Tukey’s multiple comparison test. Correlation 
was analysed by Pearson’s correlation coefficient. Statistical analyses were carried out using 
GraphPad Prism version 5.00 (GraphPad Software Inc, San Diego, CA, USA).   
2.7 Methods related to chapter 6 
Novel mutations identified by whole exom sequencing analysis were confirmed by using 
conventional Sanger sequencing using following primers designed by primer3 software (Table 
2.9). 
 
Table 2.9: primers used to amplify regions of interest in INSIG2, ADCY3 and ROCK1 genes.  
 
Primer Sequence (5’-3’) 
INSIG2 forward primer TTCCCTTCTCAACAGAGGCA 
INSIG2 reverse primer GAGTGACCACAGTTGCCAAG 
ADCY3 forward primer AGAGCTCACACATCCACGAA 
ADCY3 reverse primer  CAGTCACTCCAGGGTTCTCC 
ROCK1 forward primer ACATACCTTCCTCTGCCTTCTT 
ROCK1 reverse primer TGTCTGACCTGTCTTTATCTAGCA 
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For confirmation of mutation in INSIG2, ADCY3, and ROCK1, I performed amplification of desired 
region using Clontech (Clontech Laboratories Inc, Mountain View, CA, USA) under the following 
conditions: 95°C 1 min, followed by 30 cycles of 95°C 30 sec, 68°C 1 min, followed by 68°C 3 min. 
This was followed by direct sequencing on ABI 3730xl DNA sequencer.
  
3. Chapter three 
 
 
 
leptin (LEP), leptin receptor (LEPR), and 
melanocortin 4- receptor (MC4-R) 
deficiency in our cohort of severely 
obese children 
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3.1 Introduction 
 
As a result of genetic and molecular studies over the past two decades, the central melanocortin 
pathway triggered by the peripheral adipocyte hormone, leptin, has emerged as the critical 
signalling system regulating body weight and energy homeostasis [189]. Loss-of-function 
mutations in genes encoding proteins that make up the assembly of leptin-melanocortin 
signalling, almost invariably result in severe obesity and hyperphagia in early childhood and are 
associated with various endocrine and immune disorders [128-130].  
Pathogenic mutations identified in leptin (LEP) and leptin receptor (LEPR) genes are rare and have 
so far been described in less than 50 obese individual worldwide and mainly from consanguineous 
families [125, 131, 132, 153, 157, 169-171, 173-175, 372]. Whereas LEP mutations result in a 
complete lack of its circulating protein, the loss of function mutations in the LEPR renders the 
carrier insensitive to leptin. In mice both leptin and leptin receptor deficiency results in almost 
identical early-onset severe obesity [373]. However, the human LEPR deficiency has been 
suggested to have a less severe effect than that caused by leptin deficiency [132].  
Unlike LEP and LEPR mutations, the pathogenic mutations found in the MC4R gene cause the most 
prevalent form of monogenic obesity known so far. Indeed, prevalence of MC4R mutations 
associated with human obesity though variable among different studies has been reported to be 
5-6% in obese subjects of diverse origin [203, 204]. However, the great majority of these 
mutations have been identified in the heterozygous state. Most of studies, both in vivo and in 
vitro, are suggestive of a co-dominant mode of inheritance with heterozygous subjects having a 
less severe phenotype than homozygous carriers [202, 203]. However the degree of penetrance 
of MC4R mutations has been demonstrated to be influenced by environmental factors [202]. 
To our understanding, no systematic assessment of prevalence of loss-of-function mutations in 
these three genes has been carried out in severely obese subjects in a single population with a 
relatively high degree of consanguinity. In the present study we have attempted to identify 
genetic variance in a cohort of randomly ascertained severely obese children from a single 
consanguineous population.   
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3.2 Mutations in LEP, LEPR and MC4R Genes  
Causative variants described in these genes were identified through a multi-stage screening 
regimen involving Sanger sequencing, microdroplet PCR-enrichment (RainDance) followed by 
NGS, genotyping and WES, as detailed in chapter 2. Of a total of 175 subjects with severe obesity, 
50 probands and 10 siblings were identified to carry mutations in LEP, LEPR and MC4R genes. In 
the description that follows the mutations are referred under the specific genes they impact 
regardless of the screening procedures used in their identification.  
3.2.1 LEP gene mutations 
Sanger sequencing analysis in our cohort of severely obese children revealed 35 unrelated 
subjects (20.5%) and 7 family members carrying 6 different loss-of-function mutations.  Of these 
4 were novel. All 42 affected subjects were also shown to be clinically leptin deficient. Parents of 
leptin deficient subjects were heterozygous carriers for the respective mutation.   Physical 
characteristics of subjects with LEP mutations are given in Table 3.1 and Table 3.2.   
3.2.1.1   c.398delG (p.Gly133_VfsX14)  
This recessive frameshift mutation due to deletion of G from coding position 398 in exon 3 of the 
LEP gene in homozygous state, was identified in 29 unrelated probands. Twenty-seven of these 
were children <1-13 year (median: 1.2 year) and 2 adults (median age: 20) (Figure 3.1). The same 
mutation was also identified in 6 family members, 3 of which were adult females. This mutation 
disrupts the reading frame of the leptin gene resulting in 14 aberrant amino acids after glycine at 
133 amino acid position, followed by a premature stop codon. All affected subjects had normal 
body weight at birth but started gaining excessive weight at the age of 1-4 months. Almost all 
subjects were reported to suffer from recurrent pulmonary infections and diarrhoea. Interestingly 
28 out of 29 probands were also reported to belong to the same ethnic group (caste). Physical 
characteristics of subjects carrying this frameshift mutation are described in Table 3.1. 
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Table 3.1: Physical characteristics of subjects carrying frameshift c.398delG 
mutation in homozygous state. 
Individuals  
No 
Family 
No 
ID Gender Age SDS(BMI) 
1 1 F-4P F 0.7 4.9 
2 2 F-13P M 1.4 4.9 
3 3 F-22P M 7 4.2 
4 4 F-16P M 1 7.7 
5 5 F-30P M 3.3 7.5 
6 6 F-53P F 0.7 5.7 
7 7 F-56P F 0.7 5.5 
8 8 F-60P M 0.7 5.7 
9 9 F-62P F 2 7.4 
10 9 F-62C F 2.5 6.8 
11 10 F-42P M 1.7 9.0 
12 10 F-42D F 27.2 (63.28) 
13 10 F-42E F 16 (49.6) 
14 11 F-71P F 30 (57.7) 
15 11 F-71D F 8 4.2 
16 11 F-71H M 9 4.7 
17 12 F-76P M 0.7 6.8 
18 12 F-76C F 3 6.8 
19 13 F-82P M 9 4.9 
20 14 F-111P F 0.8 4.9 
21 15 F-110P F 1 5.7 
22 16 F-122P F 0.5 4.6 
23 17 F-127P M 21 (42.4) 
24 18 F-130P F 2 3.6 
25 19 F-134P F 0.8 7.6 
26 20 F-138P M 0.3 1.8 
27 21 F-143P F 0.7 6.6 
28 22 F-153P F 13 4.5 
29 23 F-154P M 18 (47.02) 
30 24 F-157P M 4 7.4 
31 25 F-162P F 1.2 4.9 
32 26 F-172P M 1.1 3.9 
33 27 F-194P M 0.7 4.2 
34 28 F-195P M 1.4 4.8 
35 29 F-199P M 1.1 5.8 
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Figure 3.1  Sequencing scan of LEP at the site of mutation 398delG. 
Scan demonstrating a homozygous 1 base deletion in exon 3 of LEP disrupting the reading frame. This 
mutation was identified in 29 unrelated probands and 6 family members with severe obesity. 
 
 
3.2.1.2   c.1-44del42 
This novel splice site mutation in the homozygous state identified in a 1.5 year old male child (F-
75) with severe obesity, by direct sequencing of the gene, was due to a 42bp deletion of intron 1 
of LEP (Figure 3.2A). This recessive deletion extending from position -44 to position -2 of the 
second exon (the first coding exon of LEP), involves an abnormal splicing resulting in a skipping of 
exon 2 as predicted by Automated Splice Site and Definition Analyses [374] (Figure 3.2B).  
To further characterise this mutation, RNA was extracted from the blood leukocytes and the cDNA 
was prepared. Gel electrophoresis of the amplified product from heterozygous parents resulted 
in two bands corresponding to the mutated and wild type alleles, whereas a single band of 
respective size was found in the obese child and his wild type sibling (Figure 3.2C). Direct 
sequencing of cDNA from the proband and parents revealed absence of exon 2 transcripts in the 
mRNA of the affected proband whereas heterozygous parents carried both the wild-type and 
mutant transcripts (Figure 3.2D).   
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Figure 3.2 Sequence analysis and characterization of a novel homozygous 42 bp deletion in LEP. 
(A) Sequence scans of reference and mutated LEP in the region of a 42 bp deletion in intron 1 that includes 
the splice acceptor site of exon 2. (B) Schematic presentation of the genomic organization of LEP indicating 
the position of the intronic deletion resulting in a skipping of exon 2 and the mRNA reconstruct transcribed 
by the mutated gene. (C) Gel electrophoresis of reverse transcriptase PCR amplified cDNA. The proband 
carrying homozygous deletion presents a single band of 360 bp, the heterozygous parents two bands of 
360 and 530 bp, and the wild-type sibling a single band of 530 bp. P: proband; F: father; M: mother; S: wild-
type sibling. (D) Results of sequencing of cDNA from wildtype (reference) and mutated subjects. The 
mutant sequence shows a lack of exon 2. 
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F-75: The proband was the youngest of three siblings of consanguineous parents from a village in 
the vicinity of Faisalabad city. He was presented at the hospital at the age of 1.5 years having 
difficulty in breathing. He was severely obese with a BMI SDS of 5.57 and was reported 
hyperphagic (Table 3.2). His lean brother was wild type for the mutation. Both parents were 
heterozygous for the said mutation. The eldest sister was reported to be obese and died at a 
young age. 
3.2.1.3   c.350G>A (p.Cys117Tyr) 
Sanger sequencing of the coding regions of LEP identified this novel missense recessive mutation 
in exon 3, in a 1.6 years old boy (Figure 3.3). The mutation results in a substitution of cysteine by 
tyrosine at residue 117, resulting in an impaired protein function as predicted by SIFT (score: 0), 
and MutationTaster (p-value: 1; P value in this case is the probability of the prediction. The value 
close to 1 indicates a high security of the prediction) softwares.  
F-123: The proband born to consanguineous parents had a BMI SDS of 4.1 (Table 2). The proband 
presented severe obesity and was clinically leptin deficient.  One of the paternal uncles was 
reported to be severely obese and died at the age of 10 years.  
 
 
Figure 3.3 Sequencing scan of LEP at the site of mutation Cys117Tyr 
Scan demonstrating a homozygous substitution (Cys117Tyr) in exon 3. This mutation was 
identified in F-123. 
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3.2.1.4   c.313C>T (p.Arg105Trp)  
This mutation that involves a change of arginine to tryptophan at amino acid position 105 found 
in these two siblings has previously been described in a large Turkish family but is reported here 
for the first time in a Pakistani Christian obese family (Figure 3.4). 
F-85: This missense mutation, in the homozygous state, was identified in two obese brothers 1.5 
and 10 year old boys, with BMI SDS of 5.3 and 3.8, respectively (Table 3.2). Another two severely 
obese siblings in the same family were reported to have died at the age of 3 year and 2 month.  
One of the three sisters screened was found to be wild type. 
 
 
 
Figure 3.4 Sequencing scan of LEP at the site of mutation Arg105Trp 
Scan demonstrating a homozygous substitution (Arg105Trp) in exon 3. This mutation was identified in F-
85P and F-85S.  
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3.2.1.5   p.I35del (c.104_106delTCA) 
This homozygous mutation involving deletion of three base pairs was identified in exon 2 of the 
leptin gene. The deletion involves amino acids 34 and 35 and results in deletion of isoleucine. This 
mutation is the only variant associated with extreme obesity that has so far been reported in exon 
2 of LEP (Figure 3.5). 
F-41: This three base deletion was identified in an 18 months old girl. She was normal weight at 
birth but started gaining weight after one month of age and by the age of 18 month weighed 15 
kg with a BMI SDS of 4.7. At this age she was unable to crawl but suffered no other abnormalities 
or any other disease. The parents and a 4 years old male sibling were found to be heterozygous 
carriers. Whereas hyperphagia was reported in the proband, none of the family members who 
were heterozygous for this mutation had this condition and were of normal body weight.  
 
 
Figure 3.5 Sequencing scan of LEP at the site of a 3 base deletion. 
Scan of LEP at the site of 3 base deletion (I35del) involving codons 35 and 36 in exon 2 resulting in deletion 
of isoleucine at position 34. This mutation was identified in F-41. 
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3.2.1.6   c.-29+1G>C 
This substitution from G to C positioned at the splice donor site of exon 1 (non-coding) of LEP 
gene (Figure 3.6A) was found in two unrelated siblings. This substitution  abolished the splice 
donor site  as predicted by the Human Splicing Finder [374] (Figure. 3.6B). 
F-132: This splice donor site mutation was identified in a 7 years old female from Okara district.  
She weighed normal at birth but developed hyperphagia and started gaining weight rapidly at 2 
months of age. During her examination at the time of recruitment, she weighed 56 kg and had a 
BMI SDS of 3.2. 
F-155: The same splice donor site mutation was identified in another 8 months old male child of 
consanguineous patents from Gujranwala. He was reported to belong to Ghori caste. The proband 
started developing extreme obesity and hyperphagia at 4 months of his age and at the age of 8 
months had a body weight of 13 kg with a BMI SDS of 3.8. 
 
 
 
Figure 3.6 Splice donor site mutation (c.-29+1G>C) in intron 1 of leptin gene. 
(A) Diagrammatic presentation of non-coding exon 1; the mutation is indicated by arrow. (B)  
Schematic presentation of the splice donor site abolished in the mutant gene as predicted by 
the SpliceSiteFinder [374]. Splice donor site in yellow area (arrow) presents the strongest 
candidacy (above), abolishing of which can be seen in the mutant (below). 
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Table 3.2: Physical characteristics of subjects carrying mutations in LEP gene other than the 
 frameshift variant. 
 
No of  
individuals 
No of  
families 
ID Mutation  Gender Age SDS 
1 1 F-41P c.104-106delTCA  F 1.5 4.7 
2 2 F-75P c.1-44del42   M 1.5 5.57 
3 3 F-123P c.350G>A   M 1.4 4.13 
4 4 F-85P c.313C>T   M 1.4 5.3 
6 4 F-85S   M 10 3.8 
7 5 F-132 c.-29+1G>C  F 0.7 3.2 
8 6 F-155    F 0.2 3.8 
P: proband; S: sibling 
Mutations in bold are novel 
 
3.3.2 LEPR gene mutation: 
Microdroplet PCR-based enrichment and sequence analysis of the coding and flanking regions of 
26 monogenic obesity associated genes, revealed 7, all novel, homozygous LEPR mutations in 11 
probands (6.5%) and in one sibling, with early onset severe obesity. All mutations were found in 
regions of homozygosity (Figure 3.13). Parents of affected subjects were heterozygous for the 
respective mutations and had BMI within the normal range. Physical characteristics of the 
mutation carriers are described in Table 3.3. 
3.3.2.1   c.2396-1G>T  
This novel mutation in the homozygous state, which involved a G>T base substitution in the splice 
acceptor site of exon 15 (Figure 3.7), was found in four probands (F-48, F-80, F-129 and F-146; 
Table 3.3), 3 females and one male. This mutation resulted in abnormal splicing of LEPR transcript 
by skipping of exon 15 as analysed by NetGene2 [375], Human Spicing Finder [374], and 
Automated Splice Site and Exon Definition Analyses [376].  
F-48: This proband, the first child of consanguineous parents from a remote village of the central 
Punjab province, was recruited at the age of 1.2 years when she weighed 22.5 kg and had a BMI 
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of 31.9 and BMI SDS of 5.9 (Table 3.3). She belonged to Tarrar caste. She weighed normal at birth 
but developed hyperphagia and started gaining weight rapidly at 2 months of age. During a follow 
up of the patient at the age of 2 years, she weighed 34 kg and had a BMI of 40.17.  The child had 
no dysmorphic features but was reported to suffer from recurrent chest infections, dermatitis, 
reddening of skin, and breathing difficulty.  
F-80: This proband was also a first female child of consanguineous parents. She was presented at 
hospital with excessively increasing body weight at 2 years of age. She belonged to Rajput caste. 
At the time of recruitment she had a BMI SDS of 3.3. Her parents were heterozygous for the 
mutation while a 0.6 year old male sibling was wild type. 
F-129: She was the only child from a first cousin union and weighed 31 kg at the age of 1.4 year.  
Like members of F-80 family, she also belonged to the Rajput caste. Interestingly, this proband 
also carried a homozygous missense mutation, D148N, in BBS1 gene (described in section 4.2.1.4). 
This mutation was found in the largest homozygous region (37 Mb) identified in this proband. No 
polydactyly and/or other phenotypes associated with BBS were found in this proband. This 
mutation in BBS1 has been reported in subjects from UK and US and shown to be pathogenic 
[377].  
F-146: This male proband was recruited from the Faisalabad city at the age of 7 months. He also 
belonged to Rajput caste and weighed 11 kg. 
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Figure 3.7 Sequencing scan of LEPR at the site of c.2396-1G>T mutation. 
Scan demonstrating a homozygous missense substitution from G to T at splice acceptor site of exon 15. 
This mutation was identified in 3 affected unrelated proband (F-48, F-80, F-129. F-146). 
 
3.3.2.2   c.1674 G>A (p.Trp558Stop)  
A second novel homozygous nonsense mutation of LEPR was identified in exon 10  (Figure 3.8), in 
two probands, a 0.7 year old girl (F-59) and a 1.2 year old boy (F-81) with early onset severe 
obesity and hyperphagia. A single base substitution of G to A created a premature stop codon 
resulting in a truncated protein comprising the first 558 of the 1165 amino acids of the LEPR 
protein. Both parents of the probands were verified to be heterozygous carriers for this mutation.  
F-59: This proband, the only child of first degree related parents belonging to Sheikh caste, was 
referred to the Children’s Hospital Lahore at the age of 7 months. Since 3 months of age, she had 
an insatiable craving for food and underwent a rapid increase in body weight. At the age of 0.7 
year she weighed 14.5 kg with a BMI of 36.5 and SDS for age 6.4. Two paternal uncles of the 
proband were reported to be severely obese at an early age and died during their childhood when 
they were 4-5 years old.  
F-81: The same homozygous nonsense mutation was also identified in another 1.2 year old boy 
with a BMI SDS of 5.5. The parents were heterozygous carriers for this mutation. The proband had 
developed extreme obesity and hyperphagia at an early age.  
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Figure 3.8 Sequencing scan of LEPR at the site of Trp558Stop mutation. 
Scan of a mutation demonstrating a homozygous nonsense substitution at exon 10. This mutation was 
identified in 2 affected unrelated proband (F-59, F-81). 
 
3.3.2.3   c.1810T>A (p.Cys604Ser) 
The novel missense mutation was identified as due to substitution of T to A at position 1810 
(Figure 3.9). The mutation results in a C604S residue exchange in exon 11 and is predicted to be 
deleterious (score: 0) by SIFT and damaging by PolyPhen softwares.  
F-96: This mutation in homozygous state was found in two obese brothers 1 and 5 years old. The 
older brother was reported to be a slow learner. Other features included hypodontia, beak nose 
and retracted penis. The sibling was heterozygous carriers for the said mutation and was of 
normal body weight. 
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Figure 3.9 Sequencing scan of LEPR at the site of mutation p.C604S. 
Scan demonstrating a homozygous missense substitution at exon 11. This mutation was identified in  
F-96P and F-96S. 
 
 
 
 
3.3.2.4   c.40G>A (p.Glu14Lys) 
This missense mutation was identified as a single base substitution at position 40 (last base in 
exon one) caused by a change of glutamic acid with lysine at codon4 to lysine (Figure 3.10) The 
mutation is reported to be disease causing (p-value: 1) by MutationTaster and tolerated by SIFT 
(score: 0.32). This mutation was initially identified by WES and subsequently validated by Sanger 
sequencing.  
F-14: This male proband, older of the two children of consanguineous parents from Sahiwal, was 
recruited at the age of 2.3 years when he weighed 24.2 kg with a BMI SDS of 6.5. The family 
belonged to the Rehmani caste. His body weight was normal at birth but the child developed 
hyperphagia and started gaining weight rapidly as early as 1 month of age. The child had no 
dysmorphic features although achieving developmental milestones was somewhat delayed when 
the proband was 6 years old as reported by parents. The parents and sister were heterozygous 
for the mutation and had normal body weight. 
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3.3.2.5   c.2114G>A (p.Trp705Stop) 
This novel nonsense mutation was identified in exon 13 of LEPR gene in a 9 months old boy. In 
this case a single base substitution (G>A) at position 2114 creates a premature stop codon 
resulting in a truncated protein comprising the first 705 of the 1165 amino acids of the LEPR 
protein (Fig 3.11). 
F-150: This male proband, the only child of first degree related parents belonging to Dogar caste, 
was referred to the Children’s Hospital at the age of 9 months when he weighed 14.2 kg with a 
BMI SDS of 3.8 His body weight was normal at birth but the child developed hyperphagia and 
started gaining weight rapidly as early as 2 months of age.  
3.3.2.6   c.2153A>G (p.Asn718Ser) 
The novel missense mutation, 12 codon apart from Trp705Stop, described above, was identified 
as due to substitution of A to G at position 2153 (Figure 3.11). The mutation results in an 
Asn718Ser residue exchange in exon 13 of LEPR gene and is predicted to be deleterious (score: 0) 
by SIFT and disease causing (p-value: 1) by MutationTaster. 
F-142: This female proband, younger of the two children of consanguineous parents from 
Faisalabad, was referred to the Children’s Hospital Lahore at the age of 8 months. She belonged 
to Jatt caste. Since 2 months of her age, she had an insatiable craving for food and underwent a 
rapid increase in body weight. At the age of 8 months she weighed 17.5 kg and had a BMI SDS for 
age of 5.8.  
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Figure 3.10 Sequencing scan of LEPR at the site of mutation Glu14Lys. 
Scan demonstrating a homozygous missense substitution at exon 1. This mutation was identified in F-14 
 
 
 
 
 
 
 
Figure 3.11 Diagrammatic presentation of p.Trp705Stop and p.Asn718Ser mutations. 
Scan of nonsense and missense mutations identified in exon 13 of LEPR gene. The mutations were 
identified in F-150 and F-142, respectively. 
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Table 3.3: Physical characteristics of subjects carrying novel LEPR mutations in homozygous state. 
 
No of individuals  
with mutation 
No of 
families 
ID Mutation* Gender Age SDS 
1 1 F-48 P c.2396-1G>T  F 1.2 5.9 
2 2 F-80 P  F 2 3.3 
3 3 F-129 P  F 1.6 8.6 
4 4 F-146 P  M 0.6 3.0 
5 5 F-59 P c.1675G>A  F 0.7 6.4 
6 6 F- 81 P  M 2.2 5.5 
7 7 F-96 P c.1810T>A  M 6 3.2 
8 7 F-96 S  M 0.9 3.4 
9 8 F-14 P c.40G>A M 2.3 6.5 
10 9 F-142 P c.2153A>G F 0.7 5.8 
11 10 F-150 P c.2114G>A M 0.8 3.8 
12 11 
F-95 P 
1.3kb & 58.8kb 
homozygous deletion 
M 0.6 4.5 
 P: proband; S: sibling 
Mutations in bold are novel 
*All mutations are novel 
 
 
 
 
 
3.3.2.7  1.3 kb and 58.8 kb homozygous deletion 
 g.[66053156-66054477del1322];[66056233-66115089del58857insGTGTGTATATGGGGGT] 
This type of homozygous deletion reported here for the first time in LEPR was identified in a 7 
months old male child presenting early onset severe obesity. Conventional sequencing of LEP and 
MC4R and subsequent analysis by droplet PCR-based targeted enrichment followed by NGS 
against a panel of 27 obesity-associated genes failed to identify any pathogenic point mutation in 
this proband. Failure to get a signal in the latter assay prompted us to carry out CNV analysis of 
genotyping data that indicated deletions in a DNA segment spanning intron 3 of LEPR, extending 
to the end of the gene, and including the 3´-untranslated region and part of the intergenic region 
(Figure 3.12A). Deletion breakpoint mapping through primer walking revealed presence of two, 
1322 and 58857bp, deletions (Figure 3.12B). The first deletion starts from position 66,053,156 of 
 S Saeed 
 
 
  
121 
 
 
  
chromosome 1 (1p31.3) and ends at position 66,054,477 whereas the second deletion extended 
from position 66,056,233 to position 66,115,089. The intervening segment of 1755bp, 
(chr1:66,054,478- 66,056,232), is preserved and is followed by a 16 bp (GTGTGTATATGGGGGT) 
insertion (Figure 3.12C). The parents of the proband were heterozygous for this copy number 
change. 
F-95: The proband, a boy of 0.6 year of age had a body weight of 14 kg and a BMI SDS of 4.5. He 
was the only child of consanguineous parents who belonged to Rajput cast. Parents were 
heterozygous for the said deletion and were of normal body weight.  
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Figure 3.12 Two neighbouring novel homozygous deletions in LEPR. 
Detection of two neighbouring novel homozygous deletion events (1322 and 58,857 bp) in LEPR and 
characterization of deletion breakpoint junctions (A) SNP array genotypes of the proband and parents 
representing copy number losses. LogR ratios were derived from SNP array genotyping by using CnvPartition 
and are shown on the y axis. Shift in the logR ratio in parents from 0 to 21 represents deletion of one copy 
(heterozygous) whereas in the proband both copies are deleted (homozygous). (B) Sequence analysis of deletion 
breakpoint junctions and flanking regions by long-range PCR and direct sequencing. The deleted parts are shown 
by red lines. An insertion of 16 bp with a sequence of GTGTGTATATGGGGGT was found at the 30 end of the 
58,857 bp deletion. (C) Electropherogram of LEPR (1p31.3), indicates the position of breakpoint deletion 
junctions. The two deleted segments are represented by red lines. 
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Figure 3.13  ROH encompassing LEPR. 
Horizontal lines show regions of homozygosity as observed in probands with homozygous mutation in 
LEPR gene. 
 
3.3.3 MC4R gene mutations 
Through conventional sequencing technique 6 individuals from 4 unrelated families (2.3%) were 
found to carry 2 different mutations in homozygous state. One of these mutations previously 
described in the heterozygous state, is being reported here in the homozygous state for the first 
time. Physical characteristics of the mutant carriers are described in Table 3.4. 
3.3.3.1  c.482 T>C (p.Met161Thr) 
This missense mutation at coding position 161 of the only coding exon of melanocortin 4 receptor 
gene resulting in substitution of methionine to tyrosine, was identified in 2 probands and one of 
the siblings (Figure 3.14). Homozygosity of this mutation associated with extreme obesity is being 
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reported here for the first time. The mutation is predicted to be deleterious (score: 0.03) by SIFT 
and disease causing (p-value: 1) by MutationTaster. 
F-32: This mutation in the homozygous state was identified in a 7 months old girl with early onset 
severe obesity and hyperphagia. She weighed normal at birth but started gaining weight rapidly 
in the following months attaining a body weight of 16 kg in the next 5 month. The heterozygous 
parents were overweight (BMI>25) but one of the siblings who was found heterozygous for the 
mutation had a normal body weight (comparable to the wild type sibling). The family belonged to 
Pathan caste.  
F-77: This loss of function mutation in the homozygous state due to a single base substitution was 
also identified in two female obese cousins (F77 and F77S), 5 years and 10 month old with 
excessive body weight and hyperphagia. The BMI SDS of these girls was 3.7 and 4, respectively 
(Table 1). The normal weight male sibling of F-77 was wild type for the said mutation. In contrast 
to the subjects carrying the other MC4R mutation described herein, the age at onset of obesity 
was 2-3 months. The family belonged to Pathan caste. 
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Figure 3.14  Sequencing scan of MC4R at the site of mutation p.Met161Thr. 
Scan demonstrating a homozygous missense substitution (Met161Thr) at the only coding exon of the gene. 
This mutation was identified in 2 affected probands and one sibling (F-32, F-77P and F-77S) 
 
 
 
 
3.3.3.2  c.947T>C (p.Ile316Ser) 
This missense mutation found in the coding region of MC4R resulted in a replacement of 
isoleucine by serine at amino acid position 316 (Fig 3.15). The mutation was predicted to be 
deleterious (score: 0.01) by SIFT and disease causing (p-value: 1) by MutationTaster. 
F-58: This homozygous mutation in MC4R was found in a 15 years old male suffering from severe 
obesity. Hyperphagia and obesity in this boy were noticed after 10 years of age and by the age of 
15 years, he had attained a body weight of 120 kg and a BMI of more than 49. The family had a 
history of diabetes and obesity and belonged to Sheikh caste. 
F-74: This homozygous mutation in MC4R was found in two siblings, an 11 year old girl and a 13 
year old boy, with severe obesity and hyperphagia. The BMI SDS score of the girl and the boy were 
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3.3 and 3, respectively and the age at onset of obesity was 4-6 years. The family belonged to 
Rajput caste.  
 
 
Figure 3.15 Sequencing scan of MC4R at the site of mutation p.Ile316Ser 
Scan demonstrating a homozygous missense substitution at the only coding exon. This mutation was 
identified in 2 affected probands and one sibling (F-58, F-74P and F-74S). 
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Table 3.4: Physical characteristics of subjects carrying MC4R mutations in homozygous state. 
 
No of individuals  
with mutation 
No of families IDs Mutation Gender Age SDS 
1 1 F-32 Pa c.482T>C  F 0.6 5 
2 2 F-77 P  F 5 3.7 
3 2 F-77 S  F 0.9 4 
4 3 F-58 P c.947T>C M 15 4 
5 4 F-74 P  F 11 3.3 
6 4 F-74 S  M 13 3 
a P: proband; S: sibling 
The mutation in bold is reported here for the first time in homozygous state 
 
 
3.4 Discussion 
In this study we report the spectrum of monogenic obesity due to loss-of-function mutations in 
LEP, LEPR and MC4R genes, in 175 probands with early onset severe adiposity, from a 
consanguineous Pakistani population. Sequence analysis demonstrated that severe obesity in 
30% of these subjects can be explained as due to incidence of rare or novel recessive mutations 
in the three genes. Amongst these 20% (n=35) had mutations in LEP, 6.5% in LEPR (n=11) whereas 
MC4R mutations were present in 2.5% (n=4), all in homozygous state. 
By the end of 2011 and at the time the present study was initiated, only 5 different mutations in 
14 children had been identified worldwide with congenital leptin deficiency [125, 153, 157, 169-
172]. Eight of these affected children belonged to Pakistani ethnicity and were homozygous for 
an identical frameshift mutation (G133_VfsX14) in exon 3 of LEP. Later another 3 mutations in 3 
subjects have been identified [173-175] (Figure 3.16 & Table 3.5). 
In the present study we are reporting 42 children from 35 unrelated families carrying pathogenic 
mutations in the LEP gene. In the leptin deficient group we have identified 6 different mutations 
in LEP of which 4 were novel variants. Of note is the observation that a significant majority of the 
leptin deficient patients (29 of 35 unrelated probands) carried the frameshift mutation, 
G133_VfsX14, in the homozygous state unrelated for at least three generations. The same LEP 
frameshift mutation, was the first genetic variant discovered in association with severe obesity in 
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the human [125] and provided the initial impetus to genetic and molecular studies aimed at 
discovering the genetic and molecular basis of human obesity (regulation of body weight and 
energy balance) and has led to the foundation of obesity research. It is interesting to note that 
almost all the families with incidence of G133_VfsX14 mutation belonged to a closely-knit 
Pakistani caste, Arain, that constitutes one of the larger sub-ethnic populations of Punjab and that 
has preferred consanguineous marriages for many generations [356]. The foregoing leads us to 
hypothesise that G133_VfsX14 is a founder mutation in this caste.  
One of the novels LEP mutations described here was due to a 42bp homozygous deletion at splice 
acceptor site. We further functionally characterized this mutation and showed that this deletion 
results in a truncated transcript lacking the first coding exon of the leptin gene that abolishes its 
normal function (Figure 3.2). Recently, we have found another novel missense mutation involving 
substitution of G to C that lies in the splice donor site of exon 1 (non-coding exon). As predicted 
by Splice Site Finder [374], the substitution eliminates this splice site and could result in encoding 
a non-functional protein (Figure 3.6B). Biochemical analysis of the two probands carrying this 
mutation showed undetectable circulating leptin levels (<1 ng/ul) as determined by ELISA. Two 
instances have also recently been reported by Wabitsch and co-workers [173, 378] where the 
aberrant protein encoded by the mutant LEP gene was secreted in circulation but lacked 
bioactivity in subjects carrying a homozygous LEP mutation, p.D100Y and p.N103K. In none of our 
LEP mutants we have so far found a similar condition. It may be surmised that in the majority of 
cases, the mutant leptin protein even when it is secreted in the blood, is not reactive to antibodies 
against the normal ligand, and thus escapes detection in routine immunoassays. 
Another novel LEP mutation described by us was due to a missense substitution, c.350G>A 
(p.Cys117Tyr). With the exception of LEP mutation, p.Arg105Trp, identified here which has 
previously been described in a Turkish family, all pathogenic leptin variants so far identified in our 
cohort of severely obese children are population specific and have not been reported across 
various ethnic groups (Table 3.5). 
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Table 3.5: List of leptin gene mutation found by us and others 
NO Mutation found Families  Affected 
subjects 
Ethnicity Inheritance Reference  
1 N103K  1 2 Egyptian  Homozygous  [170] 
2 L72S  1 1 Australian  homozygous   [171] 
3 R105W 1 5 or 4 Turkish Homozygous  [153, 157, 176, 379, 380]  
3 R105W 1 2 Pakistani Homozygous This study 
4 398delG 5 8 Pakistani Homozygous  [123, 125, 156, 169, 172, 174]  
4 398delG 29 35 Pakistani Homozygous This study 
5 c.481_482delCT 1 1 Pakistani Homozygous  [174] 
6 Q55X 1 1 Indian Homozygous  [381] 
7 p.D100Y 1 1 Turkish Homozygous [173] 
8 c.104_106delTCA 1 1 Pakistani Homozygous  This study 
9 c.44-2del42  1 1 Pakistani Homozygous  This study 
10 C117Y 1 1 Pakistani Homozygous This study 
11 c.-29+1G>C 2 2 Pakistani Homozygous This study 
 
 
 
Figure 3.16: Position of homozygous LEP gene mutations identified in this study and by others. 
Grey: mutations identified by others; Blue: variants found by us and others; Red: novel mutations identified 
by us and described in this study.  
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Similar to those of LEP, LEPR mutations are also very rare and have so far found in less than 25 
subjects [63, 132, 185-188] (Table 3.6). Our present study adds another 12 Individuals from 11 
unrelated families with 7 novel homozygous variants (Table 3.3 and Table 3.6). This includes a 
unique copy number variation in LEPR gene found in a 0.6 year old boy, which involved two closely 
mapping homozygous deletions, 1.3 kb and 58.9 kb, starting from intron 3 and extending to the 
intergenic region. Two main mechanisms have been proposed for the formation of CNVs: non-
allelic homologous recombination (NAHR) and non-homologous end joining (NHEJ) depending on 
‘miocrohomology’ in place of long stretches of homologous sequences, at the CNV breakpoints 
[382]. A small insertion of 16 bp of unknown origin was observed at 3’ of the deletion, which likely 
occurred as part of the NHEJ process. Previously, a deletion in LEPR was reported that includes 
the promoter, exons 1 and 2 [188] whereas deletion in our proband starts from intron 3.  
In 4 of the unrelated probands, we identified a homozygous LEPR mutation involving a base 
substitution (G>T) at the intron/exon junction of the splice acceptor site of exon 15 resulting in 
an abnormal splicing of LEPR  transcripts due to skipping of exon 15. This mutation renders the 
protein with 798 amino acids of the LEPR extracellular domain while it lacks both transmembrane 
and intracellular domains of the receptor. 
The third loss-of-function LEPR mutation is a nonsense mutation (p.Trp558Stop) identified in the 
two unrelated probands. The said mutation results in a premature stop codon thus translating for 
a truncated LEPR protein comprising the first 558 amino acids of the extracellular domain, and 
lacking both trans-membrane and intracellular domains of the receptor. The fourth novel 
missense mutation, p.Cys604Ser, in exon 11 of LEPR gene was reported in two brothers from a 
consanguineous family. The older of the two (3 years old) was also reported suffering from 
developmental delay and mental disability. Two novel 12 amino acid apart mutations c.2114G>A 
(Trp705Stop) c.2153A>G (Lys718Ser) were also found in two unrelated severe obese probands.  
As reported earlier by others [131, 132, 186, 187], all our LEPR deficient subjects presented with 
extreme adiposity and hyperphagia. However, we did not find any difference between the 
phenotypic features of the LEPR mutations and BMI and age matched leptin deficient children 
drawn from the same population. These observations are in contrast to a previous study in which 
phenotypic features of LEPR deficient subjects have been reported to be less severe and strikingly 
different from LEP mutant carriers [132, 204]. Our data match with animal studies where leptin 
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deficient mice, and mice lacking LEPR are phenotypically identical [152]. This phenotypic 
difference reported previously may be due to heterogeneity in patients' ethnic origin and age (as 
suggested by the investigators), which is not the case in our study. 
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Table 3.6: List of leptin receptor gene mutation found by us and others 
 
 
 
Melanocortin deficiency has been regarded as the most common type of monogenic obesity in 
the West with 166 distinct variants of MC4R gene identified to date [201]. Previous studies 
demonstrate a co-dominant mode of inheritance and the majority of the variants described so far 
are documented in the heterozygous state. In our study we identified 6 subjects carrying MC4R 
homozygous mutation p.Met161Thr or p.Ile316Ser. The former mutation has previously been 
reported only in the heterozygous state in a 12 years old obese subject of Turkish origin [203]. 
No Mutation Affected 
subjects 
Ethnicity Reference 
1 G>A in the donor splice site 3 (1 
deceased) 
Algerian [63] 
2 4-bp deletion in codon 22 3 (1 
deceased) 
Bangladeshi [132] 
3 11-bp deletion in codon 70 2 Turkish [132] 
4 66-bp deletion in codon 514 1 
(deceased) 
Iranian [132] 
5 W31X 3 Southern European [132] 
6 A409E 1 Turkish [132] 
7 W664R 1 Turkish [132] 
8 H684P 1 White (UK) [132] 
9 1-bp deletion in codon 15 
and R612H 
1 White (UK) [132] 
10 P316T 2 Egyptian [187] 
11 Uniparental Disomy 1 Not mentioned [186] 
12 p.C186AfsX27 1 Guinean [185] 
13 p.H160LfsX9 2 Sudanese [185] 
14 Deletion containing ex1 & 2 of 
LEPR 
1 Not mentioned [188] 
15 p.799-1G>T 4 Pakistani This study 
16 p.Trp558* 2 Pakistani This study 
17 p.C604S 1 Pakistani This study 
18 1.3kb and 58.8kb deletion 1 Pakistani This study 
19 p.W705* 1 Pakistan This study 
20 p.N718S 1 Pakistan This study 
21 p.E14K 1 Pakistan This study 
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The other homozygous MC4R mutation, I316S, previously reported in both homozygous and 
heterozygous carriers [383], was found by us in three 11-15 years old subjects. It is of note that 
the onset of obesity and hyperphagia, in these probands were reported to occur at a much 
advanced age (10–11 years) as compared to that of the child with the homozygous Met161Thr 
mutation.  
Interestingly, we failed to identify any MC4R heterozygous mutants with obesity in our study. 
Heterozygous sibling of the probands with homozygous p.Met161Thr and p.Ile316Ser mutations 
were of normal weight and were not reported hyperphagic. In a previously reported multi-
generational family study suggests that penetrance of heterozygous MC4R mutations is 
dependent of the obesogenic environment [202]. In the present investigation on severely obese 
Pakistani children, we also show that whereas onset of obesity in subjects with MC4R mutation 
p.I316S, was between 4-6 years, in those carrying M161T mutation, hyperphagia and increased 
adiposity were  first noticed at a much earlier age of 3 months. The foregoing observation leads 
us to speculate that expression of obesity resulting from MC4R deficiency may not only be 
influenced by environmental factors but also in relation to age. 
Hormone replacement therapy given to patients with congenital leptin deficiency brings about 
almost a complete reversal of clinical symptoms and results in normalisation of food-intake, body 
weight and energy homeostasis. Treatment with recombinant leptin of such rare cases has been 
in place in the West for more than a decade on a restricted or trial basis [169, 380] but has been 
lacking in countries like Pakistan until now, where there is a much higher incidence of the disease. 
During the last four years we have been in constant contact with drug companies that successively 
became responsible for the supply and compassionate use of recombinant leptin including 
Amylin, BMS, AstraZeneca and now Aegerion Pharmaceuticals, with the aim to deliver treatment 
to affected children in Pakistan but unfortunately with no significant success. The recent approval 
of the drug Myalept (recombinant leptin) by US Food and Drug Administration (FDA), for use in 
cases of congenital leptin deficiency and lipodystrophy, brings potential hope that treatment of 
affected children in other countries, may become available in the near future and to help provide 
these children a near normal life and prevent further child mortalities due to this disease.  
Leptin replacement therapy for treatment of congenital leptin deficiency, as yet the only 
successful form of personalized medicine in the context of obesity, is obviously ineffective in LEPR 
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deficiency. It is imperative, therefore, to develop novel pharmacological strategies that could help 
in a direct activation of the downstream signalling of the melanocortin pathway thus 
circumventing its dependence on LEP-LEPR binding. Some of the potential candidates in this 
context include biomolecules such as the ciliary neurotropic factor (CNTF) and its receptor 
agonist, axokine [384, 385]. Preliminary studies indicate that treatment with CNTF is accompanied 
by a decrease in adiposity both in humans and db/db mice [386].  
Furthermore, novel small molecule compounds acting as pharmacological chaperones have been 
identified that can facilitate in vitro trafficking of the receptor protein to plasma membrane in 
cases of human MC4R mutants that result in intra-cytoplasmic retention of receptor protein and 
poor surface expression [387-389] but in vivo a positive impact in MC4R-deficient obese patients 
remains to be demonstrated. There is also the possibility that these pharmacological chaperones 
and highly potent MC4R agonists may find their use in the treatment of some types of common 
obesity for inducing a decrement in food intake and normalization of energy homeostasis [387, 
388]. It is to be expected that personalized medicine based on molecular diagnosis shall in future 
play a key role in management of severe obesity with an unfolding of the genetic cause of 
different forms of this disease. The foregoing further emphasizes the importance of elucidating 
monogenic forms of obesity in consanguineous populations, in this perspective. 
In summary, by using a multi-stage screening regimen we were able to identify genetic causality 
in 30% of unrelated obese children from this consanguineous population due to pathogenic 
mutations in LEP, LEPR or MC4R gene, compared to 3-5% in such cases reported from other 
populations. In our cohort of extremely obese subjects a lack of incidence of pathogenic variants 
in the remaining 25 known obesity associated genes is noticeable warranting a more thorough 
and exhaustive exome (or genome) analysis in the next phase. These findings also underscore the 
advisability of undertaking a comprehensive screening of obesity associated genes in other large 
consanguineous populations that offer a unique and valuable genetic material and which 
presumably could reveal new genes and pathways associated with body composition and energy 
balance. 
  
4. Chapter four 
 
 
 
Variants causing Prader-Willi-
Syndrome (PWS) and Bardet-Biedl-
Syndrome (BBS)
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4.1 Introduction 
Syndromic form of obesity presents besides excessive adiposity a wide range of associated clinical 
phenotypes such as organ specific developmental abnormalities and variable degrees of mental 
retardation. About 30 syndromic forms of obesity have so far been identified [235, 390]. In 
comparison with monogenic form of obesity, the genetic and molecular basis of syndromic 
disorders appears to be much more complex. 
Bardet Beidl syndrome (BBS) is an example of genetically heterogeneous disorders, which is 
characterized by obesity, pigmentary retinopathy, polydactyly, hypogenitalism and mental 
retardation. The condition has been associated with 18 genes (BBS1-18) [248, 249]. This syndrome 
has been considered as a pleiotropic genetic disorder because of a significant variation in its 
expressivity and clinical variability [249, 391]. Although the causal factors of the BBS have 
remained obscure for a long time, more recent data and experimental evidence indicate that the 
condition is mainly attributable to a dysfunction of primary cilia. Inheritance of BBS is traditionally 
considered as autosomal recessive although notable exceptions exist suggesting its 
‘oligogenic‘nature [392].  
Whereas, BBS exemplifies pleiotropy and heterogeneity, Prader Willi syndrome (PWS) presents a 
complex interaction between epigenetic and genetic events during foetal development. PWS is 
phenotypically characterized by obesity, short stature, mental retardation, minimal pain 
perception and hyperphagia, and is caused by a deletion on the paternal chromosome 15 
(15q11.2-q12). Three main events have been reported where loss of expression of paternal genes 
on the imprinted region is the most prevalent cause and explaining genetic basis in 75% of 
patients with PWS. However less than 3% of the affected subjects carry imprinting errors caused 
by microdeletions of the imprinting center at the SNURF-SNRPN gene locus and less than 1% due 
to paternal translocations. As described in Chapter 1, section 1.4.3 the vast majority of individuals 
with deletions in 15q11.2 region have one of two proximal breakpoints (BP1 or BP2) and a 
common distal breakpoint (BP3). These breakpoints arise due to presence of recurrent tandomly 
repeat sequences flanking the breakpoint regions that result in interstitial deletions of about 5-6 
Mb in size. Some unique deletion(s) with specified breakpoints have been reported in a small 
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number of cases [239]. More recently, deletions between BP1 and BP2 and associated phenotypes 
have also been described [393, 394]. Until now, the definitive mechanistic link between defective 
gene products and the phenotype including dysregulation of energy balance remains to be 
elucidated. 
It may be mentioned that categorization of the two forms of obesity, monogenic and syndromic, 
is arbitrary and mostly a matter of convenience. Syndromic obesity can also be caused by 
mutation in a single gene and monogenic obesity where the more prominent presenting feature 
is undoubtedly increased adiposity, is associated with more subtle and less emphasized 
phenotypic characteristics such as red hair, increased linear growth etc. and physiological 
abnormalities such as dysfunction of endocrine, reproductive and immune systems. However, 
various degrees of mental disability almost invariably an outcome of incidence of syndromic 
obesity have only rarely been reported in subjects with monogenic obesity.  
To our understanding not much published information is available on the incidence of syndromic 
obesity in Pakistani population. In this chapter we are reporting cases of syndromic obesity 
identified to date in our cohort of Pakistani children with early onset severe obesity. We believe 
that continuation of such efforts will contribute to a better understanding of the phenotype-
genotype relationship and lead to evidence-based diagnosis and management of patients afflicted 
with such a complex disease. 
4.2 Results 
In our cohort of severely obese children, 8 subjects from 6 unrelated families were identified with 
causal variations in BBS and PWS related genes by using microdroplet-based PCR followed by NGS, 
and CNV and MLPA analyses already described in detail in chapter 2. The variants identified in BBS 
genes included 2 frameshift insertion mutations of which one was novel and one compound 
heterozygous mutation. Deletions in PWS associated region were found in 2 probands and one of 
these subjects carried a novel intermediate size deletion with distinct breakpoints. In addition, a 
1.3 Mb duplication in chr17 in a proband, was suggestive of Albright hereditary osteodystrophy 
(AHO). Altogether these mutations explain syndromic obesity in 4% of cases registered with us. 
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4.2.1 Mutations related to Bardet-Biedl syndrome (BBS) 
4.2.1.1  Bardet-Biedl syndrome 2 (BBS2) 
c.406insG (p.Ala136Glyfs*15) 
Droplet PCR using RainDance technology and next generation sequencing revealed this novel 
insertion mutation at 406 position of exon 3 of the BBS2 gene. The mutation results in a shifting 
of the frame starting from codon position 136 due to substitution of glycine in place of alanine 
followed by a premature stop codon after 13 aberrant amino acids. This results in a 450 amino 
acid long truncated protein compared to the normal 721 amino acid chain (Figure 4.1). 
F-93: The two male siblings, 9 and 13 years old (F-93 and 93C, respectively), from a 
consanguineous family were found to carry this novel insertion mutation in the BBS2 gene. Both 
siblings were severely obese with a BMI SDS of 3.9 and 3.0.  They weighed normal at birth but 
rapidly started gaining weight at the age of 2-4 months accompanied by an insatiable craving for 
food. In both siblings, the vision became progressively impaired after 5 years of age and both were 
reported to have learning problems. A younger sister of affected brothers was of wild type while 
the parents were heterozygous carriers. 
4.2.1.2   Bardet-Biedl syndrome 10 (BBS10) 
 c.271insT (p.Cys91Leufs*5) 
This frameshift mutation in homozygous recessive state was identified in the last exon (exon 2) of 
BBS10 gene due to the insertion of T between amino acid positions 271 and 272. This insertion 
resulted in a shifting of frame due to a substitution of cysteine by leucine at amino acid position 
91 and appearance of the stop codon after three aberrant amino acids. Consequently, the 
mutation caused encoding of a 95 amino acid truncated protein compared to the normal 723 
amino acid sequence (Figure 4.2). 
 S Saeed 
 
 
  
139 
 
 
  
F-73 and F-114: This recessive frameshift mutation in the BBS10 was identified in two unrelated 
6.5 and 1 year old boys. The older boy (F-73) was born with normal body weight but was reported 
to experience intense appetite in early childhood and started to gain excessive body weight which 
was 43 kg with a BMI SDS of 4.2, at the time of recruitment. He also had defective vision and was 
slow in learning. The boy presented postaxial (ulnar) polydactyly of both hands. The other 
proband (F-114), identified with identical mutation, was reported to have low body weight at birth 
but rapidly gained weight from 2 months onwards and attained a BMI SDS of 4.93 at the age 1 
year. In contrast to the other proband this child suffered postaxial polydactyly of feet.  
 
 
Figure 4.1 Sequencing scan of BBS2 at the site of mutation 406insG. 
Scan of BBS2 at the site of mutation demonstrating a homozygous 1 base deletion in exon 3 disrupting the 
reading frame. This mutation was identified in F-93P and F-93S. 
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Figure 4.2 Sequencing scan of BBS10 at the site of mutation 271insT. 
The scan demonstrates a homozygous 1 base deletion in exon 2 disrupting the reading frame. This mutation 
was identified in F-73 and F-114. 
 
4.2.1.3   Bardet-Biedl syndrome 9 (BBS9 )  
c.635T>C (p.Leu212Ser) & c.662A>G (p.Glu221Gly) – compound heterozygous mutation 
Another proband was found to carry 2 missense mutations in BBS9, c.635T>C and c.662A>G, both 
in heterozygous states. The two mutations were located 8 codons apart in exon 7 (Figure 4.3). 
One of the mutations was due to a substitution of leucine to serine at coding position 212 and 
was predicted to be disease causing (p-value: 0.791) by MutationTaster and deleterious (score: 0) 
by Sift. While the second substitution mutation was at position 221 resulting in a change of 
glutamate to glycine. The change is predicted to be disease causing (p-value: 1) by MutationTaster 
and deleterious (score: 0) by SIFT. This is the first report of the presence of a compound 
hetetrozygous mutation in a proband from our cohort of severely obese subjects.  
F-128: The proband identified with this compound heterozygous mutation in BBS9 was a 2.5 year 
old girl with a body weight of 21kg. She developed hyperphagia and started gaining excessive 
weight at 3 month after birth. The patient presented postaxial polydactyly of both hands, weak 
eyesight and learning problems. 
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Figure 4.3 Diagrammatic presentation of two heterozygous missense mutations  
The mutations, Leu212Ser and Glu221Gly in BBS9.were identified in exon 7 of proband F-128. 
 
 
 
Figure 4.4 Diagrammatic presentation of missense mutation c.442G>A identified in BBS1. 
The mutation was identified in F-129. 
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4.2.1.4   Bardet-Biedl syndrome 1 (BBS1) 
c.442G>A (p.Asp148Asn) 
This homozygous missense mutation in BBS1 gene was identified in a female proband and is 
predicted to be disease causing by Mutation Taster (P = 1.0) although tolerated by Sift software 
(score: 0.5) (Figure 4.4). The mutation is recorded in db SNP database under rs200688985 with a 
MAF < 0.01. The same mutation is reported in subjects from UK and US and shown to be 
pathogenic [377]. Interestingly, this proband simultaneously carried a loss-of-function 
homozygous mutation in the LEPR gene described in chapter 3 (section 3.3.2.1).  
F-129: The proband was the only child and was the outcome of a first cousin union. She weighed 
31 kg at the age of 1.4 year with a BMI SDS of 3.4 and was reported hyperphagic. The parents 
noticed her insatiable hunger soon after she was bornh and excessive body weight gain when the 
child was about 3 month old. 
4.2.2  Prader-Willi syndrome (PWS) related genomic deletions 
Whole genome genotyping followed by copy number analysis by PennCNV identified 2 female 
probands carrying deletions associated with PWS, One of these deletions is being reported here 
for the first time. The presence of deletions and their breakpoints were confirmed by carrying out 
MLPA.  
4.2.2.1   4.85 Mb heterozygous deletion 
CNV analysis of genotyping data identified a 4.8 Mb heterozygous deletion on chromosome 15 in 
a proband (Figure 4.5A). Validation of CNV predicted by PennCNV was carried out by MLPA using 
P343 probemix. The analysis showed deletion of 18 probes in 15q11-13 region associated with 
PWS. Breakpoint analysis revealed that MKRN3 was the first deleted gene on centromeric site and 
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HERC2 was the last deleted gene from the telometric site thus categorizing it as a class II deletion 
(Figure 4.5B). The mother of the proband was found wild type for the said deletion. 
F-87: The proband found to carry this deletion was a 22 years old female with body weight of 101 
kg, height of 1.36 m and a BMI of 54. The proband was reported to have a low birth weight but 
started gaining weight after 1.5 years of age. Her IQ was recoded much lower than normal subject 
of her age and as per report she has not yet attained puberty.   
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Figure 4.5 Identification and validation of copy number deletion in PWS associated region found in F-87 
(A) Log R Ratio and B Allele Frequency plot for 15q11 deletion region in F-87. (B) MLPA of patient using P343 probemix representing 18 probed deletion in  
15q11.2-q12 region.
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4.2.2.2   3.35 Mb heterozygous deletion 
This 3.35 Mb heterozygous deletion was also identified in PWS associated region in chr15 (Figure 
4.6A). Screening for duplications and deletions through MLPA analysis by using 343probemix 
confirmed a heterozygous deletion encompassing nine pairs of primers within the 15q11 (Figure 
4.6C). This deletion is part of the conventional interstitial deletions at 15q11-13 that have been 
associated with PWS syndrome. Moreover, the assay revealed that the said deletion carries 
distinct breakpoint at the telomeric end. However due to non-availability of the probes at 
centomeric end, we were unable to access deletion breakpoint at this end. 
Copy number changes and CpG island methylation of the 15q11 
Methylation specific MLPA (MS-MLPA) with high density of probes at the centromeric end of the 
15q11-q13 region was, therefore, used to check for breakpoint copy number deletions as 
identified by MLPA using P343 probemix. MS-MLPA (ME-028 probemix) used here comprised a 
total of 48 probes with 32 of these probes specific for PWS critical region of which 13 probes 
contained a Hha I recognition site in their target specific sequence to analyse methylation of the 
CpG island. The assay confirmed a unique and atypical deletion encompassing 28 of total 32 
probes in chromosomal position 15q.11.2 with distinct breakpoints (Figure. 4.6D). The genomic 
position of the proximal deleted probe was 204,751,54 that lies between BP1 and BP2 and of the 
proximal deleted probe 232,352,21. Thus, the possible size of the deletion could be approximately 
2760067 bp. DNA methylation within 15q11-q13 identified altered methylation pattern in 
proband (Figure 4.6 C). Identical analyses of rest of the 8 family members revealed normal copy 
number and methylation status. 
F-39: The proband with these unique breakpoints was a 7.5 years old girl weighing 44 kg (BMI 
SDS: 6.0) born to consanguineous parents. The child had a history of onset of obesity at 6 months 
of age although she had a low birth weight. The patient was reported hyperphagic, short 
tempered and with learning disability and other behavioural problems.  
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Figure 4.6 Identification and validation of 3.35 Mb deletion in 15q11.2-q12 region. 
(A) Log R Ratio and B Allele Frequency Plot for 15q11 deletion region. (B) MLPA of patient using P343 
probemix representing 9 probed deletion in 15q11.2-q12 region. (C) Upper: MS-PLMA (ME-028 probemix) 
of patient describing incidence of copy number deletion of 28 probes in PWS/AS region. Lower: Abnormal 
methylation status at SNRPN–CpG region. (D) Schematic overview of human chromosomal region 
15q11q13. Class I and class II deletions and atypical familial deletions in patients with AS and PWS are 
drawn as horizontal lines (derived from [395]). Red horizontal line depicts deletion breakpoints found in F-
39. 
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4.2.3 1.3 Mb duplication in chromosome 17 – A suspected case of Albright hereditary 
osteodystrophy (AHO) 
A 7 years old girl presented at the hospital had phenotypic had features similar to those of patients 
with AHO. WES analysis failed to identify any mutation in the GNAS region. However, CNV analysis 
revealed a 1.3 Mb duplication in chromosome 17 (chr17:29060212-30380381) (Figure 4.7A). A 
previous investigation reports a duplication of 1.3 Mb in 17q11.2 including the NF1 gene in a patient 
[396]. This study demonstrated a significant loss of the maternal methylation pattern at all three sites 
in the GNAS region. The duplication found in our proband was identical to the one reported in this 
study. To check for differential imprinting in the chromosome 20q13.32 - GNAS locus, MS-MLPA using 
ME031 probemix was performed. With this procedure we failed to determine any aberrant 
methylation in one or more sequences within this locus (Figure 4.7B). 
F-55: The proband (F-55) was a 7 years old female who was born to non-consanguineous parents. At 
the time of examination her body weight was 39 kg and a height of 1.01 m. She had a round face, 
general obesity, short stature, brachydactyly, delayed development of permanent dentition and 
suffered mental retardation.  She was unable to walk by herself, had kyphosis and restricted 
movement of her right arm and she also had kyphosis. Her mother, elder sister and younger brother 
were mentally and physically normal but the father had short stature and also suffered kyphosis 
(Figure 4.8). 
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Figure 4.7 Identification and validation of 1.7 Mb deletion in 17q11.2 region. 
(A) Log R Ratio and B Allele Frequency Plot for 17q11.2 duplication region.  (B) Upper: MS-PLMA (ME031 GNAS probemix) of patient describing absence 
of copy number change in this region. Lower: Normal methylation status at the GNAS locus at chromosome 20q13.32.  
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Figure 4.8 Photographs of proband (F-55) suspected with AHO and her parents. 
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4.3 Discussion 
This part of study was carried out to identify the genetic variants associated with syndromic type of 
obesity in subjects from Pakistan. The genetic analysis was carried out by using a combination of 
techniques including targeted sequencing, whole genome genotyping followed by copy number 
variation analysis, and MLPA analysis. Here we have identified 4 probands with BBS and 2 probands 
with PWS. In addition, AHO syndrome was suspected in one of the probands from this cohort. 
Targeted sequencing analysis resulted in identification of 6 subjects from 5 unrelated families with 
causative mutations in BBS genes. These included a novel homozygous insertion mutation in BBS2, a 
novel compound heterozygous missense mutation in BBS9 and a previously reported insertion 
mutation in BBS10, in homozygous state [397]. The variant in BBS10, (c.271insT), has been reported 
in several subjects and considered as one of the commonest mutations found in the BBS10 gene 
[397]. Interestingly, one of the probands in addition to a homozygous p.Asp148Asn mutation in the 
BBS1 gene also carried a loss-of-function mutation, p.799-1G>T, in the LEPR gene that was also  found 
by us in another four unrelated children from the same population, as described in chapter 3 (section 
3.3.2.1). The BBS1 mutation in this proband has previously been reported causative in cohorts from 
UK and US [377]. The specific impact due to the simultaneous presence of these two variants on the 
obese phenotype is obviously not clear. However, it may be mentioned that some of the BBS 
associated features such as polydactyl and vision impairment, were not reported in this proband.  
Whereas, one of the probands (F- 87) with PWS was shown to carry the more typical type II deletion 
with BP2-BP3 breakpoints in the PWS associated 15q11 region, the other proband (F-39) was found 
carrying a 3.3Mb intermediate size deletion with distinct breakpoints. The presence of these unique 
breakpoints was indicated by whole genome genotyping and CNV analysis. MLPA and MS-MLPA, 
confirmed 3.3 MB interstitially deleted region and methylation defects in SNRNP-CpG region. This 
deletion and methylation profiling of the subjects validates the presence of PWS in this patient.  The 
proband carrying this deletion had a below average birth weight, early onset obesity and 
hyperphagia, short stature in relation to age, microcephaly and small hands and feet. The centromeric 
deletion breakpoint was localized between BP1 and BP2 including GCP5 but spared NIPA1, NIPA2, 
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and CYFIP1.  The latter three genes are widely expressed in the central nervous system, while GCP5 
is primarily expressed in the subthalamus part of the brain [398]. In two previous studies 10 subjects 
have been identified carrying a deletion between BP1 and BP2, presenting delayed development, 
dysmorphic features and behavioural problems. Moreover, the deletion was found to be inherited 
from normal or mildly affected parents [399, 400]. More recently another 83 subjects were identified 
carrying the same BP1-BP2 deletion [394]. These data indicate the involvement of related genes in 
neurodevelopmental and motor developmental anomalies. Since a wide range of phenotypes has 
been observed in subjects carrying a deletion in this region, it is difficult to determine whether all the 
four non-imprinted genes (NIPA1, NIPA2, CYFIP1 and GCP5) localized to the interval between BP1 and 
BP2 contribute towards the PWS phenotype.  
The last proximal deleted gene in this subject, was ATP10A thus sparing the immediate GABRB3 and 
more distal genes. However, this distal cluster of genes not included in the deleted part, was not 
imprinted.  In a subject with PWS identified previously with almost identical distal breakpoints, a low 
threshold of pain and skin picking behaviour have been observed [239].  A decreased sensitivity to 
pain along with skin picking behaviour was also reported in our patient with PWS. Previous finding 
suggests that  GABA gene may be implicated in pain perception  [401] and low threshold of pain 
observed in PWS patients  has been attributed to haploinsufficiency of GABA gene receptor [239]. 
Previous findings in subjects carrying small deletions with normal copy number for GABA gene 
receptors are conflicting and inconclusive [240, 241]. However, our observation of decreased 
sensitivity to pain in the PWS patient, is consistent with a previous finding suggesting that  GABA gene 
may be implicated in pain perception  [401]. 
Hyperphagia and low energy expenditure resulting in excessive adiposity, are the more commonly 
shared traits in subjects identified with PWS. These features are suggestive of hypothalamic 
abnormalities that may affect satiety signals. However, genetic and molecular determinants 
responsible for this function are yet to be elucidated [402-404]. In a previous study the hyperphagic 
response of PWS patients has been ascribed to elevated levels of the orexigenic gut hormone, ghrelin 
[405]. 
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It is expected that our finding of a unique intermediate size deletion in one of the probands (F-39), in 
contrast to the previously reported typically larger deletions or microdeletions in 15q11.2 region, can 
substantially help in predicting association of specific genetic factors with distinct clinical features. 
However, such an assumption necessitates verification through recording of additional aspects of the 
phenotype and carrying out relevant clinical tests. No detailed examination on the other proband (F-
87) with conventional BP1-BP3 deletion and phenotypic comparisons with affected subjects carrying 
intermediate size deletion has been carried out so far, in an attempt to elucidate the phenotype-
genotype relationship in such cases. 
One of the probands in our cohort of obese children presented a striking resemblance to the AHO 
phenotype. Sequence analysis revealed a duplication of a 1.3 Mb region (17q11.2) that has previously 
been associated with AHO [396]. However, unlike the aforementioned report, our proband carried a 
normal methylation status. Microduplications in this region that includes the NF1 gene have also  
been described in two affected cases [406] associated with mental retardation, cardiac anomalies 
and dysmorphic features. In the present case, evaluation of calcium and phosphorus in blood and 
cyclic AMP levels in urine should help in further validation of our findings.  
In summary, the present study records a relatively high incidence of Bardt Biedel and Prader Willi 
syndromes in a Pakistani population, due to rare and novel variations in associated genes and 
imprinting errors. These findings definitely warrant further genetic and clinical investigations in a 
larger group of subjects with suspected syndromic obesity. We believe that such efforts while 
unravelling rare and novel mutations, genes and susceptible genomic regions, would be instrumental 
in narrowing down the existing genotype-phenotype gap in relation to this complex disease. 
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5. Chapter five 
 
 
Hormone Profile of Subjects with 
Monogenic Obesity 
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5.1 Introduction 
The availability of food and nutritional state of the body are relayed to the hypothalamus via multiple 
afferent signals through hormones, neuropeptides, neurotransmitters and circulating metabolites 
[272]. These signals are integrated by the hypothalamus and after processing by the brain result in 
changes in eating behaviour affected by efferent pathways and thus regulate the energy balance 
[126]. Of the peripheral hormonal signals, leptin, insulin and thyroid hormones, and peptides 
produced by the gut including ghrelin, peptide YY (PYY), glucagon-like peptide (GLP) 1 and 
cholecystokinin (CCK), are the main components of the food intake regulatory mechanism [274].  
Several studies indicate that plasma levels of ghrelin secreted by oxyntic glands of the stomach and 
the only orexigenic gut hormone known so far, are elevated before meals and decline postprandially, 
supporting its role as a meal initiator [407]. Ghrelin action mediated by its receptor, GHS-Rs, triggers 
neuronal activity of orexigenic neuropeptide Y (NPY)/agouti- related peptide (AgRP) neurons and 
inhibits proopiomelanocortin (POMC) neurons resulting in appetite stimulation [408]. Peripheral 
ghrelin levels have been shown to be inversely correlated with fat mass and circulating levels of 
insulin and leptin [371]. Thus, ghrelin levels are lower in subjects with common obesity and higher in 
anorectic patients as compared to normal lean individuals [371, 409]. Although excessively high 
ghrelin levels have been associated with excessive appetite in subjects with Prader-Willi syndrome 
(PWS), yet the role of this orexigenic hormone in hyperphagic response in leptin-melanocortin 
pathway deficient states  [405, 410] has not been elucidated [274].  
Anorexigenic peptides, PYY and GLP-1, produced in the L cells of the distal gut act by inhibiting food 
intake through their effect on the arcuate nucleus [410]. In contrast to ghrelin, levels of PYY and GLP-
1 are low in fasting state and rise following meal in proportion to the calories intake [411, 412]. 
Fasting PYY levels are negatively correlated with the body-mass. Peripheral administration of PYY(3–
36) reduces the  body weight in ob/ob mice [370]. Similar to PYY, circulating GLP-1 levels are inversely 
related to the body mass [413]. Exogenous GLP-1 administration reduces appetite and energy 
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utilization both in normal weight and obese persons [414]. PYY appears to act through a gut-
hypothalamic pathway, mediated by its Y2 receptors in the arcuate nucleus to inhibit feeding whereas 
GLP-1 action mainly involves both the hypothalamus and the brainstem-vagus complex [411, 414]. 
Whereas the nutritional state of the body is transmitted to the hypothalamus via multiple afferent 
signals, regulation of food intake and body weight is mediated by the hypothalamic melanocortin 
pathway. Leptin, besides having long-term role in energy homeostasis, has also been implicated in 
regulation of food intake through affecting meal-size and appetite [415]. The satiety effect and meal 
termination response to this hormone, have been attributed to a blocking of NPY neurons and an 
enhanced POMC/ cocaine- and amphetamine-regulated transcript (CART) signalling [416, 417].  
Loss-of-function single-gene mutations disrupting leptin melanocortin pathway result in a disruption 
of energy homeostasis. This perturbation in energy balance not only results in severe obesity and 
hyperphagia but also leads to varying degrees of endocrine pituitary dysfunction. This is exemplified 
in leptin deprived ob/ob mice that exhibit a wide range of phenotypic abnormalities other than severe 
obesity, such as infertility (hypogonadotrophic hypogonadism) [418], dysregulation of hypothalamo-
pituitary-thyroid axis [419, 420] and stunted body growth [421, 422]. These mouse models also show 
increased adrenal stimulation by ACTH [423] and high circulating glucocorticoid level [424]. 
It may be pointed out that certain hormones do not show the same trend in leptin deficient humans 
as observed in mice (described above). For instance the GH axis in humans is not affected by leptin 
in the same manner or to the same extent as it is in rodents and most of the children with congenital 
leptin deficiency undergo normal linear growth [156, 425]. Similarly, the functional response of the 
pituitary-adrenal axis to leptin deficiency in rodents has not been replicated in the human in previous 
studies [131, 132, 156, 425].  
Available data on endocrine profile in leptin and leptin receptor deficient states in the human as 
reported by various laboratories, are derived mainly from sporadic cases and consequently lack 
consistency as illustrated by conflicting observations on thyroid gland function in LEP mutation 
carriers [131, 169, 170, 372, 425] or with regard to GH profiles in LEPR deficient subjects [131], in 
various studies.  
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In this section we describe for the first time the endocrine profile of severely obese subjects with 
homozygous pathogenic mutations in LEP, LEPR and MC4R genes in a single population, by measuring 
serum levels of leptin, insulin, thyroid stimulating hormone (TSH) and cortisol. Additionally, leptin 
levels have also been determined in subjects with heterozygous mutation in the leptin gene and 
compared with normal wild type individuals to re-address the question of a state of  ‘partial leptin 
deficieny’ [426] due to the presence of a single functional allele in the former group.  
Congenital leptin deficiency also presents a unique model to assess a possible contributory role of 
gut hormones underlying hyperphagia and lack of satiety that are the most characteristic traits of the 
disease. We have, therefore, in a separate experiment assessed the fasting and postprandial 
responses of gut hormones (ghrelin, GLP-1 and PYY) in a group of subjects comprising homozygous, 
heterozygous and wild type carriers for the leptin gene mutation, c.398delG. 
5.2 Results 
5.2.1 Hormone levels in subjects with monogenic obesity 
Mean hormone concentrations in study subjects are shown in Table 5.1. Leptin levels were <1.0 ng/ml 
or undetectable in leptin deficient children and were significantly higher in LEPR mutants compared 
to MC4R deficient subjects. Also, leptin levels in subjects with heterozygous leptin mutation, similar 
to those of normal subjects, were robustly correlated with BMI (r = 0.77, P\0.001), and B) and (r = 
0.78, P\0.001) respectively) (Table 5.2 and Figure. 5.1). Insulin levels were not significantly different 
from each other in the 3 mutant groups and were variable within groups.  
Notably, serum cortisol values were significantly increased in leptin and LEPR deficient subjects as 
compared to those with MC4R mutations and with wild type sequence. Hypercortisolemia was more 
pronounced in leptin deficient children compared to the leptin receptor deficient subjects.  TSH levels 
were within the normal range in all subjects and were comparable to the controls. 
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Table 5.1: Serum hormone levels in children with homozygous mutations in leptin (LEP),  
leptin receptor (LEPR) and melanocortin 4 receptor  (MC4R) genes. 
 
Mutant gene LEP LEPR MC4R 
Age  range 
years 
0.5 - 10 
(n=37) 
0.6 - 6 
(n=12) 
0.6-15 
(n=6) 
BMI SDS  5.3±0.2b* 
(n=37) 
5.0±0.4 
(n=12) 
3.7±0.3 
(n=6) 
Leptin ng/ml <  1.0a***, b*** 
(n=37) 
67.2±6.7c** 
(n=11) 
37.5±3.0 
(n=6) 
Insulin µIU/ml 13.5±1.9 
(n=34) 
16.5±2.6 
(n=11) 
16.8±5.4 
(n=6) 
TSH µIU/ml 2.4±0.2 
(n=19) 
1.9±0.2 
(n=8) 
1.7±0.2± 
(n=6) 
Cortisol µg/dl 26.7±1.3a**, b*** 
(n=29) 
19.3±1.4c* 
(n=10) 
10.0±1.6 
(n=6) 
Reference values (n=11): age-matched subjects with wild type sequence:  BMI SDS: 0.2±0.3;  
leptin: 2.4±0.3 ng/ml; insulin: 4.7±0.6 µIU/ml; TSH: 3.0 ±0.4; cortisol: 7.9 ±1.4. 
 
Significant difference among mutant groups: a LEP vs LEPR; b LEP vs MC4R; c LEPR vs MC4R; 
*P<0.05, **P<0.01, ***P<0.001 (Tukey’s multiple comparison test)  
a Mean ±SEM 
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Figure 5.1 Relationship between BMI and leptin. 
A) In heterozygous carriers of LEP mutation (r = 0.77, P<0.001), and B) in normal 
lean subjects (r = 0.78, P<0.001). 
  
 
 
 
 
 
 
Table 5.2: Age, BMI and leptin levels of heterozygous carriers of leptin gene mutations and wild type controls. 
 
Group N Age (years) BMI Leptin(ng/ml) 
Heterozygous carrier 15 37.9 ± 1.7 27.3 ± 0.9 7.6 ±1.3 
Control (wild type) 15 23.3 ± 1.4 21.4 ±1.2 4.9 ± 1.0 
Mean leptin levels in the two groups were not significantly different: P=0.112 (t test, 2-tailed) 
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5.2.2 Fasting and postprandial levels of gut hormones 
The physical characteristics and hormone levels are shown in Table 5.3 and 5.4. Plasma ghrelin levels 
in subjects with homozygous LEP mutation remained remarkably unchanged following food-intake 
(344±14 vs 343±13 pg m/L) whereas a significant postprandial fall in ghrelin levels (16-23% of baseline 
values) was observed in heterozygotes and normal subjects. Mean fasting levels of ghrelin tended to 
be lower in homozygous mutation carriers compared to the other 2 groups but the differences were 
not statistically significant among the three groups. The relatively higher mean fasting ghrelin levels 
and a more acute postprandial fall of the hormone in subjects with wild type sequence, could be 
attributed to a lower BMI as compared to the heterozygous carriers. 
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Table 5.3: Physical characteristics of study subjects. 
 
Group LEP 
mutatants1 
N Sex 
(M : F) 
Age (y) 
Mean±SEM 
Median (range) 
Height(m) 
Mean±SEM 
Median (range) 
BW (kg) 
Mean±SEM 
Median 
(range) 
BMI 
Mean±SEM 
Median 
(range) 
 
I Homozygous    
(-/-) 
52 1 : 4 18.0±4.5 
16(8-30) 
1.49±0.07 
1.58(1.29-1.67) 
108.0±25.6 
124(44-
161) 
45.1±7.4 
49.7(26.4-
63.3) 
II Heterozygous 
(-/+) 
8 4 : 4  39.8±2.8 
37.5(32-52) 
1.67±003 
1.69(1.54-1.81) 
77.3±4.5 
81(59-91) 
27.5±1.3 
27(24.1-
32.2) 
III Wild type         
(+/+) 
(Control) 
1
03 
8: 2 21.9±1.4 
23.5(8-25) 
1.56±0.08 
1.42(1.24-1.75) 
61.6±4.9 
63(21-72) 
20.2±0.9 
20.5(15.1-
24.3) 
 
1Frameshift mutation, c.398delG, in exon 3 of LEP. 
2 2 subjects were <16 y of age with z-score for BMI 3.34 and 4.07. 
31 subject was <16 y of age with z-score for BMI -0.31. 
BMI: Body mass index; BW: body weight; M: male; F: female. 
Homozygous and heterozygous carriers for LEP mutation belonged to two unrelated consanguineous families. 
The control group (wild type) consisted of unrelated normal subjects.  
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Table 5.4:  Fasting and postprandial hormone and glucose levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1  Frameshift mutation, c.398delG, in exon 3 of LEP 
2 P value, paired two-way t test, fasting vs postprandial (meal) levels, significantly different:P<0.05 
3 Percent change in postprandial levels 
4 Not detectable or below the sensitivity level of assay  
 
  
 
Homozygous1 Heterozygous1 Wild type (Control) 
Mean±SEM P value2 Percent 
change3 
Mean±SEM P value Percent 
change 
Mean±SEM P value Percent 
change 
Ghrelin 
pg/ml 
Fasting 344±14 0.327 -0.30% 415±29 0.028 -16% 489±53 0.011 -23% 
Meal 342.8±13   347.4±13   373±24   
PYY 
pmol/L 
Fasting 23.7±5.5 0.219 25% 18.7±3.4 0.011 34% 21.4±4.3 0.003 65% 
Meal 29.6±4.2   25.1±3.2   35.5±4.0   
GLP 
pmol/L 
Fasting 55.9±8.9 0.019 82% 43.7±2.8 0.012 169% 38.0±6.0 0.007 168% 
Meal 93.0±15.8   117.8±20.0   102.6±18.6   
Glucose 
mg/dl 
Fasting 115±30 0.014 40% 101.1±9 0.005 72% 91±4 0.000 63% 
Meal 161±37     186.7±28.3     149±10     
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Differences in fasting plasma PYY levels among the three groups were insignificant. A variable 
postprandial increase was observed in all the 3 groups (25-66%) but was not statistically 
significant in leptin deficient subjects (Table 5.4). The mean fasting values of plasma GLP-1 levels 
though tending to be higher in leptin deficient subjects were not significantly different in the three 
groups. A significant postprandial rise in GLP-1 levels (82-169%) was observed in all subjects 
including those carrying homozygous mutation (Table 5.4). However, the increase was minimal in 
the latter group. 
5.3 Discussion 
As expected, serum leptin levels were <1.0 ng/ml or non-delectable in subjects with homozygous 
LEP mutations. Two instances have also recently been reported by Wabitsch and co-workers [173, 
378] where the aberrant protein encoded by the mutant LEP gene was secreted in circulation but 
lacked bioactivity in subjects carrying a homozygous LEP mutation, p.D100Y and p.N103K. In none 
of our LEP mutants we have so far found a similar condition. It may, therefore, be surmised that 
in the majority of cases, the mutant leptin protein even if released in circulation, is not reactive 
to antibodies against the normal ligand, and thus escapes detection in immunoassays.  
Interestingly, in a previous study leptin levels were reported to be significantly lower in 
heterozygous carriers of LEP mutation as compared to those of normal subjects, resulting in a 
condition termed as partial leptin deficiency [426]. In the present study, however, we failed to 
find a significant difference in levels of this hormone between the heterozygous and wild type 
subjects. It may be pointed out that serum leptin levels are affected by other variables such as 
age, gender, diurnal variations and nutritional state, independent of the BMI. It is, therefore, 
rather difficult to carry out a strictly objective comparison between leptin levels measured in 
heterozygous and wild type subjects especially when the sample size is relatively small and the 
subjects are drawn from a heterogeneous cohort.  
Previously, very high leptin levels have been reported in association with a pathogenic mutation 
of LEPR located in the splice donor site of exon 16 [131]. Excessively increased levels of leptin in 
this case were attributed to the presence of a truncated LEPR protein that lacked both 
intracellular and transmembrane domains, secreted in blood and capable of binding to circulating 
leptin in high concentrations. In the present study, hyperleptinemia was observed in majority of 
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the subjects with homozygous LEPR mutations and leptin levels in these subjects were higher than 
those of MC4R deficient children. However, other studies based on multi ethnic subjects with 
different LEPR variants demonstrate a wide range of circulating leptin concentrations presumably 
in relation to the extent of adiposity [132, 187, 427].  
Mean insulin levels were raised in subjects with LEP, LEPR and MC4R mutations over the control 
values but were variable in all the three mutant groups. Hyperinsulinemia, therefore, cannot be 
regarded as a direct outcome of leptin, leptin receptor or MC4R deficiency but is possibly 
consequent to an increased fat mass and extent of inflammation and hypertension, or due to an 
independent disposition of diabetic condition. More remarkably, cortisol levels in our subjects 
were significantly and consistently higher in leptin deficient subjects. Although increased levels of 
serum cortisol levels were also evident in children with LEPR mutations, the severity in this class 
of mutants was found to be less than that observed in leptin deficient subjects. In sharp contrast 
to our observations, previous studies indicate that humans with inactivating mutations in LEP or 
LEPR have normal cortisol levels and do not show abnormal basal or corticotropin-releasing 
hormone-stimulated response [156]. Cortisol levels in MC4R mutants were not markedly different 
in the present study, from those of wild type normal weight subjects. TSH levels were 
unremarkable in all the three mutants groups and were shown to be within the normal range. 
In a separate study we assessed the response of gut hormones to food intake primarily to address 
the possible role of these hormones and especially of ghrelin, in the hyperphagic drive, which is a 
distinctive behavioural trait of subjects with monogenic obesity. Under normal circumstances 
ghrelin levels increase during fasting before meals and drop postprandially and its physiological 
role in appetite stimulation is now well established [407]. Furthermore, peripheral ghrelin 
administration has been shown to increase food intake in normal subjects [428]. In this study we 
have shown that ghrelin levels are relatively low and do not undergo a postprandial fall in leptin 
deficient subjects. On the other hand, in heterozygous individuals, baseline ghrelin concentrations 
and the acute fall following food intake were almost indistinguishable from that of the controls.  
Since ghrelin levels have been shown to be inversely related to fat mass, therefore, relatively low 
levels of ghrelin in obese subjects could be ascribed to accumulation of body fat and possibly 
hyperlipidemia [429]. The hypothesis that excessive eating and increase in body fat mass in 
subjects with common obesity could be partly due to a lack of fall of postprandial ghrelin levels, 
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has not been substantiated [371].  Interestingly, ghrelin knockout mice or mice lacking GHS-R type 
1a receptor have normal appetite and maintain normal body weight demonstrating thereby that 
a chronic lack of this hormone or its action does not necessarily affect energy homeostasis [430].  
In contrast to morbidly obese subjects with congenital leptin deficiency and subjects with 
common obesity, patients with PWS have markedly increased levels of ghrelin that have been 
associated with hyperphagia and development of obesity [431].  
In this study, responses of PYY and GLP-1 to food intake in leptin gene mutants were not 
remarkably different from those observed in normal subjects. Majority of studies in subjects with 
common obesity and PWS patients, also report a postprandial rise in these gut hormones 
comparable to normal weight individuals [432]. However, as in case of PWS, the hyperphagic 
response of leptin deficient subjects appears to be refractory to increased levels of gut satiety 
hormones. Most probably, this refractoriness is not associated with resistance to these peptides 
but is due to an overriding central orexigenic signal in obese patients. This is evidenced by the 
observation that infusion of PPY3-36 in pharmacological doses reduces the food intake by 30% in 
obese subjects [433]. Our results in leptin deficient and normal individuals further demonstrate 
that basal and postprandial peripheral levels of PPY and GLP-1 are not correlated with leptin levels 
and support the notion that the response of these peptides to food intake is independent of 
regulation by leptin [434].  
In summary, the present data indicate a negligible role if any, of gut hormones in driving the 
hyperphagic response observed in subjects with congenital leptin deficiency. This supposition is 
corroborated by experimental data in animal models. Ghrelin deficient and leptin deficient double 
mutant mice (ghrelin -/- and ob/ob) show little change in food intake and body weight as 
compared to ob/ob mice [435].  In view of the forgoing, we speculate that hyperphagia in leptin 
deficient subjects can mainly be ascribed to an over expression of NPY neurons unrestrained due 
to insufficiency of leptin rather than due to an alteration in the level of gut hormones. 
Furthermore, our data on hormone profiles suggest that levels of none of the hormones 
investigated here with the exception of leptin, can be used as reliable biomarkers of leptin, leptin 
receptor or MC4R deficient states. Undoubtedly genetic analysis remains the only option so far 
for the diagnosis of early onset severe obesity. 
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6. Chapter six 
 
 
Putative genes associated with severe 
obesity as identified by whole exome 
sequencing (WES) 
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6.1 Introduction 
Discovery of causative genetic variants associated with disease including obesity, has remained 
an important and challenging task in the realm of human molecular genetics [436]. In spite of the 
discovery of a number of pathogenic mutations in genes especially those that directly influence 
the leptin-melanocortin signalling, the genetic basis of a large percentage of cases with severe 
obesity is still unaccounted for.  
 The recent progress in the discovery of novel disease related candidate genes has proceeded 
hand in hand with the phenomenal advances in analytical technologies such as massively parallel 
new generation sequencing (NGS) techniques. Of these, whole exome analysis (WES) that 
investigates protein-coding regions spanning across the whole genome [437] has emerged as a 
significantly efficient and a time and cost effective technique to identify disease related mutations 
in known and novel genes particularly those that follow the Mendelian inheritance [438]. The 
usefulness of WES analysis is emphasised by the fact that about 85% of the disease-related 
mutations in monogenic disorders have been found in the protein-coding regions (exons and 
splice sites). Furthermore, in the recent past use of WES has resulted in the discovery of more 
than 100 such causative genes including those associated with monogenic and syndromic forms 
of obesity [311, 316, 317] thus also establishing its specificity and potential utility in clinical 
settings [318, 319].  
Use of exome sequencing has proved instrumental in identifying several new forms of Mendelian 
obesity genes in subjects with obesity. Kabuki syndrome was one of the initial cases in which 
genetic causality was elucidated by the use of WES and had led to the identification of pathogenic 
mutations in the MLL2 gene [439]. This discovery was followed by a growing list of causative 
genes/mutations identified through WES, leading to  other forms of syndromic obesity such as 
Bardet Biedl [440, 441] Alström [442, 443] and Coffin-Siris syndromes [444], as well as to non-
syndromic types of  obesity [232, 445]. As an adjunct to WES, homozygosity mapping can further 
facilitate and improve efficiency in identification of recessive pathogenic mutations in 
consanguineous cases by focusing on genetic variants that lie in a critical locus homozygous only 
in the affected individual [446].  
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Here we report novel pathogenic mutations in three candidate genes, INSIG2, ROCK1 and ADCY3, 
in subjects with early onset severe obesity, identified by using WES data analysis and 
homozygosity mapping.  
6.2 Subjects   
Forty probands with severe early onset obesity and their family members were selected for this 
study. All probands were from consanguineous families. Thirty-nine of these subjects were 
previously screened for 27 obesity associated genes by Sanger sequencing and RainDance 
targeted sequencing techniques but were found negative. One of the subjects that could not be 
screened by these procedures due to small amount of the sample was also included in the WES 
analysis. Interviews were carried out to obtain family history of patients and construct pedigrees 
spanning at least 3 generations. Written informed consent was obtained in all cases. 
Anthropomorphic measurements and physical examination were carried out and blood samples 
were obtained in each case for subsequent DNA extraction and hormone estimations.  
6.3 Variant prioritization 
In WES performed on a total of 96 samples the achieved mean depth was ~100X (median ~80X). 
The total coverage was about 69.8Mb and approximately 68.5Mb were covered with a minimum 
of 8X. Since the subjects were the outcome of consanguineous parentage, therefore, autosomal 
recessive homozygosity in all the probands for the disease causing mutation(s) was expected. 
Variants from each family were filtered independently to find specific homozygous mutations in 
affected individuals. In the initial filtration step, I excluded all variants in heterozygous state. Since 
the chances of any variant present in publically available databases to be causative/deleterious 
were rather low, in the next filtration those variants that are enlisted in db SNP and 1000 Genome 
Project were excluded. Also variants present in homozygous state in the Exome Aggregation 
Consortium (ExAC) and Exome Sequencing Project (EPS) were excluded. Mutation prediction 
softwares, Polyphen and MutationTaster, were used to envisage fate of mutation. Variants that 
were synonymous or predicted to be benign by in silico prediction softwares were also ignored. 
At the end of filtration steps I was left with a small number of high priority candidate variants. On 
these variants, I performed filtration based on available biological and functional information. 
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Careful considerations were given to potentially deleterious variants detected in regions of runs-
of-homozygosity. Association of genes in polygenic form of obesity through GWAS, was also taken 
into account. Biological pathways of genes carrying mutations were studied to find their direct or 
indirect relevance to the observed phenotypes. Finally, those genetic variants that were likely to 
be associated with the phenotype were selected for Sanger sequencing for confirmation.  
6.4 Whole exome sequencing data analysis - significant findings 
The whole exome sequencing of samples from 40 unrelated probands and 56 family members 
carried out to identify genetic variants/alleles associated with severe obesity resulted in an 
indication of causative mutations in 3 genes. Although association of these candidate genes with 
obesity has already been suggested through genome wide association (GWAS) and/or animal 
studies, their involvement in a predisposition to extreme obesity in the human is being reported 
here for the first time.  
By employing the approach as described in the Material and Methods section 2.3.3, an average 
of ~16000 high quality variants were generated per individual from paired end reads that were 
filtered down to less than 10 novel homozygous variations (Table 6.1) through various exclusion 
steps described above.  Here we have described WES results in only 3 probands and their family 
members whereas data from the remaining affected subjects and their family members is still 
under process.  
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Table 6.1: Variants identified in major prioritisation steps applied on exome  
sequencing of DNA from 3 probands 
Sample F-46 F-103 F-107 
Total SNP 14340 13519 14393 
    Homozygous SNP 5738 5045(3862)b 5323 (1395)c 
    Homozygous Novela SNP 41 14 16 
    SNP after filtration  5  1  3 
Total Indels 1300 1309 1345 
    Homozygous Indels 324 3862(358) 460(117) 
    Homozygous novel Indels  37 37 20 
    Indels after filtration  0  4  3 
a: Not present in db SNP database 
b: Homozygous SNP also present in the obese brother 
c: Homozygous SNP not present in the lean mother 
 
 
6.4.1 insulin induced gene 2 (INSIG2) 
c.425T>C (p.Ile142Thr) 
This mutation was identified in the INSIG2 gene involving substitution of T to C at position 425 
resulting in isoleucine to threonine change at codon position 142. Following the already described 
filtration strategy we ended up with four novel predicted deleterious homozygous mutations in 
the proband. These other four genes included NCK-associated protein (NCKAP5), family with 
sequence similarity 96, member A (FAM96A), keratin 36, type II (KRT3), neural precursor cell 
expressed developmentally down-regulated 4-like (NEDD4L). However, c.425T>C mutation in 
INSIG2 gene was the most convincing variant owing to its association with BMI in GWAS and its 
role in cholesterol and lipid metabolism. The mutation in INSIG2 gene is predicted to be 
deleterious by Sift (score: 0.01) and disease causing by MutationTaster (p-value=1). This mutation 
also lies in the second largest homozygous region in chromosome 2 starting from position 
107,673,715 to 155,381,331, spanning 47.7 Mb of ROH region. This mutation that lies in the 
moderately conserved region (Figure 6.1C) of exon 4 of INSIG2 gene was also confirmed and 
validated by PCR amplification from genomic DNA and subsequent Sanger sequence analysis (Fig 
6.1B). Whereas this specific mutation was not found within dbSNP variation database or Exome 
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Sequencing Project (ESP), its presence in heterozygous state in the Exome Aggregate Consortium 
was documented in only one subject of an unknown origin from a total of 121382 alleles. The 
other four genes although passed the filtration criteria but none of these had any functional 
relevance with the phenotype of interest (Table 6.2). 
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Figure 6.1 Pedigree of F-46 and sequencing scan of INSIG2 at the site of mutation. 
 A) Pedigree drawing of F-46; B) Sequencing scan of INSIG2 at the site of mutation demonstrating a homozygous missense variation, c.425T>C, in exon 4. This 
mutation was identified in F-46; C) Sequence alignment and conservation of residues across specie; D) Diagrammatic presentation of role of INSIG2 in lipogenesis 
by the sterol regulatory element-binding protein (SREBP) transcription factor. In the event of low sterol levels in the cell, conformational changes in SCAP 
dissociates it from INSIG2 and escorts  SREBP to the golgi complex (or vesicles) thus mediating cholesterol and fatty acid biosynthesis
  
 
  
172 
 
 
  
 
 
Table 6.2:  Potentially pathogenic mutations in homozygous state identified in F-46 by whole exome sequencing. 
 
Gene Category Protein function Position cDNA change Aminoacid change  Mutation Taster Sift ROH ExAC 
INSIG2 Missense Lipid homeostasis 2:118864368 c.425T>C p.Ile142Thr 
Disease causing 
(p-value: 1) 
Deleterious 
(score: 0.01) YES NO 
NCKAP5 Missense Hypersomnia 2:133543192 c.1192G>A p.Glu398Lys 
Disease causing 
(p-value: 0.99) 
Deleterious 
(score: 0) YES NO 
FAM96A Missense 
Chromosome 
segregation 15:64381036 c.139A>C p.Ile47Leu 
Disease causing 
(p-value: 1) 
Deleterious 
(score: 0) YES NO 
KRT36 Missense 
Keratins to form hair and 
nails 17:39642711 c.1321A>C p.Thr441Pro 
Disease causing 
(p-value: 0.849) 
Deleterious 
(score: 0) YES NO 
NEDD4L Missense 
Degradation of the 
single-stranded DNA-
binding protein 18:55998034 c.878C>A p.Pro293Gln 
Disease causing 
 (p-value: 1) 
Deleterious 
(score: 0.01) YES NO 
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F-46 - clinical characterization  
This homozygous missense mutation in INSIG2 was found in a 5 year old girl with severe obesity. 
She is the only child of her consanguineous parents from Shakargarh District of Punjab and 
belongs to the Pathan caste. The proband was reported to start gaining excessive weight at the 
age of 1 month. Both parents were of normal bodyweight. The father of the affected girl was 
reported to be diabetic. Physical and clinical data of the proband are presented in Table 6.3.  
Table 6.3: Anthropometric and clinical investigation of proband F-46. 
 
ID F-46 
Gender Female 
Age (year)  5  
Height (m) 1.06 
Weight (kg) 27 
BMI SDS 3.6  
Leptin (ng/µl) 79.4 
TSH (µIU/ml) 1.9 
Insulin (µIU/ml 39.2 
Cortisol (µg/dl) 3.8 
 
6.4.2 Rho-associated protein kinase 1 (ROCK1) 
c.2824G<A (p.Glu942Lys) 
Another missense mutation caused by substitution of G with A at coding position 2824 in the 
ROCK1 gene resulted in a change from glutamate to lysine at codon position 942. This mutation 
was identified in the proband and two severely obese siblings (BMI: 59, 42 and 49 respectively) in 
the homozygous state and in a third sibling (BMI: 37) in heterozygous state (Figure 6.2A). This 
mutation in exon 24, is predicted to be deleterious according to Sift (score: 0) and disease causing 
by the MutationTaster (p-value=1). Evidence of pathogenicity was also supported by a high 
conservation of substituted residues (Figure 6.2C). The said mutation was also confirmed and 
validated by Sanger sequencing (Figure 6.2B). This mutation is not listed in the dbSNP Variation 
Database and Exome Sequencing Project (ESP) but is recorded in the Exome Aggregate 
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Consortium in heterozygous state in 12 subjects of South Asian origin, from a total of 119802 
alleles.  
Mutations in 4 other genes in the proband also passed the filtration criteria. These genes comprise 
dachshund family transcription factor 1 (DACH1), family with sequence similarity 157, member A 
(FAM157A), arfGAP With GTPase domain (AGAP3) and fatty acid desaturase 6 (FADS6). Whereas 
none of the variants identified in these genes provided an obvious explanation for the phenotypes 
and were also found to be present in homozygous state in ExAC datebase, ROCK1 turned out to 
be the solo highly convincing candidate based on available literature on functional analysis as well 
as mouse modelling (Table 6.5).  
F-103 - clinical characterization 
This mutation in homozygous state was found in the proband and his two brothers. The proband 
was initially recruited for the study at the age of 25 years. At this age he weighed 147 kg with a 
59 BMI. During a follow-up 2 years later his body weight increased to 185 kg with a BMI of 73. . 
His two male siblings with BMI 42.2 and 49.1 were also found to carry identical mutation in the 
homozygous state. Another sibling with a BMI of 37.5 was found heterozygous for this mutation 
(Table 6.4). The proband was reported to start gaining weight at the age of 5 years. The parents 
had died earlier and were reported to be overweight and diabetic. 
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Figure 6.2 Pedigree and mutation in ROCK1. 
A: Pedigrees of F-103 with a mutation in ROCK1; B: Sequencing scan of ROCK1 at the site of mutation 
demonstrating a homozygous missense substitution c.2824G<A C 1 in exon 24. This mutation was identified 
in homozygous state in F-103, F-103C and F-103E; C: Sequence alignment and conservation of residues 
across species. 
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Figure 6.3 Diagrammatic presentation of different domains of ROCK1 protein 
(Modified from Rikitake and Liao 2005 [447]). 
 
 
 
 
 
 
Table 6.4: Anthropometric and clinical investigation of F-103. 
 
ID F-103 F-103C F-103E F-103D 
Mutation c.2824G<A 
(Homozygous) 
c.2824G<A 
(Homozygous) 
c.2824G<A 
(Homozygous) 
c.2824G<A 
(Heterozygous) 
Gender Male Male Male Male 
Age (year)  25  32   26   28  
Height (m) 1.58 1.6 1.66 1.58 
Weight (kg) 147(185)A 110 135 94(106) 
BMI 59 (73.6)B 42   49 37(42)  
Leptin (ng/µl) 30 N.A. N.A. 19 
TSH (µIU/ml) 2.1 N.A. N.A. 0.9 
Insulin (µIU/ml 36.6 N.A. N.A. 22.7 
Cortisol (µg/dl) 7 N.A. N.A. 12 
A: Weight on follow-up 
B: BMI on follow-up 
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Table 6.5: Potentially pathogenic mutations in homozygous state identified in F-103 by whole exome sequencing. 
  
Gene Category 
Protein 
function Position 
cDNA 
change Aminoacid change  
Mutation 
Taster Sift ROH ExAC 
ROCK1 Missense  
Insulin and 
leptin 
signalling 18:18549166 c.2824G>A p.Glu942Lys 
Disease 
causing Deleterious NO Yes (het in 11) 
      (p-value:1) (score: 0)   
DACH1 Indel 
Tumor 
growth  13:72440659 c.245_251del p.Gly82Alafs*112 N.A. N.A. NO Yes ( homo) 
FAM157A Indel Unknown 3:197880131 c.210_219del p.Trp70Cysfs*43 N.A. N.A. NO Yes ( homo) 
AGAP3 Indel 
Synaptic 
plasticity 7:150783909 c.81dup p.Gln28Alafs*102 N.A. N.A. NO Yes ( homo) 
FADS6 Indel Unknown 17:72889677 c.17_18ins54 p.Met7_Leu350delinsAlaPro* N.A. N.A. NO Yes ( homo) 
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6.4.3 Adenylyl cyclase 3 (ADCY3) 
c. 3315delC (p.Ile1106Serfs*3) 
This frameshift mutation in ADCY3 gene was caused by a homozygous one base deletion of G 
nucleotide at the base position 3315 and was identified in a 10 year old girl.  This mutation in last 
exon (exon 21) of the gene (Figure 6.4D) resulted in truncated protein by introducing a stop codon 
after two aberrant amino acids starting from 1065 where isoleucine was changed to serine (Figure 
6.4B). This mutation which is within the ROH region, was not found in any of the available data 
bases. Association of this gene with regulation of body weight is supported by several GWAS 
studies. Variants in other genes that qualified the predetermined filtration criteria included TSPY-
Like 6 (TSPYL6), Keratin Associated Protein 29-1 (KRTAP29-1), Otoferlin (OTOF),  ATP-Binding 
Cassette, Sub-Family B (MDR/TAP), Member 4 (ABCB4), Alcohol Dehydrogenase, Iron Containing, 
1 (ADHFE1) (Table 6.4). Due to its recurrent association with BMI and its functional relevance with 
obesity, ADCY3 was considered as a potential causative gene. The mother of the proband was 
heterozygous for this mutation. 
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Figure 6.4 Mutation in ADCY3 and pedigree of affected subject. 
A: Pedigrees of F-107 with mutations in ADCY3; B: Sequencing scan of ADCY3 at the site of mutation 
demonstrating a homozygous 1 base deletion c. 3315delC in exon 21 disrupting the reading frame. This 
mutation was identified in homozygous state in F-107 and in heterozygous state in mother F-107B: C:  
Conservation of amino acid across twelve different species; D: Diagrammatic presentation of different 
domains on ADCY3 protein and position of mutation are indicated by red arrow. 
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Table 6.6: Potentially pathogenic mutations in homozygous state identified in F-107 by whole exome sequencing. 
 
Gene Category Protein function Position 
cDNA 
change 
Amino acid 
change  
Mutation 
Taster 
Sift ROH ExAC 
TSPYL6 Indel Unknown 2:54482704 c.580_586del p.Gly194* N.A. N.A. YES Yes(Homo) 
KRTAP29-1 Indel Unknown 17:39458574 c.136_151del p.Ser46Alafs*63 N.A. N.A. YES Yes(Homo) 
ADCY3 Indel Formation cAMP 2:25042921 c.3315del p.Ile1106Serfs*3 N.A. N.A. YES NO 
OTOF Missense  Recessive deafness 2:26707394 c.1153A>G p.Asn385Asp 
Disease 
causing 
Deleterious YES Yes(Het) 
ABCB4 Missense  ATP-Binding Cassette 7:87083858 c.337A>G p.Met113Val 
Disease 
causing 
Deleterious YES Yes(Het) 
ADHFE1 Missense  
Oxidation of 4-
hydroxybutyrate 
8:67364217 c.764C>G p.Pro255Arg 
Disease 
causing 
Deleterious YES Yes(Het) 
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F-107 - clinical characterization 
The proband, a 10 year old girl, was the only child of consanguineous parents (Figure 6.4A). She 
was reported to be hyperphagic soon after birth and started gaining weight at the age of 2 years. 
She has been slow in learning and at the age of 13 years is in Grade 3. Also, reportedly she has no 
sense of smell. It is interesting to note that disruption of ADCY3 gene renders mice unable to 
detect odour [448]. Physical and clinical data of the proband are presented in table 6.7. 
 
Table 6.7: Anthropometric and clinical investigation of  
proband F-107. 
 
ID F-107 
Mutation c.425T>C 
Gender Female 
Age (year) 10 
Height (m) 1.36 
Weight (kg) 57 
SDS 3.4 
Leptin (ng/µl) 30 
Insulin (µIU/ml 31 
TSH (mIU/l) 6.23 
 
 
6.5 Discussion 
In this chapter we have described for the first time pathogenic variants in three candidate genes, 
INSIG2, ROCK1, and ADCY3, that may be associated with human obesity. These genes were 
identified by WES analysis of DNA samples from 40 severely obese subjects and their family 
members, using a rigorous and uniform filtration protocol and selection criteria for variant 
prioritization.  
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INSIG2, one of the three genes shown here to be associated with monogenic obesity, was 
indicated to be associated with BMI through the first GWAS (Farmingham Heart Study) carried 
out in 2006 [449]. In this study, a SNP rs7566605 located near the 5' end of INSIG2 was reported 
to be significantly associated with BMI in both children and adults participants. The finding was 
replicated in four additional sample sets analysed by GWASs [449] and in some subsequent 
studies conducted in subjects from diverse populations [450-452]. Moreover significant 
association of other tagSNPs in INSIG2 was also reported to be associated with BMI [453]. 
However, according to some of the follow-up studies the association remains inconclusive [69, 
454-456].  
A 225 amino acid protein, INSIG2, encoded by this gene has been shown to regulate adipogenesis 
and lipid storage [457] thus nominating INSIG2 as a strong candidate gene for disposition to 
obesity  [458, 459]. The INSIG2 protein is located in the endoplasmic reticulum and is an important 
component of feedback inhibition mechanism of cholesterol biosynthesis in regulation of 
lipidogenesis. It blocks further cholesterol synthesis in the presence of adequate levels of cellular 
sterols, by binding to SREBP-cleavage activating protein (SCAP) thus retaining the SCAP/SREBP 
complex in the ER [460]. 
INSIG2 is also expressed in adipocytes and its expression increases at the time of adipocyte 
metabolism suggesting a possible role of this protein in influencing body weight [461]. 
Furthermore, overexpression of INSIG2 protein was shown to reduce hepatic lipogenesis in obese 
Zucker diabetic fatty rats [462]. Further support of involvement of INSIG2 in body weight 
regulation comes from INSIG2 knockout mice that were reported to be heavier than control 
littermates and had higher concentration of accumulated cholesterol and triglycerides [463].   In 
the perspective of the aforementioned evidence of functional role of this gene in lipid 
metabolism, the findings of present study provide the first instance of a pathogenic mutation in 
the coding region of INSIG2, associated with early onset severe obesity in the human.  
Another mutation shown to be associated with severe obesity by WES was found in the ROCK1 
gene in three siblings. ROCK1 encodes the serine/threonine protein that is a major downstream 
effector of small GTPase RhoA [285]. The encoded protein is implicated in several cellular 
processes including actin cytoskeleton organization, muscle contraction and cell motility and also 
implicated in the pathogenesis of metabolic disorders such as hypertension and obesity/diabetes 
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[464-466]. Role of ROCK1 in central control of energy homeostasis has been attributed to its 
regulation of leptin action. Emerging data propose that ROCK1 affects leptin action through its 
mediation of JAK2 activation, which in turn promotes STAT3 activation/dimerization and its 
transportation inside the nucleus. Whereas, exogenous dose of leptin was shown to enhance 
ROCK1 activation [285], hypothalamic activity of ROCK1 is reduced in high-fat diet induced obese 
mice [467]. Also, JAK2 tyrosine phosphorylation is diminished when ROCK1 activity is biologically 
suppressed in the hypothalamus, suggesting that leptin-induced JAK2 activation is ROCK1-
dependent [285]. 
The role of ROCK1 in leptin signalling and thus body weight regulation was also highlighted by 
ROCK1 gene knockout mice. Targeted disruption of ROCK1 in POMC neurons has been shown to 
induce hyperphagic obesity by preventing leptin’s downstream anorexogenic effects. 
Additionally, adiposity due to deletion of ROCK1 in ARC is more emphasised in mice as compared 
to animals with ROCK1 deficiency in POMC neurons alone. Targeted deletion of ROCK1 in the AgRP 
neurons also resulted in increased body fat content and weight gain [285] that could be attributed 
to a significant decrease in energy expenditure through reduced locomotor activity [467]. 
In addition to its role in downstream leptin signalling, available evidence in rodents suggests that 
ROCK1 is a mediator of insulin signalling in the hypothalamus as well as in the peripheral tissues 
[285, 468, 469]. Treatment with ROCK inhibitors (Y-27632) resulted in insulin resistance by 
lowering glucose uptake in in vitro and ex vivo experiments [469]. Also, inhibition of ROCK1 
diminishes insulin signalling and subsequent glucose transport in 3T3-L1 adipocytes [469, 470], 
indicating its positive involvement in insulin signalling and glucose metabolism. An in vivo 
disruption of ROCK1 has been reported to result in an increase in insulin receptor action proposing 
its inhibitory role in controlling insulin sensitivity and signalling and a disruption of adipose tissue 
specific ROCK1 in diet-induced obese mice, led to an increased insulin signalling and improved 
insulin sensitivity [471]. These data though somewhat conflicting in different rodent models, 
comes out clearly to demonstrate a significant role of ROCK1 in influencing metabolic signals that 
regulate energy homeostasis. It is also suggested that ROCK1 regulation of glucose metabolism 
and insulin signalling in peripheral tissues/cells may be differential or conditional to specific 
metabolic states. 
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The ROCK protein is comprised of an N-terminal kinase domain (residues 73–356), a central 
coiled-coil domain (residues 422–1102) which also contains the Rho-binding site towards its end, 
and a C-terminal pleckstrin homology domain (residues 1118–1317). In the inactive form, the 
carboxyl terminal of Rho is folded back onto the kinase N terminal kinase domain. This looping 
helps in maintaining the inactive state of the enzyme [472]. Activation of the protein takes place 
by binding of the active form of Rho GTPase to the Rho-binding domain of ROCK1 leading to an 
open (active) kinase domain [472, 473] Our mutation at position 942 that falls within the 
dedicated rho-binding domain and thus could have caused a failure in its bonding to RhoA and 
subsequent activation of kinase (catalytic) domain (Figure 6.3). 
Taken together, various lines of evidence, as summarized above, strongly suggest ROCK1 as a 
central regulator of glucose metabolism and a modulator of leptin action on energy balance. 
Impaired ROCK1 activity in hypothalamus may contribute to the development/ pathogenesis of 
central leptin resistance in obesity.  Further investigations on the functional impact of this gene 
in the human could possibly open up new leads to management and treatment of certain forms 
of obesity and type 2 diabetes [285, 471]. 
The third obesity associated mutation identified through WES reported in this study was in the 
coding region of the gene, adenylate cyclase 3 (ADCY3) which encodes for an 1144 amino acid 
protein. This protein is a member of the adenylate cyclase (AC) family and is widely expressed in 
various human tissues catalysing the production of the secondary messenger, cyclic adenosine 
monophosphate (cAMP). cAMP is a crucial mediator in eliciting the biological response to a 
number of neurotransmitters, neuropeptides and hormones including those that regulate energy 
homeostasis such as α-melanocyte-stimulating hormone (α-MSH), the orexins, GLP-1 and 
glucagon[474-476] which are  important mediator of leptin downstream signalling [477]. 
ADCY3 is one of a few loci that have shown a recurrent and strong association with obesity 
through GWAS efforts [102, 104, 478-480] and also with type 1 diabetes [481] and major 
depressive disorder [482]. In most of the studies ADCY3 gene was found to be in strong linkage 
disequilibrium with other neighbouring genes including EFR3B, RJB, POMC and DNAJC27 [102, 
104]. Polymorphisms within ADCY3 were also shown to confer the risk of obesity susceptibility in 
Swedish and Chinese Han populations [483-485]. Moreover the identified SNPs in ADCY3 were 
found to be associated with expression of POMC gene which has a known function in susceptibility 
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to obesity through its role in regulating melanocortin signalling [102, 104]. Direct evidence of 
involvement of ADCY3 gene in body weight regulation comes from animal models.  Knockout 
(Adcy3-/-) mice exhibit increased fat mass attributable to low physical activity, hyperphagia and 
reduced sensitivity toward leptin [486] whereas heterozygous  gain-of-function mutations  in mice 
presented increased Adcy3 activity thus providing protection from diet-induced metabolic 
derangements [487]. 
The proband carrying ADCY3 mutation reportedly lacked sense of smell. It is interesting to note 
that Adcy3 knockout mice (Adcy3-/-) fail to detect and perceive odour. It was shown that 
disruption of Adcy3 causes a complete absence of the electroolfactogram (EOG) response that is 
normally stimulated by cAMP due to activation of receptors in the olfactory sensory neurons 
(OSNs) [448]. In summary, information derived from human and from animal models provide 
convincing evidence that ADCY3 protein expressed in CNS and adipose tissue could play a 
significant role in the regulation food intake and energy homeostasis.  
A functional characterisation of the mutant genes is necessary to finally induct them in the list of 
genes associated with monogenic obesity. Interestingly two of the three genes identified here 
have also been associated with obesity related traits though GWAS, indicating a clear overlap of 
GWAS identified loci with genes predisposing an individual to extreme form of obesity through 
single gene mutation. The aforementioned observations strongly recommend screening those 
gene/loci that have been recurrently associated with obesity related traits through GWAS efforts, 
in severely obese subjects.  
A novel homozygous mutation, p.Glu14Lys (c.40G>A), in LEPR gene was also identified through 
WES. The said mutation was predicted tolerated by Sift with the score of 0.32 and therefore, could 
not be picked up by stringent filtration criteria. This mutation lies in ROH region (details in chapter 
3 section 3.3.2.4). This incidence raises doubts on relying heavily on the in silico prediction 
methods to determine the fate of mutation.  
We acknowledge that our findings at present may not be sufficient to definitely implicate these 
mutations as determinants of the obese phenotype. The significance of our results is limited due 
to the fact that the incidence of these mutations has not yet been replicated in other obese 
  S Saeed 
 
 
  
186 
 
 
  
individuals from same population. In addition, our results lack confirmation through functional 
analysis, which should be pursued in future. 
In summary, by employing a strategy for whole-exome capture and whole genome genotyping 
analysis with a goal to identify new causal homozygous mutation, we have identified three genes 
that might explain the phenotype of the patient with severe early-onset obesity. The present 
outcome of whole exome analysis underscores the importance of systematic genetic analysis of 
other inbred populations to unravel novel genetic variants and signalling pathways modulating 
energy homeostasis. 
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7. Chapter seven 
 
 
General Discussion and Conclusions 
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7.1 General discussion 
Relatively frequent presentation of severely obese children at pediatric units in Punjab’s hospitals 
and a general lack of appropriate diagnosis and understanding of the etiology of this form of 
obesity in the country, prompted us to undertake the present study in 2012. A further incentive 
to initiate this study was provided by the first report of a loss-of-function homozygous mutation 
in the human leptin gene resulting in early onset extreme obesity, identified in a family of 
Pakistani origin residing in the UK [125]. A high degree of consanguinity in the Pakistani population 
[362, 363] provided a unique backdrop to investigate rare and novel recessive genetic variants 
associated with large effects. Since working on individuals at the extremes of their phenotype has 
established its usefulness in the field of genetics [488], we limited our study to subjects with early 
onset extreme obesity. During the course of this study a large amount of effort went to select and 
recruit patients and other members of affected families by establishing collaboration with local 
public hospitals and also by arranging field visits to contact affected families residing in remote 
villages of central Punjab. 
As a result of sequencing analysis of DNA of 175 unrelated probands for 27 known obesity 
associated genes we were able to identify recessive rare and novel pathogenic mutations in the 
homozygous state in 54 patients (or families) (32%). Remarkably, of the 21 different mutations 
identified, 15 were found in three genes, LEP, LEPR and MC4R that directly influence the 
melanocortin signalling (Figure 7.1).  The other six genetic variants identified were associated with 
syndromic obesity (PWS and BBS). Equally remarkable is a significantly high prevalence of severe 
obesity incidence due to loss-of-function mutations in the leptin gene in our cohort (20.5%).   
Amongst the several afferent peripheral signals that convey energy relevant information to the 
hypothalamus, leptin secreted by adipocytes, is regarded as the most crucial component for 
regulating food intake and body weight [189]. This is mainly achieved by leptin’s effects on two 
distinct neuronal populations within the arcuate nucleus that reciprocally regulate energy 
homeostasis and food intake mediated by the melanocortin pathway [189, 489]. Any disruption 
of this signalling pathway due to a dysfunction of either leptin or its receptor – that trigger the 
melanocortin pathway, predominantly results in a most severe form of obesity at an early age 
[490]. This notion is further strengthened by the observation that the obesity level in 42 leptin 
  S Saeed 
 
 
  
189 
 
 
  
deficient and 11 leptin receptor deficient children identified in our cohort was higher as compared 
to obese children with  melanocortin-4 receptor deficiency (Figure 7.2). 
Interestingly, among the 42 leptin deficient subjects from 35 affected families, 35 subjects carried 
an identical frameshift mutation, c.398delG. Almost all families affected by this mutation 
belonged to the Arain caste that constitutes a major sub-ethnic group of the Punjab province and 
has preferred consanguineous marriages between first or second cousins, for many generations 
[356]. Since this LEP variant has not been reported in any other consanguineous population, it 
may be a considered as a founder mutation in this caste. The exceptionally high prevalence of this 
frameshift mutation compared to the remaining LEP mutations in this population could be 
ascribed due to an earlier establishment of this variant with a founder effect in this specific inbred 
caste.  
In contrast to the relative frequency of pathogenic mutations in the three obesity associated 
genes determined by this study, in previous investigations based on samples of random 
populations mainly of European origin, LEPR deficiency has been reported to be more prevalent 
than leptin deficiency [132] and mutations in the MC4R have been regarded to cause the most 
prevalent form of monogenic obesity [201, 203, 204]. Genetic analysis on severely obese subjects 
from our cohort showed that leptin deficiency due to loss-of-function mutations in the leptin gene 
is the most prevalent form of severe obesity whereas contribution of MC4R mutations to the 
incidence of monogenic obesity in our population appeared to be minimal.  
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Figure 7.1 Mutations in three genes, playing a key role in leptin signalling and its downstream effect. 
 
 
 
Figure 7.2 Graph showing the BMI standard-deviation score of 4 groups of mutants.  
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In this study we were unable to distinguish between the clinical phenotypes of leptin and leptin 
receptor deficient age-matched children. These observations are in contrast to a previous study 
in humans [132] but corroborate well with findings drawn from mice lacking leptin (ob/ob) and 
leptin receptor (db/db) that have been shown to be phenotypically identical [491]. Interestingly, 
we failed to identify any MC4R heterozygous mutant with severe obesity in our study. This 
observation supports the hypothesis that penetrance of heterozygous MC4R mutations is 
dependent of the obesogenic environment [202]. Also our results though based on a small 
number of subjects with homozygous MC4R mutations suggest that the expression of obesity 
resulting from MC4R deficiency is not only influenced by environmental factors but also in relation 
to age.   
The absence of known or novel mutations in other monogenic obesity associated genes such as 
POMC, SIM1 and PCSK1 in our cohort of severely obese subjects is noteworthy. Also, no deletion 
in a previously established obesity locus, 16p11.2, [256, 257] could be identified. The absence of 
this deletion in our cohort could be attributable to an age dependent penetrance as seen in 
heterozygous carriers of this deletion [257] and hence may escape selection at a younger age for 
inclusion in a cohort of children with early onset severe obesity. It seems advisable, therefore, to 
investigate 16p deletion in subjects presenting a milder phenotype from this population. 
In a previous report partial leptin deficiency has been described in subjects carrying heterozygous 
loss-of-function LEP mutations based on circulating leptin concentrations in a relatively small 
group sample [426]. Interestingly, in the present study fasting and postprandial leptin levels in 
heterozygous subjects tended to be comparable with or higher than those of the control subjects 
and were significantly correlated with BMI highlighting that heterozygosity for LEP mutations, 
may not result in partial leptin deficiency. 
Although, recent technological advancements have given an impetus to disease gene 
identification process, it is obvious  from  a large proportion of missing or unexplained heritability 
of obesity that we are still a way off to fill this gap [102] and new susceptibility genes that underlie 
energy homeostasis have yet to emerge. Existing information derived from genes that have been 
associated with severe obesity provide unequivocal evidence that severe obesity is an inherited 
disorder of central regulation of food intake and energy homeostasis. Therefore, investigations 
on components of centrally located pathways are well justified. The recently identified candidate 
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genes for obesity such as MRAP2 [232], KSR2 [233] and SH2B1 [269] together with our findings of 
ROCK1 and ADCY3 prompt us to look for yet unidentified genetic variants and molecular pathways 
predisposing human to the obese phenotype. Furthermore, it can be anticipated that mediators 
of new centrally located pathways may also emerge that will influence our bodily energy balance 
by reciprocally influencing leptin melanocortin pathway, such as those involving brain-derived 
neurotropic factor and 5-HT, to provide a comprehensive outlook of underlying molecular 
mechanisms  regulating body weight and energy balance [273].  
Significantly, GWAS analyses demonstrate that most of the genes associated with Mendelian 
forms of human obesity (LEPR, POMC, MC4R, BDNF, SH2B1 and PCSK1) are also enriched with 
more common variants associated with relatively small effects on BMI thus predisposing the 
individual to a milder form of obesity in the general population [101, 110-112]. This overlap is 
suggestive of shared underlying pathways, disruption of which could predispose an individual to 
a severe monogenic or a more subtle polygenic form of obesity [113]. Our findings of potentially 
pathogenic mutations in ADCY3 and INSIG2 gene that have previously shown recurrent 
association with obesity through GWASs together with aforementioned observations, strongly 
suggest screening of GWAS derived loci in severely obese subjects with the objective to identify 
novel genetic variants that may be associated with large effects on BMI [114]. Such an approach 
can significantly help us move from GWAS derived loci to relevant disease susceptible candidate 
genes.  
In addition to rare point and indel mutations, another class of genomic variation that has been 
given considerable attention in the recent past is the copy number variation (CNV). Several studies 
have reported deletion and duplications, but these findings in most cases lack replication in other 
populations. However, an exception is a deletion of 593 kb at 16p11.2 [256, 257] that has also 
been widely replicated across different populations. It is noteworthy that in previous CNV 
analyses, consideration has been given only to large deletions due to the notion that that large 
CNV’s are associated with a higher expression of the phenotype. This view underestimates the 
contribution of small CNV’s to the phenotype. In future, careful investigations of small and rare 
CNV’s could contribute in assessing the true importance of CNVs in elucidation of obesity. 
Congenital leptin deficiency due to pathogenic mutations in the LEP gene is perhaps the only type 
of obesity where personalised medicine has been shown to be exceptionally successful. Daily 
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treatment with recombinant leptin in these subjects results in a dramatic reversal of symptoms 
due to leptin deficiency and a restoration of normal body weight, appetite and endocrine and 
reproductive functions. Also, clinical trials to manage and treat subjects with MC4R mutations 
that make up a large proportion of subjects with genetically determined obesity in the West, are 
on way. New small molecule compounds acting as pharmacological chaperones provide novel 
strategies to improve trafficking of receptor protein to cell membranes in cases of defective 
surface expression. In addition, pharmacological approaches attempting a direct activation of the 
downstream signalling of the melanocortin pathway are also under clinical trial [386]. More 
recently, attempts have been undertaken to generate hypothalamic neurons from pluripotent 
stem cells that may possibly be used in future to regulate appetite in subjects with monogenic 
obesity [492]. 
Life style intervention does not seem to be effective for long term weight management as evident 
from trials in MC4R mutation carrier where intensive life style interventions that successfully 
induce weight reduction in the initial stages  [493] but present problems in maintaining optimal 
body weight as a long term management. [493]. Such interventions are predicted to be even less 
helpful in case of leptin and leptin receptor mutation carriers that experience severe hyperphagia.  
At the time of discovery of leptin, it was thought that leptin as a satiety factor will prove a 
breakthrough in the treatment of obese individuals in general. However, it turned out that 
majority of subjects with obesity, with the exception of leptin deficient subjects, have normal or 
excessive levels of endogenous leptin and, therefore, addition of an exogenous dose of leptin 
would prove ineffective. Refractoriness to endogenous or exogenous leptin in obese subjects is 
generally ascribed to its resistance or tolerance [126, 162]. A number of mechanisms including 
impaired leptin transport through blood brain barrier and ineffective leptin signalling have been 
suggested to explain leptin resistance and the possibility that a reversal of these could be helpful 
in amelioration of obesity, has been contemplated. Pharmacologically targeting SOCS3 and PTP-
1B that negatively regulate leptin signalling by reducing STAT3 expression could also contribute 
to increase leptin sensitivity. Similarly, components that influence transport of leptin across blood 
brain barrier could be targeted to enhance leptin sensitivity. Recent work by Hung et al provides 
experimental evidence that ROCK1 that mediates leptin action to regulate food intake and 
adiposity in leptin responsive neurones (POMC and AgRP), could also act as a novel target to 
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reduce leptin resistance. [467]. Lastly, it is expected that successful development of effective 
drugs that directly activate the JAK2/STAT3 signalling pathway may help in the treatment of not 
only monogenic forms but also common and polygenic types of obesity.  
Recently scientists have focused their attention towards another area of brain that controls 
reward and hedonic aspects for regulation of food. It has been demonstrated that leptin receptors 
are expressed in the ventral striatum (VS) through which leptin exerts its effect on the mesolimbic-
dopamine system to decrease the reward associated with food intake [159, 494]. In rodents, 
administration of leptin resulted in decreased food intake while a knockdown of LepR in the VTA 
showed the opposite results. [275]. These finding provide direct evidence of action of a peripheral 
metabolic signal on the VTA dopamine neurons. It is possible that genes that determine the 
palatability of food could also be targeted to regulate appetite and eating behaviour for treatment 
of incentive-related hyperphagia – one of the features contributing to development of extreme 
and morbid obesity. Here it may be mentioned that pharmacological interventions targeting areas 
in the brain could be quite challenging and risky as it may impair signalling pathways and 
associated proteins resulting in other complications. 
Another area of research that is making its way in the field of genetics of obesity relates to the 
investigations on the gut microbiota. The human gut microbiome has been shown to be 
differentially expressed in gut of obese and lean individuals [26, 495-498].  It is, therefore, feasible 
that gut microbes could serve as potential nutritional and pharmacological targets to manage 
obesity.  
7.2 Conclusions 
By adopting a multi-layered sequencing regimen we have demonstrated a significantly higher 
incidence of monogenic obesity in Pakistani population than hitherto assessed in multi-ethnic and 
randomly organised cohorts of subjects with severe obesity. Among 175 subjects with severe 
obesity we have been able to elucidate genetic causality in 35% unrelated subjects. Of these 21% 
were shown to carry homozygous mutations in LEP, 6.5% in LEPR and 2.4% in MC4R gene. In 
addition, 4% of probands were identified with variants resulting in syndromic form of obesity. 
These findings underscore routine genetic screening particularly of the leptin gene in cases of 
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early onset severe obesity and hyperphagia as leptin deficiency can be effectively treated through 
replacement therapy. 
Initial findings through WES analysis revealed three new human obesity susceptibility genes in the 
human. A functional characterization of mutations found in these candidate genes is envisaged. 
These results further encourage us to carry out WES in the remaining of our probands in which 
the causal variants have not yet been identified.  
Lastly, it may be pointed out that a relatively higher percentage of mutations leading to 
monogenic obesity in this study could partially be due to our sustained focus on a specific 
consanguineous population and systematic genetic analysis rather than a higher incidence of 
mutations in obesity associated genes alone relative to other inbred populations. Such a 
supposition further emphasises the express need of undertaking comprehensive and systematic 
screening of cases of severe obesity in other geographical regions where consanguinity is still 
practiced. Such an enterprise is expected to narrow down the existing gap of missing heritability 
of obesity.  
Investigation on hormones levels provided evidence that gut hormones appear at best, to play a 
minimal role in inducing hyperphagia in severely obese subjects with congenital leptin deficiency. 
Moreover the results based on subjects carrying LEP gene mutation in heterozygous form indicate 
that heterozygosity for the LEP mutation, does not result in partial leptin deficiency, in contrast 
to what has been previously suggested.  
We hope that a continuation of similar efforts will lead to a better understanding of the genetic 
mechanisms underlying monogenic and common obesity. Such investigations are important not 
only in the context of furthering our knowledge of the genetic basis of obesity, but also in the 
perspective of the emerging era of personalised medicine.  
7.3 Future Directions 
-Expanding collaboration   
The results of the present study encourage us to continue with our quest of finding out the genetic 
causality of severe obesity in Pakistan’s consanguineous population and examine its incidence in 
  S Saeed 
 
 
  
196 
 
 
  
other regions of the country. This will involve planning to increase the size of our cohort and 
expansion of research collaboration with physicians and hospitals from other cities of Punjab as 
well as from other provinces. We have already started implementing this plan and new 
collaboration has been established with the children hospital in Islamabad and the local ethical 
approval has been obtained.  
-Continuation of our efforts of systematic genetic analysis 
We contemplate to continue our efforts to find the genetic causality of severe obesity in the 
Pakistani population especially in those cases in which we have still been unable to determine the 
genetic basis. This will involve a multi-layered sequencing regimen as used in the present study, 
and genome-wide genotyping to unravel structural variants. We also aim to inform and educate 
the public of Pakistan about the disease risks associated with first cousin unions and provide 
genetic counselling for members of obese families. 
-Out-reach of research benefits 
The gradual but steady increase in the number of children diagnosed with early onset severe 
obesity obligates a great deal of ethical and moral responsibility on us to make sure that the 
patients will be afforded proper personalised care, management and treatment, where feasible. 
We will continue our efforts to provide leptin replacement therapy in some of the principal local 
hospitals for treatment of subjects with congenital leptin deficiency.  
-Functional analysis of novel pathogenic variations 
We plan to carry out the functional analysis of the three obesity susceptibility candidate genes, 
INSIG2, ROCK1 and ADCY3, identified by WES analysis. The functional characterization will be 
performed in house or through collaboration with other laboratories already engaged in similar 
analyses.  
-Designing of cost effective screening of known genetic variants 
We envisage to develop a cost effective and relatively rapid method to screen pathogenic 
mutations in known susceptibility genes for rapid molecular diagnosis in subjects with severe 
obesity. The screening method will be based on SNP genotyping by Fluidigm (IFC192.24) using 
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TaqMan assays. This technique will allow screening of 24 different variants in 96 samples in a 
single step and should provide an efficient and cost effective method for screening of specific 
mutations. 
-Metabolomic profiling of severely obese children 
The relatively high prevalence of monogenic obesity in Pakistani population due to loss-of-
function mutaions in LEP and LEPR as reported in this study, provides a unique material to 
investigate metabolic changes that accompany this type of obesity by carrying out metablomic 
profiling of affected and normal subjects. The study of metabolomics allowing simultaneous 
qualitative and quantitative metabolite profiling offers a powerful tool  to reduce the existing 
genotype-phenotype gap [499]. In a previous investigation, metabolomic profiling in obese leptin 
and leptin receptor deficient (ob/ob and db/db) mice, demonstrated significant metabolic 
differences [500]. The proposed study shall focus on the end metabolites to explore the possibility 
if any of these metabolic signals could be used as clinical biomarkers for a predisposition to 
monogenic or other forms of obesity. Preliminary results of a pilot experiment in collaboration 
with the Department of Surgery and Cancer, ICL, to identify differentially expressed metabolites 
using mass spectroscopy, indicate significant differences between obese and non-obese groups.  
Characterisation of gut microbiota of severely obese subjects 
Although studies in ob/ob mice have shown a differential gut microbiome composition when 
compared to their lean counterparts [26], to our understanding no parallel studies have yet been 
undertaken in human subjects suffering from monogenic forms of obesity. A characterisation of 
the gut microbiome in leptin and leptin receptor deficient patients and subjects with common 
form of obesity from the same geographical area is, therefore, in order. Such investigations are 
expected to provide insights into the role of the gut microbiome in the development of obesity, 
and may suggest leads to individualised therapeutic options for affected subjects.  
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Table A1: Serum hormone levels in 5 adult subjects identified with homozygous  
leptin gene (LEP) mutation 
 
Age years BMI Leptin ng/ml Insulin µIU/ml TSH µIU/ml Cortisol µg/dl 
 
22 ±2.6a 
(n=5) 
 
52 ±4 
(n=5) 
<1.0 
(n=5) 
23.4 ±6.4 
(n=4) 
5.4 ±3.0 
(n=3) 
31 
(n=1) 
a
 Mean ±SEM 
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Table A2: Showing 26 probes from P343 probe mix in 15q region of which 9 probes (shaded grey) are 
deleted in F-39 
No length gene Map view chr. pos. 
1 214 SNRPN-HB2-85 15-022,848294 15q11.2 
2 475 SNRPN-HB2-85 15-022,858473 15q11.2 
3 256 UBE3A 15-023,136395 15q11.2 
4 244 UBE3A 15-023,150555 15q11.2 
5 142 UBE3A 15-023,152935 15q11.2 
6 160 UBE3A 15-023,167740 15q11.2 
7 197 UBE3A 15-023,171919 15q11.2 
8 270 ATP10A 15-023,484000 15q12 
9 136 ATP10A 15-023,659036 15q12 
10 220 GABRB3 15-024,344242 15q12 
11 292 GABRB3 15-024,357380 15q12 
12 382 GABRB3 15-024,363881 15q12 
13 148 GABRB3 15-024,376510 15q12 
14 319 GABRB3 15-024,379640 15q12 
15 184 GABRB3 15-024,417665 15q12 
16 355 GABRB3 15-024,568655 15q12 
17 436 OCA2 15-025,770116 15q12 
18 445 OCA2 15-026,017939 15q13.1 
19 202 APBA2 15-027,196749 15q13.1 
20 178 NDNL2 15-027,348739 15q13.1 
21 300 TJP1 15-027,900944 15q13.1 
22 373 TRPM1 15-029,081415 15q13.3 
23 166 KLF13 15-029,452013 15q13.3 
24 286 CHRNA7 15-030,191319 15q13.3 
25 492 SCG5 15-030,759311 15q13.3 
26 427 SCG5 15-030,776133 15q13.3 
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Table A3: Showing 26 probes from P343 probe mix from 15q region of which 18 probes (shaded grey) are 
deleted in F-87. 
No Length Gene Map view Chr. pos. 
1 214 SNRPN-HB2-85 15-022,848294 15q11.2 
2 475 SNRPN-HB2-85 15-022,858473 15q11.2 
3 256 UBE3A 15-023,136395 15q11.2 
4 244 UBE3A 15-023,150555 15q11.2 
5 142 UBE3A 15-023,152935 15q11.2 
6 160 UBE3A 15-023,167740 15q11.2 
7 197 UBE3A 15-023,171919 15q11.2 
8 270 ATP10A 15-023,484000 15q12 
9 136 ATP10A 15-023,659036 15q12 
10 220 GABRB3 15-024,344242 15q12 
11 292 GABRB3 15-024,357380 15q12 
12 382 GABRB3 15-024,363881 15q12 
13 148 GABRB3 15-024,376510 15q12 
14 319 GABRB3 15-024,379640 15q12 
15 184 GABRB3 15-024,417665 15q12 
16 355 GABRB3 15-024,568655 15q12 
17 436 OCA2 15-025,770116 15q12 
18 445 OCA2 15-026,017939 15q13.1 
19 202 APBA2 15-027,196749 15q13.1 
20 178 NDNL2 15-027,348739 15q13.1 
21 300 TJP1 15-027,900944 15q13.1 
22 373 TRPM1 15-029,081415 15q13.3 
23 166 KLF13 15-029,452013 15q13.3 
24 286 CHRNA7 15-030,191319 15q13.3 
25 492 SCG5 15-030,759311 15q13.3 
26 427 SCG5 15-030,776133 15q13.3 
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